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1. ABSTRACT
Smac mimetics (SMs) constitute a class of compounds that target the inhibitor of 
apoptosis proteins (lAPs) and enhance the cytotoxic activity of several drugs. In our work, 
we built and characterized a library of about 140 SMs and focused on SM83 due to its 
high affinity for the targets, cytotoxic activity and good pharmacokinetic profile. In vivo, 
SM83 reduced in monotherapy the primary tumor growth of two triple negative breast 
cancer xenografts. Furthermore, SM83 treatment, alone or in combinations with TRAIL- 
armed CD34+cell, resulted in the reduction of spontaneous lung metastasis formation. 
Mechanistically, by depleting clAPl, SM83 affects the expression of the tumor genes and 
inhibits the metastasis-promoting gene Snai2, thus preventing cancer cell motility.
Moreover, we tested SM83 as a standalone in ascites cancer models and described an 
in vivo anti-tumor effect against cancer cell lines that are intrinsically resistant to SM 
treatment in vitro. In the in vivo settings, SM83, in fact, triggered an inflammation event 
of the host, characterized by macrophage secretion of TNF, IL-lp and interferon-y (IFNy), 
and rapidly killed floating tumor cells within the ascites by a non-apoptotic mechanism. 
Of note, SM83 treatm ent caused the massive accumulation of neutrophils within the 
ascites and tumor nodules, which, however, was not responsible for cancer cell killing.
Finally, we described the capability of SM83 to enhance the cytotoxic activity of 
camptothecin especially in human epithelial cells expressing oncogenic KRAS. The 
increased sensitivity of these premalignant cells is caused by an ERK2-dependent up- 
regulation of NOXA. Of note, oncogenic KRAS fails to sensitize a panel of isogenic cancer 
cell lines with wild type and mutated KRAS, and we demonstrated that this 
unresponsiveness could be reverted by concomitant inhibition of AKT. Therefore, our
work suggests that the activation of AKT is capable of counterbalancing the potential pro- 
death stimulus triggered by oncogenic KRAS.
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2. INTRODUCTION
2.1. The apoptotic machinery
Apoptosis is a form of cell death regulated by an evolutionarily conserved molecular 
program (Degterev and Yuan, 2008). It is a fundamental process in the development of 
multicellular organisms and, due to its pivotal role, the deregulation leads to a number of 
diseases (Favaloro et al, 2012). Apoptosis is triggered with high specificity and efficiency 
in physiological conditions to induce suicide of excessive or misplaced cells in order to 
allow the correct development of the tissues (Clarke, 1990). Moreover, cell death can be 
induced by a plethora of both intra- and extra-cellular insults such as oxidative stress, 
DNA damages and inflammation that, when irremediable, activate the apoptotic 
machinery (Wong, 2011).
2.1.1. Pathways involved in apoptosis regulation
The apoptotic pathway is commonly divided in extrinsic and intrinsic, according to 
whether the pro-death stimulus is originated from the microenvironment and soluble 
factors outside the cells or by intracellular faults, respectively (Fulda and Debatin, 2006; 
Galluzzi et al, 2012). Even though these pathways are tightly interlinked and controlled by 
many common mediators, nonetheless it is conventionally accepted that the extrinsic 
apoptosis is initiated by the interaction between the death ligands of the tum or necrosis 
factor (TNF) superfamily and their cognate receptors (Newsom-Davis et al, 2009). When 
sufficiently stimulated, several adaptor proteins are recruited in concert to the 
intracellular portions of the TNF-receptor (TNF-R) family members leading to the 
formation of the death inducing signaling complex (DISC) (Scaffidi et al, 1998; Sprick et al,
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2000). This in turn activates the cysteine-dependent aspartate-directed proteases, or 
caspases, which are responsible for the execution of the apoptotic process by cleaving 
several substrates and finally resulting in cell dismantling. The DISC activates the apical 
caspase-8 and -10 (Barnhart et al, 2003; Dickens et al, 2012a; Ganten et al, 2004), which 
start the whole apoptotic process and are therefore called initiator caspases. These 
proteases then cleave other members of the same family that propagate the pro-death 
signal and are therefore called effector caspases (especially caspase-3 and -7). In a few  
cell types, the activation of the extrinsic pathway is sufficient to lead to cell death 
because caspase-8 activates enough caspase-3 to result in irreversible damage. These 
cells are usually referred to as "type I" cells (Barnhart et al, 2003; Jost et al, 2009). 
Contrarily, "type II" cells need the involvement of the mitochondria to efficiently activate 
apoptosis in a process often called mitochondrial amplification that is initiated by 
caspase-8-mediated cleavage of Bcl-2 homology domain 3 (BH3) interacting-domain 
death agonist (Bid) (Kantari and Walczak, 2011). Cleaved, or truncated (t), Bid then 
activates Bcl-2-associated X protein (Bax) and Bcl-2 homologous antagonist/killer (Bak), 
two pro-apoptotic Bcl-2 family members, which lead to mitochondrial outer membrane 
permeabilization (MOMP) (Green and Kroemer, 2004). This is considered a "point of no 
return" of programmed apoptosis. MOMP allows the release into the cytosol of the 
cytochrome c that, together with the initiator caspase-9 and apoptotic protease 
activating factor 1 (Apaf-1), forms the apoptosome (Dickens et al, 2012b; Reubold and 
Eschenburg, 2012), a pro-death platform leading again to caspase-3 and -7 activation (Li 
et al, 1997; Zou et al, 1997).
In absence of an extrinsic stimulus, mitochondrial death can be initiated directly by an 
intrinsic apoptotic event such as DNA damage, endoplasmic reticulum stress and
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oxidative stress. Mitochondria therefore play a pivotal role in the apoptosis process and 
represent the site where cell fate is determined (Galluzzi et al, 2012). In fact, many anti- 
(Bcl-2, Bcl-xL, Mcl) and pro-apoptosis (Bim, p53 up-regulated modulator of 
apoptosis/PUMA and NOXA) proteins localize here and the balance between them strictly 
determines the final outcome (Ploner et al, 2008; Wong, 2011). A schematic view of the 
programmed cell death pathway is shown in figure 1.
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Figure 1. Overview of the diverse pathways resulting in cell death. (Fulda and Vucic, 2012). The 
apoptotic pathway can be initiated either by external or internal stimuli. The extrinsic pathway is 
triggered by death ligands that bind to the cognate receptors and cause the recruitment of the 
DISC. This complex is responsible for the activation of the initiator caspases, which in turn cleave 
and switch on the effector caspases. The extrinsic can converge to the intrinsic pathway by 
involving the mitochondria through tBid. Mitochondria are in fact rich in both pro- and anti- 
apoptotic proteins, whose balance determines cell fate. When mitochondria undergo MOMP, the 
apoptosome is formed and activates the initiator caspase-9 amplifying the apoptotic process. On 
the other hand, the intrinsic pathway can be stimulated by internal insults such as oxidative
11
stress, DNA damage and endoplasmic reticulum stress.
Despite the many diverse events that can activate programmed cell death and the 
d ifferent mechanisms involved, the consequence of an apoptotic process is extremely 
similar in all settings. Caspases in fact proteolytically cleave a number of substrates 
including the nuclear lamin, inhibitor of caspase activated DNase (ICAD) and especially 
poly-ADP ribose polymerase (PARP), which, when cleaved, is universally exploited as a 
marker for accomplished apoptosis (Nosseri et al, 1994). Typical morphological changes 
follow  these biochemical events and include blebbing, cell contraction, nuclear 
fragmentation, chromatin condensation and chromosomal DNA fragmentation as shown 
in figure 2 (Degterev and Yuan, 2008). These features can be exploited to distinguish 
apoptotic cells by the ones dying from diverse types of death such as necrosis, 
necroptosis and autophagy (Degterev and Yuan, 2008; Galluzzi et al, 2015).
Figure 2. Morphological features of the apoptotic cells. Modified from Lamkanfi, 2011. When 
cells undergo an apoptotic process caused by activation of effector caspases, they are 
characterized by common morphological features such as DNA fragmentation, cell shrinkage, 
nuclear condensation and formation of apoptotic bodies. Cleavage PARP is commonly used as 
marker of apoptosis.
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2.1.2. Role of apoptosis in cancer
Due to its crucial role in the control of several aspects of cell life, aberrant regulation 
of apoptosis can lead to numerous diseases. In particular, pathological resistance to 
apoptosis is a hallmark of cancer cells (Hanahan and Weinberg, 2011; Igney and Krammer,
2002) and a main issue in clinical treatment (Fulda and Vucic, 2012), as traditional 
chemotherapeutic compounds work by inducing cancer cell death. Unfortunately, 
malignant cells develop many mechanisms which can prevent the apoptotic process at 
several steps, prolong cancer cell lifespan (Lehman et al, 1993) and protect cancer cells 
from an unfavorable environment (Fernandez et al, 2000) characterized by low oxygen 
content (Maione et al, 2012), nutrients and poorly vascularized. Increased resistance to 
death also results in genetic instability and the accumulation of gene mutations caused by 
aberrant cell cycle checkpoints (Bishop et al, 2000). This, together with the capacity to 
grow in the absence of growth factors and anchorage to the extracellular matrix (ECM), 
the ability to survive without hormones and evade from the immune surveillance, 
supports tumor progression and the spread of the primary tumors by metastasis to distal 
organs (Liu et al, 2006; Yawata et al, 1998) and at the same time frustrates cancer 
treatment.
As already mentioned, mitochondria play a pivotal role in the apoptosis pathway and 
it is therefore not surprising that cancer cells are characterized by aberrant expression of 
many apoptosis-related mitochondrial proteins especially belonging to the Bcl-2 family 
members (Figure 3). These can be divided in anti-apoptotic proteins (Bcl-2, Bcl-xL, Bcl-W, 
Mcl-1 and A l)  that display sequence homology in all BH1-BH4 domains, promote cell
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survival and are over-expressed in about half of the tumors (Tekedereli et al, 2013), and
pro-apoptotic factors. The latter are divided in multidomain, such as Bax and Bak, and 
BH3-only proteins, which are further divided in activators of Bax/Bak, i.e. Bim and Bid, 
and sensitizers that neutralize the effect o f the anti-apoptosis members (Lomonosova and 
Chinnadurai, 2008). This is the case, fo r example, of Bcl2-associated agonist of cell death 
(Bad), Bcl-2-interacting killer (Bik), Bcl-2-modifying factor (Bmf), NOXA, and Puma, which 
are often down-regulated or aberrantly controlled in tumors.
Anti-apoptotic kDa
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Figure 3. Members of the Bcl-2 family. (Taylor et al, 2008). Bcl-2 family members are divided in 
anti-apoptotic proteins characterized by the presence of all BH1-BH4 domains, pro-apoptotic 
multi-domain and BH3-only proteins. The latter are further divided in activators of Bax/Bak and 
sensitizers that neutralize the anti-apoptotic Bcl-2 members.
Receptors belonging to the TNF-R superfamily (TNF-RS) display an im portant function 
in cancer surveillance (Cretney et al, 2002; Finnberg et al, 2008; Grosse-Wilde et al, 2008), 
but are often de-regulated in cancer cells. Moreover, decoy receptors unable to transm it
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the death signal are also present and could compete with the other receptors, likely 
sequestering the ligands and therefore protecting cells from the pro-death stimuli 
(Riccioni et al, 2005). Interestingly, many cancer cells express normal and even higher 
levels of death receptors, but are still resistant to death-ligand activation of apoptosis. 
This observation suggests the presence of further downstream resistance mechanisms. 
This is the case, for example, of cellular FLICE (FADD-like IL-lp-converting enzyme)- 
inhibitory protein (c-FLIP) that displays high homology with caspase-8 and competes with 
it for the intracellular receptor domains (Xiao et al, 2002). This event has been shown to 
protect cells from the extrinsic apoptotic pathway because caspase-8 cannot be activated 
anymore even in the presence of high levels of TRAIL, TNF and Fas, and apoptosis is 
therefore hindered. Moreover, it has been demonstrated that tumors also develop the 
capacity to exploit the presence of death receptors using their signaling to enhance the 
cancer cell tumorigenic features (Chopra et al, 2013; Fingas et al, 2010; Ishimura et al, 
2006; Trauzold et al, 2006). For example, oncogenic KRAS has been shown to switch the 
pro-death stimulus of TRAIL-R into an inducer of cell migration and invasion (Hoogwater 
e ta l, 2010).
Importantly, tumor cells - through the mutation, amplification and over-expression of 
oncogenes - strongly activate some pro-survival pathways that can counterbalance the 
environmental or chemical pro-death signals. In accordance to this, the AKT/ 
phosphatidylinositol 4,5-bisphosphate 3-kinase (PI3K) and mitogen-activated protein 
kinases (MAPK) pathways are often triggered by activating mutations (Cancer Genome 
Atlas Network, 2012; Wood et al, 2007) or continue stimulation of up-stream receptors 
such as the epidermal growth factor (EGF)-receptor (EGFR) (Yarom and Jonker, 2011). In 
this way, cancer cells switch off the pro-death cascades and trans-activate several genes
that promote tumorigenesis.
The nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB) pathway is 
usually activated in tumors and controls the transcription of many genes that increase 
cancer aggressiveness and favor cell survival. Cytokines and chemokines (Shakhov et al, 
1990), cell adhesion molecules (Bunting et al, 2007), stress response genes (Xu et al,
2007), cell receptors (Thornburg and Raab-Traub, 2007), growth factors (Au et al, 2005), 
ligands (Saha et al, 2006) and regulators of apoptosis (Kreuz et al, 2001; Stehlik et al, 
1998; You et al, 1997) are all NF-kB targets. In our work, we focused on the inhibitor of 
apoptosis proteins (lAPs), which both regulate and are targets of the NF-kB pathway as 
well as prevent apoptosis.
2.2. The inhibitor of apoptosis protein (IAP) family
All human IAP members are characterized by the presence of a conserved region 
within their sequence with high homology to baculovirus proteins (Duckett et al, 1996). 
As baculoviruses exploit these domains to block caspases and thus prevent the apoptotic 
cascade triggered by the host cells (Crook et al, 1993), lAPs were originally considered 
mainly apoptosis negative regulators. Nonetheless, later works have clearly shown that 
this definition is extremely simplistic as lAPs control several cell features and mechanisms 
(Rothe et al, 1995), whilst their effect on caspases is only a prerogative of 2-3 members of 
the family and probably is important in limited settings (Choi et al, 2009; Eckelman et al, 
2006).
2.2.1. IAPs and their conserved domains
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So far, eight members of the IAP family have been identified (Srinivasula and Ashwell,
2008) according to the presence of one or three conserved baculoviral IAP repeat (BIR) 
domains of about 70 aminoacids (Figure 4), important for protein-protein interactions 
and homologous to the baculoviral domains. The BIR domains can be classified into two  
types, I and II, where only type II can interact to caspases, while type I is responsible for 
the binding with other proteins such as TNF-R-associated factor (TRAF) 1 and 2 (Gyrd- 
Hansen and Meier, 2010). Type II BIRs display a conserved groove that can be occupied by 
the IAP binding motif (IBM). This sequence is composed by a tetram er that is conserved 
not only in caspases, but also in the IAP antagonist second mitochondria-derived activator 
of caspases (SMAC) (Srinivasula et al, 2001). Among the lAPs, only X-linked IAP (XIAP) is 
considered a direct inhibitor of caspases and it has been shown to interact with caspase-9 
through its BIR3 domain, preventing its activation, whilst it sequesters both activated 
caspase-3 and -7 in the region containing the BIR2 and the upstream linker region (Chai et 
al, 2001; Datta et al, 2000; Riedl et al, 2001). However, the anti-caspase activity of other 
lAPs, such as cellular IAP1 (clAPl) and clAP2, is still controversial. Some groups suggested 
their capability to regulate caspases by favoring their degradation (Choi et al, 2009), but 
the evidence of a physical interaction with them is still lacking.
Besides the BIR domains, XIAP, clAPl, clAP2, Livin and insulin-like peptide 2 (ILP2) also 
display a really interesting new gene (RING) domain endowed with E3 ubiquitin-ligase 
activity. Through their RINGs, lAPs ubiquitinate numerous substrates (Cheung et al, 2008) 
causing not only their proteasome-dependent degradation, but also regulating several 
signaling cascades (Gerlach et al, 2011). Caspases themselves are substrates of some lAPs 
that could therefore block apoptosis also by reducing their levels (Choi et al, 2009; 
Gillissen et al, 2013; Suzuki et al, 2001). Finally, clAPl and clAP2 contain a caspase
17
recruitment domain (CARD), whose role has not been fully understood yet, but seems to 
be responsible fo r the inhibition of RING dimerization and prevention of clAPl activation 
(Lopez et al, 2011).
Mammals
Bruce/Apollon [~~~ T~~~ BIR i_____________________ ________________
i lp 2 n b Ir  I n r a m iT :2Jc
ML-IAP/lJvin j 1 BIR 1  I RING ,11 * * *
I.... BIU.
TT"ki BIR?.... . BIR3... ....... // ........ .........  i
....................................... ...........  . ...................
L  B1R1 . L I BIR? j  BIR3 , t CARD J L J M L J J
I.L t fn l _..i mkWfoad 1__ ...................... — J
................ -.............. ................. ............................  407
. i_J3£L!-------J — §)R2— i J -------------------------- H E H J
Caspase-3. -7 Caspase-9
Figure 4. Members of the IAP family and their conserved domains. Modified from Riedl and Shi, 
2004. The IAP family is constituted by 8 members, characterized by the presence of a conserved 
BIR domain.
2.2.2. The regulatory activity of IAPs in signaling cascades: MAPK and NF-kB
lAPs, and in particular clAPl and clAP2, have been described as components of the 
TNF-R complex where they contribute to TNF signaling (Haas et al, 2009). The TNF-R 
superfamily members are characterized by the presence of a cysteine rich domain (CRD), 
repeated up to six times in the extracellular region of these transmembrane receptors 
(Branschadel et al, 2010).
In the intracellular region, some of them (e.g. TNF-R1, CD95, TRAIL-R1 and TRAIL-R2) 
display the conserved death domains (DD) (Lavrik et al, 2005) necessary fo r death 
induction (Figure 5). Despite what the name would suggest, the death receptors such as 
TNF-R1 usually induce gene transcription more readily than cell death (Wajant et al, 
2003), by activating the MAPK pathway and stimulating the activity o f the transcription
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factors belonging to the NF-kB family (Varfolomeev et al, 2012). These pathways result in 
the rapid expression of several pro-survival proteins such as cFLIP (Kreuz et al, 2001) that 
counteract the possible killing effect of TNF. Accordingly, TNF often becomes toxic when 
cells are stimulated by this death ligand in the presence of inhibitors of protein 
translation (Autelli et al, 2005) such as cycloheximide (CFIX).
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Figure 5. Death ligands and death receptors. Modified from Lavrik et al, 2005. The death ligands 
bind to and stimulate several receptors, which are constituted by a cysteine-rich extracellular 
domain. The vast majority is also characterized by cytosolic death domains. The few receptors 
that lack the DD are unable to trigger an apoptotic event after ligand stimulation.
Mechanistically, when TNF binds to TNF-R1, the receptors form  a trim er and its 
intracellular portion recruits the receptor interacting protein 1 (RIP1) and TNF-R1- 
associated death domain (TRADD), which in turn serves as a scaffold fo r TRAF2 bound to 
clAPl and clAP2 (Emmerich et al, 2011; Walczak, 2011). The latter lAPs catalyze the 
formation of several ubiquitin chains that further stabilize the signaling receptor complex 
and allow the recruitment of the NF-kB essential modulator (NEMO) and inh ib ito r o f NF- 
kB (IkB) kinase (IKK), and TNF-associated kinase (TAK)/ transforming growth factor (TGF)- 
beta-activated kinase 1-binding protein (TAB) complexes, triggering the activation of
canonical NF-kB and MAPK pathways, respectively (Figure 6).
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Figure 6. Model of the tumor necrosis factor-receptor signaling complex. (Walczak, 2011). The 
binding of TNF to TNF-R1 causes the trimerization of the receptor that recruits RIP1 and TRADD 
through its intracellular portion. TRADD in turn serves as a scaffold for TRAF2 that is bound to 
clAPl and clAP2. The lAPs then catalyze the formation of several ubiquitin chains that stabilize the 
complex and allow the recruitment of NEMO and IKK, and TAK/TAB complexes, activating 
canonical NF-kB and MAPK pathways. clAPl and clAP2 also favor the recruitment the receptor of 
HOIL-1, HOIP and Sharpin which prolong NF-kB activation.
Another complex made of heme-oxidized IRP2 ubiquitin ligase 1 (HOIL-1), HOIL-1- 
interacting protein (HOIP) and SHARPIN, and called linear ubiquitin chain assembly 
complex (LUBAC) is recruited to the TNF-R1 complex thanks to the ubiquitin chains 
formed by clAPl and clAP2. This event is not essential fo r TNF-mediated signaling, but it 
strengthens and prolongs its effect (Gerlach et al, 2011; Ikeda et al, 2011; Tokunaga et al, 
2011).
2.2.3. NF-kB: canonical and non-canonical pathways
As described above, lAPs regulate various signaling pathways tha t result in the 
transactivation of a plethora of genes. Accordingly, XIAP, clAPl and clAP2 regulate the
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activity of the transcription factors belonging to the NF-kB pathway (Zarnegar et ol, 2008). 
Five members of this family are known: RelA (p65), RelB, CRel, NF-kBl (p l05 /p 50) and 
NF-kB2 (p l00 /p52). NF-kBl and NF-kB2 do not contain a transactivation domain and 
therefore need to interact with the other members of this family to regulate the 
transcription of target genes. The NF-kB pathway is generally divided into "canonical" and 
"non-canonical" depending on the stimulus that causes the initial trigger and the 
mediators involved (Perkins, 2007).
The best characterized inducer of the canonical pathways is TNF that, upon binding to 
the TNF-R1, mediates the formation of complex I made of TRADD, TRAF2, TRAF5, clAPl 
and clAP2 (Emmerich et al, 2011). In this setting, clAPl-mediated ubiquitylation of the 
diverse components, in particular of RIP1 (Bertrand et al, 2008), allows the recruitment of 
the LUBAC, of the TAK1/TAB2/TAB3 and IKKy/IKKa/IKKp complexes. IKKp is responsible 
for the ubiquitination and degradation of the IkB resulting in the release of NF-kB, which 
can then move from the cytosol to the nucleus where it trans-activates the target genes. 
In this process, clAPl and clAP2 are fundamental for the up-stream activation of this 
pathway and consequently protect cells from the cytotoxic effect of TNF.
The non-canonical NF-kB pathway is mainly stimulated by CD40L, B cell activating 
factor (BAFF) and (TNF-related weak inducer of apoptosis) TWEAK, and relies on the 
apical NF-kB inducing kinase (NIK), which in turn activates IKKa (Demchenko et al, 2010; 
Razani et al, 2010). IKKa then is responsible for NF-kB2 phosphorylation that causes its 
ubiquitination and proteasome-mediated processing into the mature p52 form. 
Importantly, NIK levels are constitutively kept low by continuous ubiquitination by clAPl 
and clAP2 (Zarnegar et al, 2008), with consequent degradation. Contrary to the canonical
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one, this pathway is therefore inhibited by clAPl and clAP2 (Figure 7).
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Figure 7. Schematic representation of the canonical and non-canonical NF-kB pathways. (Fulda 
and Vucic, 2012). The NF-kB pathway is usually divided in canonical and non-canonical. The 
canonical one is stimulated by several death ligands such as TNF and is promoted by the assembly 
of a cytosolic complex on the receptors. TRADD, RIP1 and TRAF2 are recruited and allow the 
activity of clAPl and 2, which in turn produce a net of ubiquitins that stabilize the complex and 
allow the signaling mediated by NEMO/IKKs which phosphorylate NF-kBl, which is then activated 
and moves to the nucleus. Here, it trans-activate the target genes by interacting with other 
members of the NF-kB family. The involvement of the LUBAC can enhance and stabilize this 
signaling pathway. The non-canonical pathway is activated by other ligands such as BAFF, CD40L 
and TWEAK, and it is promoted by the apical kinase NIK, which phosphorylates and activates IKKa. 
The expression of the target genes is mainly controlled by p52 and RelB.
2.2.4. IAPs in the regulation of immunity
The first response of the immune system to infection and tissue injury is mediated by 
the innate immune pattern recognition receptors (PRRs) superfamily members, which
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sense various stress signals and activate the inflammatory response. In fact, these 
receptors detect the presence of conserved microbial components and activate the MAPK 
and NF-kB signaling pathways, which lead to the transcription of various mediators of 
inflammation (e.g. cytokines, chemokines, adhesion molecules, acute phase proteins and 
antimicrobial peptides). clAPl, clAP2 and XIAP, by their ubiquitinating activity, have been 
shown to regulate these pathways both at the receptor and downstream levels, thus 
regulating nucleotide-binding oligomerization domain-containing protein (N O D )l/2 , toll­
like receptors (TLRs), retinoic acid-inducible gene 1 (RIG-1) and pro-inflammatory 
cytokines signaling, including TNF (Estornes and Bertrand, 2014). Of note, at the site of 
infection, TNF further modulates the inflammatory response by stimulating the 
production of other cytokines and chemokines and cells of the immune system.
2.3. lAPs and their role in cancer
Due to their capability to promote resistance against cell death and control many 
survival pathways, it is not surprising that several cancer types have been reported to 
aberrantly express lAPs, which could also play a role in patients' prognosis (Che et ol, 
2012; Hundsdoerfer et ol, 2010; Miura et ol, 2011; Yang et ol, 2012). lAPs are therefore 
considered potential targets in clinical treatment and much effort has been put into the 
development of lAPs-antagonizing small compounds (Fulda, 2014b).
2.3.1. Aberrant expression of IAPs in cancer cells
lAPs are over-expressed in many cancer types, where they often play a role in 
progression and resistance to therapy, and in some instances affect prognosis. This is the 
case, for example, of acute myeloid leukemia (AML), in which lower XIAP levels
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correlate with longer survival (Tamm et al, 2000). In contrast, other works showed no 
correlation between XIAP expression and remission rate and overall survival (Carter et al,
2003). Indeed, over-expression of both XIAP and survivin was reported to be associated 
with a particularly poor prognostic impact and the same conclusion was made by a three- 
gene expression signature including clAP2 that accurately predict poor overall survival 
(Ibrahim et al, 2012). Moreover, high levels of XIAP, clAPl and clAP2 are found in chronic 
myeloid leukemia (CML), while melanoma-lAP (ML-IAP) and XIAP high levels have been 
related to poor prognosis and worse response to therapy in acute lymphocytic leukemia 
(ALL) (Fulda, 2014a).
Importantly, many tumor types often bear the Ilq 2 1 -q 2 3  amplification, in which 
both clAPl and clAP2 are found. This is the case, for example, of esophageal carcinoma, 
hepatocellular carcinoma, cervical cancer, liver cancer, medulloblastoma, glioblastoma, 
non-small-cell lung cancer (NSCLC), small cell lung cancer and pancreatic cancer in which 
these lAPs are therefore expressed at high levels. In clear contrast, SMAC and XIAP- 
associated factor 1 (XAF-1), two well-characterized lAP-antagonizing proteins, are often 
down-regulated in cancer and their levels inversely correlate with prognosis (Fulda, 
2014a).
2.3.2. Mutations affecting members of the IAP family
Despite the increased expression of lAPs due to gene amplification, active trans­
activation and post-translational events, the lAPs are sometimes found mutated in 
tumors. For example, the (Il;18)(q21;q21) translocation occurs frequently in mucosa- 
associated lymphoid tissue (MALT) lymphoma. This event results in the fusion of the BIR 
domains of clAP2 with the paracaspase MALT1 (Rosebeck et al, 2011). The CIAP2-MALT1
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fusion protein constitutively activates the NF-kB signaling pathway in this type of tumor 
(Darding et al, 2011). Moreover, in multiple myeloma (M M ), a tumor type characterized 
almost always by the aberrant activation of the NF-kB pathway (Annunziata et al, 2007; 
Demchenko et al, 2010), clAPl and clAP2 are often deleted, resulting in the constitutive 
activation of the non-canonical NF-kB pathway through stabilization of NIK.
2.3.3. Controlling migration and invasion: the effect on metastasis
lAPs are therefore responsible for the increased tumor aggressiveness by protecting 
cancer cells from apoptosis, modulating the microenvironment through the expression of 
cytokines and aberrantly increasing the activation of many pro-survival pathways. 
Altogether, these mechanisms promote tumor growth in harsh conditions and hamper 
therapy efficacy. Moreover, growing evidence shows that lAPs control migration, invasion 
and metastasis (Mehrotra et al, 2010), even if data are still controversial. On the one 
hand, XIAP has been reported to increase cell motility in a caspase-independent manner 
by physical interaction via its RING domain with the Rho guanosine diphosphate (GDP) 
dissociation inhibitor (RhoGDI). Wild type, but not H467A-mutated, XIAP promotes cell 
migration and it is associated to reduced RhoGDI activity as well as enhanced 
polymerization of actin (Liu et al, 2012). XIAP was reported to modulate also the activities 
of Raf-1, focal adhesion kinase (FAK) and FAK-related non kinase, stabilizing the a(5)- 
integrin-associated focal adhesion complex (Kim et al, 2010). Finally, XIAP protects cells 
from anoikis and, in complex with survivin, promotes cancer cell invasion and eventually 
metastasis by engaging an NF-kB-dependent expression of fibronectin (Mehrotra et al, 
2010), without the morphological features of epithelial to mesenchymal transition (EMT).
Furthermore, high levels of clAPl have been related to increased motility, even if in
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normal conditions its CARD domain inhibits cell migration by preventing RING 
dimerization (Lopez et al, 2011). Finally, the targeting of IAP proteins by means of specific 
compounds was shown to interfere with TRAIL-mediated invasion and metastasis in a 
cholangiocarcinoma model (Fingas et al, 2010).
In clear contrast, a number of other studies support the notion that lAPs can even 
suppress migration and invasion. Accordingly, XIAP, clAPl, clAP2 and ML-IAP were 
reported to cause the degradation of Raf-1 (Dogan et al, 2008) and Ras related C3 
botulinum toxin substrate (Racl), thereby modulating the MAPK signaling pathway and 
cell migration. Consistently, down-regulation of XIAP or clAPl resulted in stabilization of 
Racl and increased cell motility associated with elongated morphology (Oberoi et al, 
2011; Tchoghandjian et al, 2013).
2.4. Targeting lAPs: Smac mimetics
The IAP family members play an important role in cancer progression and treatm ent 
failure and are therefore considered an attractive target for cancer chemotherapy (Fulda, 
2014b). The observation that the XIAP natural antagonist, SMAC, interacts with the BIR 
domains of the lAPs through the defined region IBM inspired a class of protein-protein 
interaction (PPI) inhibitors called Smac mimetics (SMs), designed to target especially the 
BIR3 of XIAP (Figure 8).
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Figure 8. X-Ray structure of XIAP BIR3 dimer in complex with SM83. Modified from Cossu et al, 
2012. SMs target the BIR domain of XIAP by interacting with a conserved groove present in the 
BIR domains of several lAPs.
2.4.1. A physiological (X)IAP natural antagonist: SMAC
SMAC is a pro-apoptotic protein, which is usually localized w ithin the mitochondrial 
membranes. Upon an apoptotic stimulus, SMAC is released w ith cytochrome c into the 
cytosol (Du et al, 2000) where it undergoes maturation through dimerization and 
cleavage of the N-terminal region of 55 aminoacids, which allows the exposures of the 
tetrapeptide IBM constituted by the alanine-valine-proline-isoleucine (AVPI) sequence 
(Liu et al, 2000; Wu et al, 2000). This region can interact w ith the groove present in the 
BIR domains of the lAPs and in particular the BIR3 (Srinivasula et al, 2001), and to a lesser 
extent the BIR2, of XIAP, causing the displacement of caspase-3, -7 and -9, and therefore 
counteracting the anti-apoptotic function o f the lAPs. Moreover, SMs were shown to 
reduce the levels of clAPl and clAP2 (Petersen et al, 2007; Varfolomeev et al, 2007; Vince 
et al, 2007), but neither of XIAP nor Livin, by inducing the ir auto-ubiquitination followed 
by proteasomal-dependent degradation. Interestingly, SMAC also caused XIAP
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ubiquitination, without affecting its levels (Yang and Du, 2004).
2.4.2. Targeting XIAP BIRs with SMAC-mimicking peptidic compounds
In an attempt to mimic the pro-apoptotic activity of SMAC, several groups have 
synthesized small synthetic peptides covering the first 7-8 aminoacids of the N-terminal 
region of matured SMAC (Fulda et al, 2002). These molecules were fused to cell- 
permeabilizing peptides and showed to be able to bypass the mitochondrial blockage and 
sensitize either in vitro and in vivo the cancer cells to TRAIL or chemotherapeutic drug 
treatments such as cisplatin, taxol, etoposide, paclitaxel and doxorubicin (Arnt et al, 2002; 
Yang et al, 2003). Later works have shown that the first 4 aminoacids are necessary and 
sufficient for the interaction with the BIR domains and that dimeric compounds are much 
more effective than the monomeric in targeting lAPs. Moreover, the aminoacid sequence 
was modified to increase the affinity towards the BIR domains (Li et al, 2004), focusing in 
particular on the BIR3 of XIAP. The resulting peptides interact with recombinant XIAP and 
displace caspases, and induce cell death in a caspase-dependent manner especially in 
combination with TRAIL.
2.4.3. Chemical modification of SMs: non-peptidic molecules
Having proved that small peptides mimicking the N-terminal region of SMAC can 
efficiently target lAPs, several groups modified the original peptidic sequence of the IBM 
to enhance the affinity for the target, permeability and pharmacological properties (Oost 
et al, 2004; Sun et al, 2004; Sun et al, 2006). For example, valine and proline were fused 
to form a scaffold constituted by a ring with increased rigidity (Sun et al, 2007), the 
alanine was modified by methylation to increase permeability (Sun et al, 2006) and 
several modifications were introduced to increase the molecular stability while containing
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the molecular weight. Importantly, two classes of compounds were designed, monomeric 
(Seneci et al, 2009) and dimeric (Lecis et al, 2012), the latter synthesized by the chemical 
tethering of two AVPI-mimicking SMs.
Even though monomeric SMs were thought to be more "drug-like” due to the ir low 
molecular weight and thus respecting the "Lipinski's rules", dimeric SMs have been 
shown to be much more effective both in vitro and in vivo, killing sensitive cancer cells 
w ith much lower EC50s (Fulda, 2014b). The reason for this enhanced activity has not been 
fully understood yet, but it is speculated that dimeric compounds might interact 
simultaneously w ith two BIR domains w ith in the same XIAP molecule (Cossu et al, 2009b; 
Cossu et al, 2012), therefore stabilizing the interaction with the target and displacing 
caspases more efficiently. Furthermore, dimeric compounds are more effective in causing 
the depletion of clAPl and clAP2 (Varfolomeev et al, 2007). The vast m ajority o f IAP- 
antagonizing peptide-mimetics have been designed to target XIAP BIR3 (Figure 9), but in 
few cases combinatorial library screenings were performed to select BIR2-specific 
compounds that showed in vitro  and in vivo activity (Schimmer et al, 2004).
Figure 9. Model of SM83 interaction with the BIR3 groove of XIAP. Modified from Cossu et al, 
2012. One residue of the dimeric SM83 compound enters the groove in the BIR domain of XIAP.
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2.4.4. Mechanism of action of SM
As already mentioned, SMs were specifically designed to target XIAP and displace 
caspases, thus favoring the apoptotic cascade triggered by other compounds. SMs were 
therefore considered essentially as cancer cell sensitizers to chemotherapeutic drugs. 
Surprisingly, about 10-15% of cancer cell lines are efficiently killed in vitro by SMs as 
standalones (Petersen et al, 2007) with low nanomolar EC50s, depending on the 
molecules used. In 2007, three independent works showed that the cytotoxic effect of 
the SMs in monotherapy does not depend on their activity against XIAP, but it stems from  
a rapid SM-dependent depletion of clAPl and clAP2 and subsequent autocrine TNF- 
mediated killing (Petersen et al, 2007; Varfolomeev et al, 2007; Vince et al, 2007). It was 
shown that clAPl and clAP2 undergo a self-ubiquitination event after administration of 
different SMs, and this is followed by a proteasome-dependent degradation in a m atter 
of a few minutes. SM interaction with clAPl and clAP2 causes a conformational change 
(Figure 10) that allows clAPl dimerization and the exposure of the RING domain (Dueber 
et al, 2011; Feltham et al, 2011), which is normally inhibited by the CARD domain (Lopez 
et al, 2011). This event occurs in all treated cells, but in sensitive cancer cells it is 
sufficient to trigger a TNF-dependent apoptosis event. In fact, some cancer cell lines 
constitutively express high levels of TNF, which, after SM administration, is further 
increased. In fact, TNF is a target of the NF-kB pathway that, as already described, is 
regulated by clAPl and clAP2. When these lAPs are depleted, NIK is stabilized and 
activates the non-canonical NF-kB pathways, causing a further increase of TNF expression 
(Varfolomeev et al, 2007). This ligand then stimulates the TNF receptors, which, in 
absence of clAPl and clAP2, are no longer able to activate the NF-kB and MAPK pro­
survival pathways and therefore recruit the formation of complex II, in which caspase-8 is
activated (Gaither et al, 2007). Studies on sensitive cell lines, such as the breast 
carcinoma MDA-MB231, the ovarian cancer SK0V3 and the rabdomyosarcoma Kym-1 
demonstrated that caspase-8 silencing, IKK inhibition or blockage of TNF de novo 
expression and secretion can prevent SM toxicity (Varfolomeev et al, 2007).
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Figure 10. Model describing the conformational modification that occurs when clAPl is 
activated. (Lopez et al, 2011). The RING domain of clAPl is usually blocked through an intra­
molecular interaction with the CARD domain. When a SM hits the BIR domain of clAPl, it causes a 
rapid morphological modification that allows the dimerization of the RING with the same domain 
of another clAPl molecule, and its exposure and activation.
The majority o f cell lines do not respond to SM administration in monotherapy and 
the reason fo r this resistance is not fully understood. It has been demonstrated that other 
pathways, such as the one controlled by PI3K can confer resistance to SM treatm ent and 
that cells can also acquire resistance (Petersen et al, 2010). In fact, when both c lAP l and 
clAP2 are depleted and the NF-kB pathway is activated, clAP2 rebounds quickly because it 
is a target of the non-canonical NF-kB pathway. Importantly, upon SM treatm ent the 
degradation of clAP2 was shown to be clAPl-dependent (Darding et al, 2011). Therefore, 
after an initial effect on the clAPs, clAP2 is quickly replaced by newly-synthesized protein 
and, due to the absence of clAPl, cannot be degraded anymore, conferring resistance 
and unresponsiveness to SMs (Darding et al, 2011). In fact, although less effective in
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controlling some molecular pathways, clAP2 however displays some common features 
with clAPl and redundant activities and its presence is sufficient to confer resistance to 
SM treatment.
Importantly, also cells that are extremely sensitive to SMs in vitro, often acquire 
resistance in vivo. Although this event has not been fully understood yet, the expression 
levels of leucine-rich repeats and immunoglobulin-like domains protein 1 (LRIG-1) could 
mediate it, at least in part (Bai et al, 2012). Interestingly, also the opposite effect can be 
observed in vivo, i.e. cells refractory to SM treatm ent in vitro become partially sensitive in 
vivo and SM administration results in the inhibition of primary tumor growth in animal 
xenografts (Lecis et al, 2013). Even in this case, the precise mechanisms have not been 
dissected, but it is likely that the cytokines expressed by the microenvironment might 
interact with the SMs becoming toxic for the tumor.
2.4.5. Regulation of the ripoptosome: decision between apoptosis and 
necroptosis
Exploiting SM-dependent depletion of clAPl and clAP2, two independent groups 
described a novel platform, called ripoptosome (Feoktistova et al, 2011; Tenev et al, 
2011), constituted by RIP1, Fas-associated protein with death domain (FADD), and 
caspase-8, which activates cell death independently of death receptor activation, contrary 
to complex II. The ripoptosome is inhibited by clAPl, clAP2 and cFLIP and can activate 
both caspase-dependent and -independent cell death (Vince et al, 2012). The latter is 
usually referred to as necroptosis and relies on RIP3 and mixed-lineage kinase domain­
like protein (MLKL), and RIP1 kinase activity as its inhibitor necrostatin-1 can prevent it. 
Ripoptosome, depending on the cellular settings, can activate both apoptosis and
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necroptosis, which mutually control each other (Dickens et al, 2012b; Oberst et al, 2011). 
Accordingly, chemical inhibition of caspases and in particular of caspase-8 can strongly 
activate a necroptotic event (Wu et al, 2011), especially in cells such as the macrophages 
(Muller-Sienerth et al, 2011). In fact, caspase-8 and RIP1 mutually inhibit each other as 
genetically demonstrated by the means of knock-out mice (Dillon et al, 2014).
2.4.6. Hybrid SMs
Dimeric Smac mimetics are usually synthesized as homodimeric compounds in which 
the same monomer is tethered by a chemical linker resulting in a symmetric molecule. In 
a few cases, molecules were modified in order to link the two monomers at different 
positions, therefore forming asymmetric molecules (Servida et al, 2010). Further studies 
have also been undertaken to establish the effect of different linkers on the efficacy of 
these compounds (Lecis et al, 2012).
Moreover, we and others have also produced heterodimeric compounds with the aim 
to link two different monomeric SMs, one highly affine for the BIR3 and the other with 
increased affinity for BIR2, in an attempt to stabilize the intramolecular interaction with 
two different BIR domains. Furthermore, to exploit the ubiquitinase activity of lAPs and 
target specific proteins to proteasomal degradation, SM compounds were also linked to 
all-trans retinoic acid (ATRA), a cellular retinoic acid binding protein (CRABP-II) ligand, in 
order to cause the ubiquitination and down-regulation of this receptor and result in the 
inhibition of cancer cell proliferation (Itoh et al, 2012). A similar approach was used to 
increase the delivery of lAP-antagonizing compounds to cancer cells. In this case, 
monomeric SMs have been linked to the sigma-2 ligand to target pancreatic and ovarian 
tumor (Garg et al, 2014; Hashim et al, 2014; Zeng et al, 2013), in which the sigma-2
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receptor is over-expressed, or to integrin inhibitors. In both circumstances, the aim was 
to enhance the molecular uptake of the SM (Mingozzi et al, 2014). For this purpose, we 
recently described the conjugation of SMs with nano-conjugates (Seneci et al, 2014). 
Finally, in an attem pt to enhance the cytotoxic activity, we have also linked a monomeric 
SM to procaspase activating compound (PAC)-l, a Zn chelator described as a direct 
activator of caspase-3 (our unpublished data). The idea is therefore to simultaneously 
activate the apoptotic machinery by direct activation of caspases and simultaneously 
prevent their inhibition by the lAPs.
2.5. SMs in anti-cancer treatm ent
Given the crucial role of lAPs in favoring aggressiveness of cancer and resistance to 
therapy, the discovery of SMAC-based compounds raised great enthusiasm in cancer 
therapy. As already mentioned SMs are very rarely cytotoxic in monotherapy and have 
therefore been tested in combination with a plethora of other drugs (Greer et al, 2011). 
Despite the fact that preliminary pre-clinical experiments showed little toxicity for non­
transformed cells, in vivo experiments and the first clinical trials revealed some side- 
effects and unwanted toxicity caused especially by immune system activation and 
cytokine production (Amaravadi et al, 2011; Infante et al, 2014; Sikic et al, 2011). Much 
effort is thus currently being made to comprehend the mechanisms responsible for this 
toxicity and to possibly modify the molecules in order to prevent the undesired effects.
2.5.1. SMs in combination therapy
Since the description of the first SMs, they have been shown to enhance the activity 
of diverse compounds and potently activate apoptosis by blocking lAPs. Due to the
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crucial role of lAPs in preventing TRAIL-mediated toxicity, the SMs were proposed 
particularly in combination with the death ligands belonging to the TNF family (Dai et al, 
2009; Lecis et al, 2010; Lu et al, 2011; Metwalli et al, 2010; Vogler et al, 2009). Whereas 
TNF and FasL are not considered good candidates for clinical purposes due to systemic 
toxicity and acute hepatotoxicity respectively, great expectation was raised on the 
employment of TRAIL In melanoma (Lecis et al, 2010), head and neck (Raulf et al, 2014), 
breast (Foster et al, 2009), pancreatic (Vogler et al, 2009) and many other cancer models, 
genetic and chemical inhibition of XIAP was shown to sensitize cells to TRAIL treatment, in 
some cases also employing mouse xenografts.
2.5.1.2. TRAIL and its application in anti-cancer treatment
TRAIL is a ligand of the TNF family, which can both activate apoptosis and trigger 
various signaling pathways by interacting with its cognate receptors TRAIL-Rl/death  
receptor (DR4), TRAIL-R2/DR5. Moreover, three decoy receptors have been described 
TRAIL-R3/decoy receptor (DcRl), TRAIL-R4/DcR2 and the soluble osteoprotegerin (OPN) 
that bind TRAIL ligand but are unable to trigger apoptosis (Walczak, 2011). TRAIL seems to 
play a physiological role in controlling cancer, as knock-out (KO) of TRAIL-R promotes 
susceptibility to tumor and metastasis development (Cretney et al, 2002; Grosse-Wilde et 
al, 2008). TRAIL has been shown to kill cancer cells whilst sparing normal tissues (Walczak 
et al, 1999). Nonetheless, later work and the first clinical trials dampened the initial 
enthusiasm by reporting that TRAIL-based treatments have a very modest effect in curing 
tumors (Falschlehner et al, 2009; Yang et al, 2010).
Several hypotheses have been made to explain the limited efficacy in vivo. The first is 
that TRAIL has an extremely short half-life and it is therefore rapidly eliminated (Wang,
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2008); the reaching of clinically active concentrations is therefore extremely arduous. 
Furthermore, soluble TRAIL (sTRAIL) seems to efficiently activate only the TRAIL-R1 
(Muhlenbeck et al, 2000) and therefore its efficacy is reduced when this receptor is poorly 
expressed in cancer cells. To overcome these issues, many approaches have been 
proposed such as the design of modified TRAIL molecules or the use of agonist 
antibodies. First of all, TRAIL has been cloned with tags that increase its stability and allow 
its trimerization such as leucine zipper-TRAIL (IzTRAIL) (Ganten et al, 2004; Walczak et al, 
1997) and isoleucine zipper TRAIL (izTRAIL) (Ganten et al, 2006). Stabilized complexes of 
ligands can in fact enhance the activation of the receptors both in vitro and in vivo. 
Moreover, several humanized agonist antibodies against TRAIL-R1 or TRAIL-R2 are 
currently tested in phase I/ll clinical trials advanced solid tumors (Falschlehner et al,
2009).
Another method to increase the efficacy of TRAIL consists in the exploitation of a 
gene therapy-based approach in which cells are engineered to express a membrane- 
bound form of TRAIL (mTRAIL). mTRAIL can activate both TRAIL-R1 and TRAIL-R2 
(Muhlenbeck et al, 2000), and due to its continuous expression by mTRAIL-bearing cells, it 
results in increased stability and concentration within the tumor, where these cells seem 
to accumulate. So far, mesenchymal stem cells transduced with lentiviruses bearing the 
sequence for mTRAIL (Luetzkendorf et al, 2010) and CD34+ transfected with adenoviruses 
have been employed (Carlo-Stella et al, 2006). These approaches demonstrated that 
mTRAIL reduces growth of primary colon cancer and multiple myeloma in vivo (Lavazza et 
al, 2010), and inhibit spontaneous formation of lung cancer in a breast xenograft model 
(Rossini et al, 2012). Interestingly, and in agreement with a recent paper describing a 
soluble trimerized version of TRAIL, the effect of mTRAIL seems more directed at tumor-
associated vasculature than at the tumor itself (Wilson et al, 2012). The reason has not 
been fully understood yet and the expression of TRAIL-Rs does not seem to be correlated 
with cell sensitivity to TRAIL treatment. In fact, TRAIL-Rs are expressed also in normal 
tissues and tumor cells, but these cells are not killed by TRAIL treatment. Nonetheless, 
the destruction of the neo-vasculature reduces the growth of the primary tumors and 
causes the formation of large necrotic areas within the solid tumors (Lavazza et al, 2010; 
Rossini et al, 2012).
TRAIL and receptor agonists are therefore currently tested in clinical trials in 
combination with diverse compounds, e.g. paclitaxel, carboplatin, gemcitabine, cisplatin, 
bortezomib, pemetrexed, doxorubicin, FOLFIRI, rituximab, avastin and capacitabine to try 
to increase their efficacy (Falschlehner et al, 2009). A high percentage of patients showed 
partial response and stable disease, a promising result given that most tumor patients 
enrolled in these clinical studies had already been unsuccessfully treated.
2.5.1.3. SMs in association to traditional chemotherapy
Besides having been tested in combination with TRAIL, SMs have also been combined 
with traditional chemotherapeutic drugs (Probst et al, 2010) and radiation, and shown to 
induce apoptotic and also necroptotic death (Laukens et al, 2011; Steinhart et al, 2013). 
Recent reports have shown that SMAC can induce an inflammatory type of tum or cell 
death (Emeagi et al, 2012) and SMs cancer cell killing in monotherapy is known to be TNF- 
dependent. Nonetheless, the role of the cytokines and in particular of TNF in combination 
therapy is still a matter of debate as there are many reports showing that the 
SM/chemotherapy combination kills cells in a NF-kB (Berger et al, 2011; Stadel et al, 
2011) and TNF-dependent manner (Laukens et al, 2011; Probst et al, 2010), while others
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present a diametrically opposite conclusion (Allensworth et al, 2013; Eschenburg et al, 
2012; Greer et al, 2011).
Despite the diverse speculated mechanisms of activity, all these works agreed that 
SMs could increase the in vitro activity of many classes of compounds. In vivo, as already 
mentioned, SM treatm ent could take advantage of cytokines and TNF produced by the 
host (Lecis et al, 2013). Accordingly, SMs have been shown to synergize with compounds 
activating the innate immunity (Jinesh et al, 2012), such as 5' cytosine-phospho-guanine 
(CpG) and polyinosinic-polycytidylic acid/poly(l:C), causing a "perfect cytokine storm" 
(Beug et al, 2014).
2.5.2. Testing SMs in clinical trials
An enormous amount of pre-clinical data supports the employment of SMs in 
combination therapy and hence five different IAP antagonists combined with paclitaxel, 
daunorubicin, cytarabine, or gemcitabine are currently tested in phase I/ll clinical trials 
for solid and hematologic malignancies. Monovalent GDC-0917/CUDC-427 (Genentech, 
Inc./Curis), LCL161 (Novartis) and AT-406 (Ascenta Therapeutics) can be administered 
orally, while bivalent compounds such as HGS1029 (Aegera Therapeutics/Human Genome 
Sciences) and TL32711 (TetraLogic Pharmaceuticals) require intravenous administration. 
Completed phase I trial for safety and pharmacologic properties demonstrated that SMs 
are usually well tolerated, even if inducing an increase of cytokines in patients (Fulda, 
2014b).
Recently, the clinical trial testing of CUDC-427 was suspended due to the death of a 
patient because of liver failure. Even though the patient's treatm ent had been 
discontinued one month before death and that no sign of liver toxicity was found in other
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patients making this event most likely not attributable to SM treatm ent, nonetheless it 
caused alarm regarding the possible risks of SMs. In line with this, it has been recently 
shown that SM-triggered cytokine release stems from the inhibition of XIAP and, to avoid 
this, the new compound Birinapant has been designed with reduced affinity for XIAP, but 
still conserving the same effect on clAPl and clAP2. The efficacy of this compound was 
shown to be independent of TNF and more tolerability was suggested (Allensworth et al, 
2013; Condon et al, 2014), in agreement with a role of XIAP inhibition in cytokine toxicity 
(Wong et al, 2014).
Compound Combination Cancer type Status Phase I/ll Trial
LCL-161 None Solid tumors Completed Phase 1 NCT01098838
LCL-161 Paclitaxel Solid tunors Recruiting Phase 1 NCT01240655
LCL-161 Paditaxei Breast cancer Recruiting Phase II NCT01617668
AT-406 None Solid tumors, lymphomas Recruiting Phase 1 NCT01078649
AT-406 Daunorublcin, cytarabine AML Terminated Phase 1 NCT01265199
HSG1029 None Solid tumors Completed Phase 1 NCT00708006
HSG1029 None Lymphoid malignancies Terminated Phase 1 NCT01013818
TL32711 None Solid tumors Active, not recruiting Phase I/ll NCT01188499
7L32711 GEM Solid tumors Recruiting Phase 1 NCT01573780
TL32711 None Solid tumois, lymphomas Completed Phase 1 NCT00993239
7L32711 None AML Recruiting Phase I/ll NCT01486784
7L32711 5-Aza MDS Not yet recruiting Phase I/ll NCT01828346
TL32711 None Ovarian, peritoneal cancer Recruiting Phase II NCT01681368
GDC-0152 None Solid tumois Completed Phase 1 NCT00977067
CUDC-427 None Solid tumors, lymphomas Recruiting Phase 1 NCT01908413
Abbreviations: AML, acute myeloid leukemia; GEM, gemcltabine; MDS, myelodysplastic syndrome; 5-Aza, 5-azacytidine.
Table 1. Clinical trials with IAP antagonists. (Fulda, 2014b). 5 different SMs are being currently 
tested in several clinical trials for solid and hematological malignancies.
2.6. Cancer and oncogenes
It has already been mentioned that lAPs are aberrantly expressed and even mutated 
in a number of different cancer types. Multiple myeloma for example is known not be 
particularly affected by mutations involving the NF-kB pathway (Annunziata et al, 2007; 
Keats et al, 2007), lAPs included. Nonetheless, also the other cancer types are all variably 
characterized by aberrant IAP expression, suggesting a general mechanism of cancer 
resistance more than a peculiar feature of a specific tumor type. In line with this
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observation, SM efficacy is not associated to a particular cancer and this class of 
compounds has therefore been employed in models of many different malignancies 
(Fulda and Vucic, 2012). Furthermore, cancer cells sensitive to SMs in monotherapy 
belong to various cancer types and, although the triple negative breast carcinoma cell line 
MDA-MB231 is probably the most employed to test the efficacy of the lAP-antagonizing 
molecules, also ovarian cancer SKOV3, rabdomyosarcoma Kyml and several lung cancer 
cell lines have been shown to be killed by SMs as standalones (Varfolomeev et al, 2007). 
Therefore, in our work, we did not focus on a particular cancer type, but we employed in 
vitro and in vivo models deriving from several different tumors and normal tissues as 
controls along with premalignant models. When possible, to study the effect of a specific 
mutation on drug resistance, we took advantage of isogenic pairs of cell lines with knock- 
in (Kl) and knock-out mutations in the oncogene of interest. This technique constitutes a 
powerful tool to study the effect of a specific mutation independently from the genetic 
environment (Arena et al, 2007) and is therefore exploited to study the capacity of a gene 
to affect drug resistance (Di Nicolantonio et al, 2008), gene expression, aggressiveness, 
and to identify drugs particularly effective in a certain genetic setting. This is the case, for 
example, of the so-called "synthetic lethality", which renders cancer cells bearing a 
particular mutation sensitive (Farmer et al, 2005), while normal wild type cells remain 
completely resistant to a drug.
2.6.1. Exploiting the synthetic lethal effect in pharmacology
Most of the chemotherapeutic agents currently used in clinics have low therapeutic 
indices and therefore narrow therapeutic windows. This results in high toxicity for 
patients when effective anti-tumor concentrations are reached or poor efficacy when the 
concentration of the drug is maintained low due to excessive toxicity. The perfect drug
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should in theory target a specific protein or a pathway essential only for cancer cell 
viability and not present or not essential in normal cells. This is the case, for example, of 
fusion proteins that sometimes are caused by chromosome translocations (Rosebeck et 
al, 2011) and result in the expression of a protein not expressed in normal cells and so 
representing a potential specific target. Unfortunately, this event is infrequent and rarely 
provides a drug-able target for therapy. On the contrary, it is more recurrent that a 
particular protein becomes more important in cancer cells compared to normal cells and 
could therefore be exploited as a pharmacological target (Farmer et al, 2005). Sometimes, 
cancer cells depend so much on a protein that this becomes essential, while it is 
dispensable in normal cells. This phenomenon is often referred to oncogene (Roulston et 
al, 2013) and non-oncogene addiction (Chaturvedi et al, 2011).
An opportunity in cancer treatm ent is also represented by the so-called synthetic 
lethality. Two genes are considered synthetic lethal when the mutation of either gene 
alone is viable, but not the mutation of both of them. This effect was initially described in 
yeasts and is frequently caused by loss-of-function mutations. Only rarely, it can be 
associated to gain-of-function events (Kaelin, 2005). New drugs have therefore been 
designed to target a particular pathway essential for cancer cells due to the simultaneous 
mutation impairing parallel pathways (Weidle et al, 2011). The same compound spares 
healthy tissues because they can rely on the alternative pathway that is not functional in 
cancer cells. This is the case of PARP inhibitors, which become toxic only in the presence 
of breast cancer susceptibility genes-1 (BRCA1) mutations (Farmer et al, 2005). Cancer 
cells bearing BRCA1 mutations in fact depend on PARP to repair DNA damages, while 
normal cells can employ both alternative pathways going through BRCA1 or PARP.
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2.6.2. Colorectal cancer
Colorectal cancers (CRC) are among the most widespread cancer types and are 
characterized by low survival rates especially in advanced stage patients. Several 
multidrug combinations are used to treat colorectal cancer employing oxaliplatin, 5-FU 
and the camptothecin (CPT) analogue irinotecan (Meyerhardt and Mayer, 2005). 
Moreover, cetuximab and panitumumab, two antibodies blocking the EGFR, are approved 
in combination with chemotherapy for metastatic CRC and as maintenance therapy in 
chemorefractory tumors. Receptor tyrosine kinases such as EGFR, through the activation 
of the downstream guanosine triphosphate (GTP)ases, regulate several pro-survival 
pathways such as the ones regulated by the MAPKs and PI3K. Cetuximab activity stems 
from the blockage of these pathways even if mutations or amplification of KRAS are often 
associated to unresponsiveness and acquired resistance (Misale et al, 2012). Of note, 
about 40% of CRCs display mutated KRAS, the most frequent in codon 12 and 13, and 
resulting in constitutive hyperactivation.
2.6.2.1. Oncogenic KRAS
KRAS is a 21 KDa protein that plays a pivotal role in cell signal transduction belonging 
to the RAS subfamily, which comprises several other small GTPases endowed with GTP- 
hydrolyzing activity. In unstimulated conditions, GTPases bind to GDP and are unable to 
trigger the down-stream signaling processes. RAS proteins therefore require GTP to be 
activated and undergo rapid cycles of activation and inactivation that are essential for 
physiological signaling (Pylayeva-Gupta et al, 2011). Because the cascades regulated by 
RAS stimulate cell growth and division, amongst many other cellular effects, aberrant 
signaling can ultimately lead to cancer transformation. The 3 human RAS genes (HRAS, 
KRAS, and NRAS) encoding for 4 Ras isoforms (KRAS exists in two alternatively-
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spliced variants) are among the most prevalent drivers of human cancer, with KRAS being 
mutated in about 20%-25%  of all human tumors and up to 90% in certain cancer types 
e.g. pancreatic cancer (Eser et al, 2014). In these settings, KRAS activates several down­
stream effectors leading to the stimulation of the RAF/MAPK/ERK kinase 
(MEK)/extracellular signal-regulated kinase (ERK) and PI3K pathways. Despite oncogenic 
KRAS being often associated with poorer prognosis, it can also result in synthetic lethality 
(Steckel et al, 2012; Weidle et al, 2011). In fact, the presence of constitutively active KRAS 
sensitizes cancer cells to MEK and BCL-xL (Corcoran et al, 2013) or RAF inhibition (Lamba 
et al, 2014), TRAIL (Huang et al, 2011), 5-FU and oxaliplatin (de Bruijn et al, 2010). 
Nonetheless, KRAS activation is usually associated with reduced capacity to undergo 
apoptosis and increased resistance to chemotherapy by activating several pro-survival 
pathways (Di Nicolantonio et al, 2010; Hata et al, 2014; Tao et al, 2014) that often cause 
the upregulation of anti-apoptotic factors such as the members of the IAP family 
members (Hadj-Slimane et al, 2010; Moller et al, 2014).
2.6.3. Breast cancer classification
Breast cancer is a heterogeneous disease, with many subtypes displaying distinct 
biological features and leading to different treatm ent responses and clinical outcomes. 
Traditional classification made according to biological characteristics (tumor size, lymph 
node involvement, histological grade, patient's age, estrogen Receptor/ER, progesterone 
receptor/PR and human epidermal growth factor receptor 2/HER2 status) is now 
associated to gene expression microarray studies that identify distinct molecular tumor 
classes.
Approximately 75% of breast cancers are positive for ER and/or PR. ER-responsive
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genes encode proteins typical of luminal epithelial cells and therefore ER-positive tumors 
are termed "luminal". Further studies have divided this group in two luminal-like 
subclasses (Yersal and Barutca, 2014).
2.6.3.1. Luminal A breast cancer
The luminal A is the most common subtype. It represents about half of all breast 
cancers and is generally associated to good prognosis. These tumors usually show low 
histological grade, a degree of nuclear pleomorphism and mitotic activity, and include 
special histological types (i.e., tubular, invasive cribriform, mucinous and lobular). The 
luminal A subclass is characterized by high levels of ER, expression of cytokeratin CK8 and 
CK18 and lower levels of proliferation-related genes. Despite the fact that relapse rate of 
patients belonging to this group is significantly lower than other subtypes, recurrence 
may occur in bone, whereas liver, lung and central nervous system metastases involve 
less than 10% of patients. Treatment is mainly based on hormonal therapy.
2.6.3.2. Luminal B breast cancer
Luminal B tumors cover about 15%-20% of all breast cancers and are more aggressive 
than luminal A subtype. Luminal B tumors are characterized by higher histological grade, 
proliferative index and recurrence rate. This results in worse prognosis and lower survival 
rates after relapse compared to subtype A.
2.6.3.3. Basal-like breast cancer
The basal-like subtype comprises from 8% to 37% of all breast cancers and is 
associated with high histological grade, mitotic and proliferative indices, poor tubule 
formation and inner necrotic or fibrotic zones. This type of tumor is characterized by 
pushing borders, lymphocytic infiltrate and medullary features. About 80% of basal-like
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tumors are triple-negative, expressing no PR and ER, and with HER2 not amplified. Most 
of these tumors are infiltrating ductal tumors, extremely aggressive and with high 
capacity to form brain and lung metastasis. Claudin-low breast cancer is one of the triple­
negative subtypes characterized by poor clinical outcome, low expression of genes 
involved in tight junctions and cell-cell adhesions including claudins, occludin and E- 
cadherin, but high expression of EMT genes and displaying stem cell-like features.
2.6.3.4. Metastasis and the epithelial to mesenchymal transition process
Cancer metastasis is the major issue in cancer therapy because it is responsible for 
around 90% of cancer deaths even though the dissemination of the primary tum or is an 
extremely inefficient process (Chiang and Massague, 2008). In fact, only a small fraction 
of cancer cells, less than 0.01% in experimental animal models, will form metastases. 
Accordingly, cancer cells can be found also in the bloodstream of patients that will not 
develop metastases.
To disseminate from the primary tumor, cancer cells invade the surrounding tissues 
as single cells (Giampieri et al, 2009) or clumps (Friedl and Gilmour, 2009). Environmental 
conditions determine whether single cells will move by elongated-mesenchymal or 
rounded-amoeboid migration (Sahai and Marshall, 2003). The intravasation process in 
which invading cells cross the blood vessel walls and enter the circulation is the first step 
of metastasis formation. Few cells survive the stress and the immune cells of the 
bloodstream, finally attach to endothelial walls, extravasate and start proliferating in the 
stroma. If these micrometastases efficiently survive in the new environment, they 
eventually grow into clinically detectable macrometastases. Therefore, attachment to the 
endothelium is not sufficient for metastasis formation, but cancer cells also need growth
45
signals and the appropriate environment to invade a target tissue (Reymond et al, 2013).
EMT is a physiological step of early embryonic development. It is characterized by 
cell-cell adhesion reduction and acquisition of motility, together with the appearance of 
mesenchymal markers. This process seems to play a role in allowing the detachment of 
cancer cells from primary tumors even if its importance is still controversial. During the 
EMT, cells express a number of E-cadherin repressors such as Twist-1, Twist-2, ZEB-1, ZEB- 
2, Snail and Slug that bind to the E-boxes at the CDH1 (E-cadherin) promoter. The loss of 
E-cadherin is an essential step of EMT (Acloque et al, 2008) that, in this way, reduces the 
intercellular adhesion junctions therefore increasing cell detachment.
2.6.4. Ovarian cancer ascites
Ovarian carcinomas are characterized by the formation of ascites especially at 
advanced stages. Ascites are formed by the mechanical constriction exerted by the tum or 
and is characterized by the peritoneal increase of fluid production and decreased 
absorption. Ovarian cancers rarely spread by metastasis outside the peritoneum and 
ascites themselves are often the cause of death (Lengyel, 2010). The ascitic fluid is rich in 
soluble factors that constitute the cross-talk between cancer, stromal and inflammatory 
cells, and support tumor development. This microenvironment also promotes 
immunosuppression and favors tumor escape from the immune system, although the 
ascitic fluid is usually enriched in immune cells such as macrophages.
Macrophages are plastic cells that can be classically activated (M l)  and 'alternatively' 
activated (M2) (Sica and Mantovani, 2012). Tumor-associated macrophages are classified 
as M2 macrophages and produce immunosuppressive cytokines such as interleukin-10 
(IL-10). In contrast, M l  macrophages produce pro-inflammatory cytokines including
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interferon-v (IFNy) and IL-12. M l,  but not M2, macrophages can elicit an effective 
antitumor response. Importantly, the NF-kB pathway controls the plasticity of 
macrophages.
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3. AIM OF STUDY
Resistance to cell death is a hallmark of cancer cells and is responsible for 
unresponsiveness to therapy and tumor progression. Several findings support the notion 
that lAPs play a pivotal role in conferring resistance to apoptosis by blocking caspases and 
stimulating several pro-survival pathways. A chance to target the lAPs is now offered by 
the SM compounds, which are currently tested in a number of clinical trials and widely 
employed in pre-clinical studies. SMs rapidly deplete clAPl and clAP2, and prevent the 
activity of XIAP in blocking caspases but few cancer cell lines are killed by SM treatm ent in 
monotherapy. There is therefore the need to identify new drugs that can be successfully 
combined to enhance their cytotoxic activity. Furthermore, it is fundamental to fully 
understand the mechanisms of SM activity in order to predict the cancer settings where 
they are likely to be more effective, and avoid side effects and toxicity.
The aim of this study is therefore to characterize new SMs compounds that we have 
developed in collaboration with the University of Milan, focusing on SM83, in particular. 
We describe its capability to interact with the known SM targets and to be effective both 
in vitro, killing sensitive cell lines, and in vivo, reducing the growth of both solid tumors 
and cancer ascites. Importantly, we also study the effect of SM83 treatm ent on 
metastasis formation and begin to explain the mechanisms responsible for the anti­
metastatic effect observed. Finally, we look for genetic lesions that favor the efficacy of 
SM83 treatm ent in combination with other drugs and identify a cancer mechanism able 
to counteract the potentially pro-death stimulus of oncogenic KRAS.
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4. MATERIALS AND METHODS
4.1. Reagents
SMs were synthesized at the CISI institute as recently described (Manzoni et al, 2012), 
dissolved in dimethylsulfoxide (DMSO) (Sigma-Aldrich) to obtain a 10 mM solution and 
stored at -20°C. Recombinant TNF (Emmerich et al, 2011) and TRAIL (Ganten et al, 2006) 
were produced by the University of Milan and the UCL respectively, London using two 
plasmids encoding for tagged human TNF and TRAIL kindly provided by Prof. Henning 
Walczak. Recombinant human TWEAK was kindly provided by Prof. Harald Wajant 
(Salzmann et al, 2013). Mouse bearing cancer ascites and IGROV-1 were treated with 
commercial TRAIL purchased by Enzo Life Sciences. TNF blockers Infliximab (Schering- 
Plough) and Enbrel (Wyeth Pharmaceuticals) were kindly provided by Prof E Berti 
(Ospedale Policlinico Maggiore). Double strand break inducer neocarzinostatin (Sigma- 
Aldrich), topoisomerase inhibitors etoposide (Teva) and camptothecin (Sigma-Aldrich) 
were used in combination therapy with SM83.
The antibodies targeting the following proteins were used in western blot 
experiments: NIK, NF-kBl, NF-kB2, cleaved PARP, cleaved caspase-3, cleaved caspase-9, 
LRIG-1, Snai2, Beclin-1, LC3B, total RAS, ERK1/2 and phospho-ERKl/2 Thr202/Tyr204, AKT 
and phospho-AKT (Cell Signaling Technology), clAPl (R&D Systems), clAP2 and XIAP (BD 
Biosciences), caspase-8 (Enzo Life Sciences), NOXA (CalBiochem), M c ll (Santa Cruz 
Biotechnology), actin and vinculin (Sigma-Aldrich), and RIP1 (Ab Frontier).
Transient ectopic expression of KRAS G13D was achieved by transduction of the 
employed cells with viral particles collected from conditioned medium of packaging cells 
HEK293FT (Life Technologies), transfected with Lipofectamine 2000 and ViraPower
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(Life Technologies) and the plNDUCER20 inducible lentiviral vector kindly provided by 
Stephen Elledge (Howard Hughes Medical Institute). Cells efficiently transduced were 
selected with 500 pg/ml G418 (Life Technologies). Pan-caspase inhibitor z-VAD(OMe)- 
FMK was purchased by BIOMOL, RIP1 inhibitor Necrostatin-1 from Enzo Life Sciences. 
MEK inhibitors PD98059 and U0126 were purchased from CalBiochem, PI3K inhibitor 
LY294002, IKK inhibitor BAY 11-7082 and transcription inhibitor cycloheximide from  
Sigma-Aldrich, AKT inhibitor Triciribine from Selleckem.
4.2. Fluorescence polarization-based binding assay
4.2.1. XIAP BIR3 cloning, expression and purification
The cDNA sequence coding for the human XIAP BIR3 domain (residue 241-356) 
cloned in pET28 vector (Novagen) was used to transform the Escherichia coli strain BL21. 
Protein expression was induced for 3 h at 37°C with isopropyl-b-D-thiogalactopyranoside 
(IPTG) to a final concentration of 1 mM in the presence of 100 pM zinc acetate (ZnAc). 
Bacteria were grown in 2YT medium plus kanamycin and harvested, resuspended in a 
buffer containing 50 mM Tris HCI pH 7.5, 200 pM NaCI and protease inhibitors, treated  
with 100 pg/ml lysozyme for 30 min in ice and then lysed by sonication. After elimination 
of debris by centrifugation, the recombinant protein was purified using Ni-NTA (His-trap 
FF crude, Ge-Healthcare) followed by gel filtration (Superdex 200, Ge-Healthcare). BIR3- 
His-tag was eluted with 250 mM imidazole and thereafter stored in 20 m M Tris HCI pH
7.5, 200 mM NaCI and 10 mM dithiothreitol (DTT).
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4.2.2 Fluorescence polarization assay: XIAP BIR3 saturation and competitive 
binding experiments
Fluorescent polarization experiments were performed in black, flat-bottom 96-well 
microplates (Greiner Bio-One) and fluorescent polarization was measured by Ultra plate 
reader (Tecan). Fluorescent-labelled SMAC peptide [AbuRPF-K(5-Fam)-NH2] - fluorescein 
isothiocyanate (FITC)-SMAC, stocked in DMSO - to a final concentration of 5 nM and 
increasing concentration of BIR3 His-tag from 0 to 20 pM were added to an assay buffer. 
The final volume in each well was 120 pL, with the assay buffer consisting of 100 mM  
potassium phosphate, pH 7.5; 100 pg/mL bovine y-globulin; 0.02% sodium azide. After a 
15 min shaking at room temperature (RT), the plate was incubated for 3 h at room 
temperature. Fluorescence polarization was measured at an excitation and emission 
wavelengths of 485 nm and 530 nm respectively. The equilibrium binding graphs were 
constructed by plotting millipolarization units (mP) as function of the XIAP BIR3 
concentration. Data were analyzed using Prism 5.02 software (Graphpad Software).
Dimers were evaluated for their ability to displace FITC-SMAC probe from  
recombinant protein. 5 nM of FITC-SMAC, XIAP BIR3 His-tag and serial dilutions of the 
dimers (concentrations ranging from 4 pM to 0.4 nM) were added to each well to a final 
volume of 120 pL in the assay buffer described above. The concentration of BIR3 His-tag 
used was 60 nM, able to bind more than 50% of the ligand in the saturation binding 
experiment. After being mixed for 15 min on a shaker and incubated 3 h at RT, 
fluorescent polarization was measured by Ultra plate reader (Tecan).
4.2.3. Cloning, expression and purification of human cIAP-1 BIR3
The sequence coding for cIAP-1 domain residues 245-357  was cloned in the
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pET21(a) vector (Novagen) with a C-terminal 6xHis-tag and used to transform Escherichia 
coli strain BL21(DE3). The recombinant protein was purified using Ni-NTA (His-trap 
FFcrude, Ge-Healthcare), gel filtration (Superdex 200, Ge-Healthcare) and eluted in 20 
mM Tris pH 8.0, 250 mM NaCI and 10 mM DTT.
4.2.4. Fluorescence polarization assay: cIAPl BIR3 saturation and 
competitive binding experiments
FITC-SMAC to a final concentration of 2 nM and increasing concentration of BIR3 
His-tag from 0 to 20 pM were added to the assay buffer described above. After a 15 min 
shaking, the plate was incubated for 3 h at RT. Fluorescence polarization was measured at 
an excitation and emission wavelengths of 485 nm and 530 nm respectively. The 
equilibrium binding graphs were constructed by plotting mP as function of the cIAPl BIR3 
concentration. Data were analyzed using Prism 5.02 software (Graphpad Software).
Dimers were evaluated for their ability to displace FITC-SMAC probe from  
recombinant protein. 2 nM of FITC-SMAC, cIAPl BIR3 His-tag and serial dilutions of the 
dimers (concentrations ranging from 4 pM to 0.4 nM) were added to each well to a final 
volume of 120 pL in the assay buffer described above. The concentration of BIR3 His-tag 
used was 10 nM, able to bind more than 50% of the ligand in the saturation binding 
experiment. After being mixed for 15 min on a shaker and incubated 3 h at RT, 
fluorescent polarization was measured by Ultra plate reader (Tecan).
4.2.5. Cloning, expression and purification of human XIAP linker-BIR2- 
BIR3
A pET28 vector (Novagen) with the cDNA coding for human XIAP from residue 124 
to 356 (linker-BIR2—BIR3), coding for BIR2 and BIR3 domains and the linker region
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preceding BIR2, was used to transform Escherichia coli strain BL21. Protein expression 
was induced by IPTG to a final concentration of 1 mM and 100 pM zinc acetate (ZnAc) for 
20 h at 20°C. Bacteria grown in 2YT medium plus kanamycin were harvested, 
resuspended in a buffer containing 50 mM Tris HCI Ph 7.5, 200 mM NaCI and protease 
inhibitors, treated with 100 pg/ml lysozyme for 30 min in ice and then lysed by 
sonication. After elimination of debris by centrifugation, the recombinant protein was 
purified using Ni-NTA (His-trap FFcrude, Ge-Healthcare) followed by gel filtration 
(Superdex 200, Ge-Healthcare). The linker-BIR2-BIR3-His-tag was eluted with 250 mM  
imidazole and thereafter stored in 20 mM Tris HCI pH 7.5, 200 mM NaCI and 10 mM DTT.
4.2.6. Fluorescence polarization assay: XIAP linker-BIR2-BIR3 saturation 
binding and competitive experiments
Fluorescent-labeled dimeric SMAC peptide SMAC-1F to a final concentration of 1 
nM and increasing concentration of linker-BIR2- BIR3 His-tag from 0 to 2 pM  were added 
to the assay buffer in a final volume of 120 pi. After a 15 min shaking, the plate was 
incubated for 3 h at RT. Fluorescence polarization was measured at an excitation and 
emission wavelengths of 485 nm and 530 nm respectively. The equilibrium binding graphs 
were constructed by plotting mP as function of the XIAP linker-BIR2—BIR3 concentration. 
Data were analyzed using Prism 5.02 software (Graphpad Software).
Dimers were evaluated for their ability to displace SMAC-1F probe from  
recombinant protein. 1 nM SMAC-1F, 3 nM XIAP linker-BIR2—BIR3 His-tag and serial 
dilutions of the dimers (concentrations ranging from 2 pM to 0.4 nM) were added to each 
well to a final volume of 120 pL in the assay buffer described above. After being mixed for 
15 min on a shaker and incubated 3 h at RT, fluorescent polarization was measured by
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Ultra plate reader (Tecan).
4.3. Cell cultures
The human breast adenocarcinoma MDA-MB231, the promyelocytic HL60 and the 
prostatic adenocarcinoma PC3 cell lines employed in the experiments performed to test 
the cytotoxic activity of the dimeric SMs were obtained from Interlab Cell Line Collection 
(ICLC, Genova, Italy). The cell lines were cultured in Roswell Park Memorial Institute 
(RPMI)-1640 medium supplemented with 2 mM L-glutamine, penicillin (100 
U/mL)/streptomycin (100 pg/mL), 10% fetal bovine serum (FBS) (all from Sigma-Aldrich) 
at 37°C and 5% C02 in fully humidified atmosphere.
The breast cancer cell lines used for all the other experiments were kindly 
provided by Dr. Elda Tagliabue: MDA-MB231, MDA-MB468, T47D, MDA-MB453, BT549, 
SUM149 and SUM159. Ovarian carcinoma IGROV-1 cells were provided by Dr. Nadia 
Zaffaroni. The mouse sarcoma Meth A cell line was kindly provided by Dr. Mario  
Colombo, human mammary immortalized epithelial HME and MCF10A, and CRC DLD1, 
SW48, Liml215, FICT116 cell lines were all kindly provided by Prof. Alberto Bardelli. HME 
isogenic pairs and MCF10A cell lines were cultured in Dulbecco's Modified Eagle's 
medium-F12 (DMEM-F12; Gibco), supplemented with 10% FBS (LONZA), 2 m M glutamine 
(LONZA), 20 ng/ml EGF (Immunological Science), 10 pg/ml insulin (Sigma), 500 pg/ml 
hydrocortisone (Sigma-Aldrich). SW48 and DLD1 isogenic pairs were cultured with DMEM  
(Gibco) supplemented with 10% FBS and 2 mM glutamine. Lim l215 isogenic pairs were 
cultured with RPMI (LONZA) supplemented with 10% FBS, 2 mM glutamine and 1 pg/ml 
insulin. HCT116 were cultured in RPMI, supplemented with 2 mM glutamine, sodium 
pyruvate (LONZA), and non-essential amino acids (LONZA).
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4.4. Cell viability assay
MDA-MB231 and PC3 cells were seeded in 96-well flat bottom cell culture plates at a 
density of 5000 cells/well, while HL60 cells were seeded at a density of 10,000 cells/well 
in 100 pL of complete culture medium. MDA-MB231 and PC3 cells were allowed to 
adhere for 24 h before being treated for 96 h. Cells were treated with serial dilutions of 
SMs, ranging from 0.1 nM to 50 pM. To evaluate cell viability, 10 pL of WST-8 were added 
to each well. After 4 h of incubation at 37°C, the absorbance was measured at 450 nm 
using a microplate reader. The data were then expressed as a mean percentage of 
triplicates normalized to the untreated control. The experiments were repeated twice. 
The IC50, the concentration of compound capable of inhibiting the cell growth by 50%, 
was calculated using the GraphPad Prism 4 software.
To evaluate the cytotoxic activity of SM83 in combination with izTRAIL, IGROV-1 cells 
were counted and seeded in 6-well plates. The following day, cells were treated with the 
indicated concentrations of compounds and cultured for 3 days. At the end of the 
treatment, IGROV-1 cells were trypsinized and counted. Viability is expressed as a 
percentage of untreated cells.
Another technique to evaluate cell viability was by employment of CellTiter-Glo 
(Promega). In these experiments, cells were seeded in white optical 96-well plates and 
treated as indicated. At the end of the experiments, medium was discarded and 60 pi of 
reagent diluted 1:4 in phosphate-buffered saline PBS was added to each well. After 15 
min of shaking at RT, luminescence was measured with a Tecan Ultra plate reader. 
Viability was shown as a percentage compared to untreated or mock treated cells.
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4.5. Pharmacokinetic experiments of SM83
Pharmacokinetic experiments were performed by the Test Facility of NiKem 
Research, Baranzate (M l). Briefly: male C D-I mice (Charles River Italy, Calco) were treated 
with SM83 by intraperitoneal (ip) admininistration and euthanized at eight time points (5, 
15, 30, 60, 120, 240, 480 min and 24 h) under anesthesia with ethyl ether. For the 
intravenous (iv) route of administration, mice were treated with SM83 by iv injection and 
euthanized at eight time points (2, 10, 30, 60, 120, 240, 480 min and 24 h) under 
anesthesia with ethyl ether. Blood (about 500 pL) was collected in heparinized tubes, and 
centrifuged (3500 g, 15 min, 4°C). Plasma samples were stored at -80°C and later analyzed 
by LC-MS/MS (Premiere XE, Waters). The lowest limit of quantification (LLOQ) was 1 
ng/mL.
4.6. Detection of proteins by western blot and dot blot
For western blot analysis, cells were trypsinized and harvested by centrifugation at 
4500 rpm for 5 minutes at 4°C. After washing once with PBS, cells were lysed by boiling in 
60-100 pi cell lysis buffer (125 mM Tris HCI pH 6.8, 5% sodium dodecyl sulfate/SDS) 
supplemented with 1 x complete protease inhibitors (Roche Diagnostics) and 
phosphatase inhibitors (Sigma-Aldrich), sonicated and centrifuged at 13000 rpm for 20 
min at RT. Cleared supernatants were transferred to a new tube and frozen at -20°C. To 
determine the protein concentration of cell lysates, the bicinchonic acid (BCA)-containing 
protein assay was applied according to the manufacturer's instructions (QuantumMicro  
Protein, Euroclone). In a 96-well plate, 2 pi of lysate were incubated with 148 pi water 
and serial dilutions of bovine serum albumin (BSA) used as standard protein. BCA solution 
was added in a 1:1 ratio. After incubation at RT, absorbance was measured at 485 nm
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using Ultra microplate reader (Tecan). Protein concentration was determined by 
interpolation with the curve obtained with the standard BSA.
Proteins were then separated according to their molecular weight using pre-cast 
4-12% Bis-Tris NuPAGE gels (Life Techonolgies). Cell lysates were mixed with 4x reducing 
SDS-Sample buffer and heated for 10 min at 99°C. As a molecular weight standard, Page 
Ruler Plus Pre-Stained Protein Ladder (Euroclone) was used. The electrophoretic 
separation was achieved by applying a constant voltage in MES buffer. Proteins within the 
gels were then blotted onto PVDF membranes (Millipore) using the XCell II blot module 
(Life Technologies). Membranes were incubated with blocking buffer (4% non-fat milk 
dissolved in PBS plus tween 0.1%, PBS-T) for 30' and then incubated overnight with the 
indicated primary antibodies. Membranes were then washed 3 times in PBS-T and 
incubated 1 h with the appropriate horseradish peroxidase-conjugated secondary 
antibody (Sigma). After washing in PBS-T, proteins were detected by 
electrochemiluminescence (ECL) reaction, by exposure of films to the membranes after 
incubation with luminol-based chemiluminescent substrates (Pierce).
For dot blotting, ascitic fluid samples cleared of cells were spotted on PVDF 
membranes and let to dry. After saturation with non-fat dry milk-PBS, filters were 
hybridized with anti-HMGB-1 Ab (Abeam, 1:2000). High mobility group box 1 (HMGB-1) 
was then detected as for western blotting.
4.7. Gene knock-down by silencing and ectopic expression of KRAS
To achieve transient knock-down of target genes two different protocols were used. 
Human epithelial cells were transfected with indicated short interfering RNAs (siRNAs) 
using a reverse transfection protocol in which siRNAs (Qiagen) and RNAiMAX (Life
57
Technologies) were used. Two mixes were prepared: one containing 3.25 pi of RNAiMAX 
in 100 pi Optimem (GIBCO) and the other with 3.25 pi of siRNA (20 pM ) stock in the same 
volume. The two mixes were incubated for 5 min at RT and then combined and left at RT 
for 30-40 min. Meanwhile, cells were trypsinized and counted. After the incubation, the 
siRNA/RNAiMAX mix was put in a culturing well and cells seeded on top. About 0.15 x 106 
cells were cultured in a 6-well plate in a final volume of 2 ml medium without antibiotics. 
For transfection in 96-well plates, mixes were prepared with 0.25 pi siRNAs plus 0.25 pi 
RNAiMAX and 104cells were seeded in 100 pi final volume.
Tumor cells were transfected with a similar protocol, employing the same regents 
and volumes. In this case, cells were seeded the day before the transfection and 
siRNA/RNAiMAX was added on top of the cells. After transfection, cells were incubated 
for 72 h before harvesting. If cells needed to be treated after transfection, drugs were 
added 48 h after transfection and viability or western blot analysis performed the day 
after. In each experiment, scramble siRNAs (siCtr) were used as control and siRNA 
targeting an essential gene (ubiquitin, UBB) served to evaluate the transfection efficiency.
To ectopically over-express mutated KRAS, the cDNA encoding the KRAS G13D was 
cloned in the plnducer20 lentiviral vector (kindly provided by Prof. Stephan Elledge) and 
used to produce lentiviral particles in HEK293FT packaging cells. Viruses were obtained by 
reverse transfection of HEK193FT cells following manufacturer's protocol and mixing 
plnducer20-KRAS G13D with the ViraPower packaging plasmid mix (Life Technologies) and 
the Lipofectamine2000 transfection reagent. After 24 h, medium was replaced with fresh 
medium that was collected after further 24 h and used to transduce HME and MCF10A 
cells. Cells having integrated the cDNA were selected by adding 500 pg/ml G418 (Sigma)
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to the culturing medium. Transgene expression was stimulated by adding doxycicline 
(Dox, Sigma-Aldrich) to the medium for at least 48 h.
4.8. Preparation of TRAIL-armed CD34+ cells and co-culture with cancer 
cells
CD34+ cells were purified from peripheral blood of consenting donors of allogeneic 
stem cells using the Auto-MACS device (Miltenyi Biotec, Bergisch-Gladbach, Germany, EU) 
and kindly provided by Prof. Carlo-Stella. Replication-deficient adenoviruses encoding the 
human TRAIL gene (mTRAIL) under the control of a CMV promoter were purchased from  
the Riken BioResource Center (Tsukuba). CD34+ cells were plated at 2 x l0 6/m l 
concentration in 1 ml of serum-free Iscove's modified Dulbecco's medium (IM DM ) 
containing adenoviruses at a MOI of 200 plaque-forming units (pfu)/cell. After incubation 
at 37°C in 5% C02 for 2 h, cultures were supplemented with 1 ml IM DM  plus FBS 20 % and 
BoosterExpress TM reagent (Gene Therapy Systems; final dilution 1:200) and incubated 
for 18 h, extensively washed in serum-containing medium and evaluated for transduction 
efficiency by flow cytometry, using an anti-TRAIL antibody (R&D).
For cytotoxicity experiments, TRAIL-armed CD34+ cells were co-cultured with the 
indicated cancer cell lines in a 1:1 ratio. Viability of cancer cells was measured by western 
blot detecting several markers of apoptosis, by the use of a fluorescent substrate of 
activated caspase-3/-7 or by AnnexinV/propidium iodide (PI) staining followed by flow  
cytometry gaited for CD45‘ cells to detect non-CD34+ cells and therefore analyzing only 
the cancer cells.
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4.9. In vivo experiments
Mice were maintained in laminar flow rooms keeping temperature and humidity 
constant. Mice had free access to food and water and were weighted twice a week. 
Experiments were approved by the Ethics Committee for Animal Experimentation of the 
Fondazione IRCCS Istituto Nazionale dei Tumori of Milan according to institutional 
guidelines and by the Italian Minister of Health, project INT_12_2011.
For the breast cancer xenograft models, non-obese diabetic/severe combined 
immunodeficiency disease (NOD/SCID) mice were engrafted in the left flank by 
subcutaneous (sc) injection of 200 pi physiological saline containing 5 x l0 6 MDA-MB468 
and MDA-MB231. At day 13, animals were randomized and divided in two groups. One 
group was treated with ip or iv injections with 5 mg/kg SM83, 5 tim es/week to a total of 
13 (MDA-MB231) or 17 (MDA-MB468) injections. Tumor growth was monitored by caliper 
measurement 3 times a week. Mice were euthanized 6 h after the last injection for 
biochemical analysis of the primary tumor or two weeks later for detection of lung 
metastasis. In combination experiments with CD34+ expressing mTRAIL, MDA-MB468 
were injected sc in NOD/SCID and let grow for 2 weeks; mice were then treated 4 times 
with ip injections of 5 mg/kg SM83 and/or iv administration of 106 CD34+ cells at day 14, 
18, 21 and 25. Primary tumor growth was measured until day 18 and then nodules were 
collected for immunohistochemistry (IHC) analysis. NOD/SCID mice engrafted with 106 
MDA-MB231 cells were treated with daily ip injections with 5 mg/kg SM83, 5 tim es/week  
starting at day 14, and received 2 iv injections/week of 106 CD34-TRAIL cells for two  
weeks (total of 4 injections) starting after 1 week of SM83 treatm ent. Mice were 
euthanized at day 46.
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The in vivo effects of SM83 were tested using a human ovarian carcinoma ascites 
model obtained by ip injection of IGROV-1 cells into athymic nude mice. The cells had 
previously been adapted to grow ip and maintained by serial passages of ascitic cells. 
Nude mice develop hemorrhagic ascites and diffuse carcinomatosis and eventually die. In 
order to assess the effects of SMs on survival, mice were inoculated ip with 2 .5 x l0 6 cells 
in 0.2 ml saline and, starting the day after cell injection, injected ip with the compounds 
(dissolved in saline) at 5 mg/kg body weight, once daily for 5 days per week for 2 weeks 
(qdx5/wx2w). The animals were inspected and weighed daily. The progression of ascites 
was assessed from an increase in body weight (measured on day 17). For ethical reasons, 
they were killed before impending death, recognized by their suffering status and loss of 
reactivity to external stimuli. The day of killing was taken as the day of death for 
calculating the median survival time. The antitumour activity of treatments was 
expressed as the ratio of median survival time in treated mice to that of untreated control 
mice xlOO (T/C%). To evaluate the effect of a single dose of SM83, 24 h after the injection 
of 5 mg/kg SM83 the ascitic fluid was collected, cells harvested by centrifugation, 
dissolved in PBS and counted. Cancer cell killing was also confirmed by evaluation of the 
levels of human CK18 in the plasma of engrafted animals. CK18 is in fact released by dying 
cells and was quantified by M65 enzyme-linked immunosorbent assay (ELISA) kit (Vinci- 
biochem) following manufacturer's protocol.
In the syngeneic ascites model, 2 x l0 5 mouse Meth A cells were injected ip into 
immunocompetent BALB/c mice and treatment, starting 7 days later, consisted of five 
consecutive daily ip injections of SM83 at a dose of 5 mg/kg body weight. The progression 
of ascites was assessed from both an increase in body weight (measured on day 13) and 
overall survival, as calculated above. For survival analyses, the percent survivorship over
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time was estimated using the two-sided Kaplan-Meier product method; differences 
between groups were compared using the log-rank test.
To deplete neutrophils, nude mice bearing IGROV-1 ascites were injected ip with the 
anti-Ly-6G antibody (clone 1A8; Affymetrix) 24 h before SM83 administration. In the Meth  
A model, mice were injected with 20 mg 1A8 antibody every second day, for 14 
consecutive days, starting one day before SM83 treatment (day 7). The efficiency of 
polymorphonuclear leucocytes (PMNs) depletion in nude mice was tested by sampling 
the bone marrow (BM) 24 h after injection of the anti-Ly-6G antibody. Cells were double­
stained with anti-CDllb/Ly-6G and cell populations were quantified by flow cytometry.
Primary tumors, lymph nodes and lungs were collected at the end of the 
experiments, dissected and lysed in 125 mM Tris HCI pH 6.8, 5% SDS for western blot 
analysis, formalin-fixed for paraffin inclusion (prepared by IHC facility of the Institute) and 
OCT-frozen for immunofluorescence (IF). IHC of mouse lungs were stained to detect 
MDA-MB231 cells by the facility of the institute using an anti-vimentin antibody (Dako). 
Primary tumors were also stained for the marker of cell proliferation KI67 and to detect 
the vasculature with the endothelial marker CD31 (data not shown), and by hematoxylin 
and eosin (H&E) stain.
4.10. Immunofluorescence
OCT-frozen primary tumors were cut in sections and laid onto poly-d-lysine- 
coated glasses, fixed in 4% paraformaldehyde (PFA) and permeabilized with PBS 0.1%  
Triton-X. Cells were then saturated 1 h with PBS BSA 2% and incubated with the anti­
cleaved caspase-3 antibody diluted 1:400 in PBS BSA 1% for 2 h in a humidified chamber. 
Slides were then washed three times in PBS and incubated with a
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(tetramethylrhodamine) TRITC-conjugated secondary anti-rabbit antibody (Life 
Technologies) for 45 min, washed again and mounted using coverslip with a drop of 4',6- 
Diamidino-2-phenylindole dihydrochloride (DAPI)-containing anti-fading mounting 
medium (ProLong Gold Antifade Mountant; Life Technologies).
Floating cells harvested from the ascites were prepared for double-marker 
immunofluorescence by centrifugation on slides using a cytospin cytocentrifuge. Briefly, 
acetone-fixed cells were re-hydrated in PBS and incubated 1 h with a primary antibody. 
Cells were then washed in PBS and incubated for 30 min with the appropriate Alexa Fluor 
488-conjugated secondary antibody. After washing, slides were incubated for 30 min with 
another primary antibody, washed and incubated for 30 min with an Alexa Fluor 546- 
conjugated secondary antibody. The primary antibodies used were: rat anti-mouse C D llb  
mAb (1:200; BD Biosciences); rat anti-mouse Ly-6G mAb (1:200; BD Biosciences); and 
rabbit anti-HMGB-1 Ab (1:400; Abeam, Cambridge, UK). In some experiments, nuclei were 
stained with 40,6-diamidino- 2-phenylindole. Slides were mounted with Prolong medium  
(Life Technologies, Monza, Italy) and examined under a RADiance-2000 (Bio-Rad, Milan, 
Italy) Nikon-TE300 laser scanning confocal microscope (Nikon Instruments S.p.A, 
Florence, Italy).
4.11. Gene expression profiling
Primary tumors collected from MDA-MB231 NOD/SCID xenografts were collected 
6 h after the last injection of SM83 and cut in pieces. One piece was lysed for RNA 
extraction using RNeasy Mini Kit (Qiagen) and then total RNA was retro-transcribed using 
Superscript II Reverse Transcriptase kit (Life Technologies) and used for gene expression 
profiling (GEP) performed by the genomic unit facility using the lllumina HumanHT-
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12_V4_0_R2 chip and results analyzed by the bioinformatic unit of the institute through R 
2.15.2, packages: "lumi" and "limma" from Bioconductor. In this way, 50 genes were 
found significantly up-regulated and 15 down-regulated by SM83 treatment.
4.12. Wound healing-based migration assay
Wound healing experiments were performed using Culture-lnsert in p-Dish 35 mm 
(Ibidi). 2 x l0 4 MDA-MB231 cells were transfected with an optimized reverse transfection 
protocol directly in the culture inserts in 12-well plates. After 72 h, inserts were removed, 
cells washed once to eliminate detached cells and multi-well plates put in a Cell-IQ 
instrument (CM-Technologies). Images were taken every hour for 24 h and analyzed with 
the provided software to measure the gap area. Data were then used to draw a sigmoidal 
curve with GraphPad Prism and determine the time necessary to close half of the wound 
area. In this way, 3 genes were selected, whose down-regulation significantly delayed the 
migration of MDA-MB231: Slug/Snai2, RING finger protein 144B (RNF144B) and (brain- 
derived neurotrophic factor) BDNF.
4.13. Cytokine quantification in ascitic fluid and cell culture medium
Conditioned medium of cell cultures and supernatant removed by centrifugation 
of the ascitic fluid collected from mice were stored at -80°C. Medium and ascitic fluid 
were then assayed for cytokines (human and murine TNF, and murine IL-1(3, IL-4, IL-10, 
IFNy and TGF-0 through ELISA kits (Affymetrix) or used in blotting and in neutrophil 
assays.
4.14. Macrophage primary cultures and reporter gene assays
BM precursors were obtained from BALB/c and TLR4-KO mice and used to isolate
64
macrophages from the precursors by cultivation in RPMI medium 10% fetal calf serum 
containing 5 ng/ml macrophage colony-stimulating factor (MCSF). On day 5, the medium 
was replaced with fresh medium containing macrophage colony-stimulating factor. On 
day 7, adherent cells were harvested and phenotypically characterized by 
immunofluorescence using mAb to the macrophage markers C D llb  and F4/80 (BD 
Biosciences). Up to 90% of the adherent population consisted of bone marrow-derived 
macrophages (BMDM). For in vitro experiments, 5x10s BMDM were seeded in six-well 
plates, allowed to attach for 1 h at 37°C and then treated or not with 1 pM SM83. The 
release of TNF and IL-10 to the culture medium, after 3, 6 and 24 h, was evaluated using 
ELISA kits (Affymetrix). In viability experiments, lx lO 4 cells were seeded in 96-well plates 
and exposed to serial dilutions of SM83 in the absence or presence of either 50 pM  
necrostatin-1 (Enzo Life Sciences) or 20 pM z-vad-fmk (Enzo Life Sciences). After 24 h, 
cells were examined morphologically by microscopy and tested for viability using the 
CellTiter-Glo (Thermo Scientific) assay. In other experiments, 104 RAW 264.7 
macrophages (kindly provided by Dr. Sabina Sangaletti) were plated in 96-well plates, 
grown for 16 h and then treated or not with 1 pM SM83 for up to 24 h. The activation of 
the NF-kB promoter was assayed using the Dual-Luciferase Reporter Assay System 
(Thermo Scientific).
4.15. Spleen neutrophil preparation and assays
Neutrophils were obtained from BALB/c (wild-type) or TNF-R1-KO mice through 
immunomagnetic cell separation of a spleen cell suspension, using the Anti-Ly-6G 
MicroBead Kit (Miltenyi Biotec). Migration of neutrophils PMNs was tested using the 
Transwell system (Corning). Briefly, 5x10s PMNs were placed in serum-free RPMI in the 
upper chamber of the Transwell insert. The lower chamber was filled with ascites
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(1:20) or TNF in serum-free DMEM. PMNs were allowed to migrate for 24 h and then 
collected from the lower chamber. In some cases, experiments were performed by adding 
100 mM HMGB-1 inhibitor glycyrrhizin (Sigma-Aldrich, St. Louis, MO, USA) to the top 
chamber.
4.16. High-throughput screening
The high-throughput screening was formerly performed in 2010 at the ICR. At day 1, 
350 HeLa cells/well were seeded in 384-well white plates in 20 pi medium. At day 2, cells 
were treated with or without 100 nM SM83 followed by 3 Food and Drug Administration 
(FDA)-approved drug libraries at the final concentration of 1 pM. At day 3, plates treated 
with SM83 were further treated with 20 pg/ml izTRAIL and viability was tested at day 5 by 
CellTiter-Glo (Promega). Compound hits were selected due to their capability to enhance 
the cytotoxic activity of SM83/izTRAIL and then validated using the same HeLa cells 
employed in the screening. In validation experiments, SM83 and izTRAIL were 
administrated alone and in combination, also changing the schedule and pre-treating cells 
with SM83 24 h before izTRAIL or administrating these compounds simultaneously. On 
the basis of these results, validated hit compounds were tested in a panel of 
premalignant and cancer cell lines.
4.17. Detection of activated KRAS
Due to the lack of a specific antibody detecting the mutated form of KRAS, presence 
of oncogenic KRAS was determined indirectly by western blot of down-stream KRAS 
targets such as phosphorylated ERK1 and ERK2 or by RAS-GTP pull-down assay. In this 
case, 2.5 x 106 cells were seeded into 10 cm dishes. The next day, cells were incubated 
with and without 250 ng/ml of Dox. Cell lysis and RAS-GTP pulldown was performed: cells
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were then lysed in 500 pi in ELB buffer (150mM NaCI, 50mM Hepes pH7, 5mM EDTA, 
0,1% NP-40) supplemented with a cocktail of protease inhibitors. To fully detach lysed 
cells, they were scratched using a cell scraper and transferred into tubes for a 30-minute 
lysis at 4 °C on a rotator. Lysates were centrifuged at 13000 rpm for 30 min and cleared 
supernatants were transferred to a new tube. RAS-GTP was precipitated using beads 
coated with the Raf-1 Ras binding domain (RBD) recombinant protein. The following day, 
beads were washed 5 times with ELB buffer and precipitated protein complexes were 
eluted from the beads via boiling in SDS-Sample buffer for 10 minutes at 80°C. Proteins 
were separated by SDS-PAGE and analyzed by western blot. As control loading, proteins 
were stained by blue coomassie (Thermo Scientific Pierce).
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5. RESULTS
5.1. Building the SM library
In 2007, we started a collaboration with the University of Milan aiming at the 
development of SM compounds. We designed and characterized several compounds. 
During my PhD studies, I focused on dimeric molecules and in particular on the SM83 
compound. The novel dimeric compounds tested are covered by the patent 
W O /2013/124701 (PCT/IB2012/000297: 'Homo- and heterodimeric smac mimetic 
compounds as apoptosis inducers').
5.1.1. Quantification of SM affinity for the IAPs: a fluorescent polarization- 
based binding assay
In collaboration with the University of Milan, we built a library of about 140 novel SM 
compounds, both monomeric and dimeric, which were developed in order to increase the 
affinity for the BIR domains of XIAP, cIAPl and clAP2, but also to improve their 
pharmacokinetic features thus increasing the solubility, the ability to cross the biological 
membranes and also trying to reduce the molecular weight. In fact, small molecules are 
more likely to pass through the biological barriers and are usually characterized by 
increased bioavailability. All the newly synthesized compounds were tested to assess 
their purity (>98%) and then employed in cell-free assays to evaluate their affinity for the 
targets. Each SM was tested by the means of four tests with recombinant proteins 
containing the BIR3 and linkerBIR23 domains of XIAP, the BIR3 of cIAPl (Table 2) and the 
BIR3 of clAP2 (data not shown). In fluorescent polarization-based assays, we evaluated 
the capability of the new compounds to displace a fluorescent probe -  monomeric when
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testing the BIR3 alone, dimeric in the case of the linkerBIR23 of XIAP -  from the 
recombinant proteins. Using serial dilutions of the SMs, it is possible to increasingly free 
the fluorescent probe and cause a reduction of the polarization that is measured as mP. 
This variation is detectable using a Tecan Ultra plate reader. By drawing a sigmoidal curve 
for each compound, we determined the concentration of the SM that displaced half of 
the probe, providing a quantification of the SM affin ity for the recombinant receptor, i.e. 
the BIR domains.
Compound XIAP-BIR3 CIAP1-BIR3 XIAP-lkBIR23
S M 073 80.7 12.6 3.3
SM12 293 <1 (0.6) 5.3
SM38 244 1.7 15.5
SM39 352 2.9 8.4
SM 40 305 1.4 3.9
S M 59b 41.2 <1 (0.7) <1 (0.8)
SM74 181 1.4 5.9
SM75 179 3.8 3.2
SM76 157 3.5 2.3
SM83 25.4 5.4 <1 (0.8)
SM84 65.7 17.6 4.4
SM85 125 1.7 15.5
SM86 120 <1 (0.6) 16.2
SM87 37.5 <1 (0.7) 1.6
SM88 29.9 1.9 <1 (0.3)
SM107 26.7 2.6 <1 (0.8)
SM 108 24.5 1.1 <1(0.1)
SM109 26.0 1.5 <1 (0.2)
SM110 31.1 3.2 <1(0.1)
SM 111 31.2 1.5 <1 (0.1)
SM 112 29.7 5.0 <1(0.1)
SM131 24.9 <1 (0.9) <1 (0.6)
Table 2. Affinities of dimeric SMs tested in fluorescent polarization-based assays. Affinities, 
expressed as concentration (nM) of dimeric SMs that can displace the 50% of the fluorescent 
probe (EC50) in binding assays, were evaluated using the recombinant proteins containing the 
BIR3 domain of XIAP, the BIR3 of cIAPl or the region including the linker region upstream the 
BIR2, the BIR2 and the BIR3 domains.a Called Compound 3 elsewhere (Li et al, 2004);b Called SM- 
164 elsewhere (Sun et al, 2007).
In this experiment, we used also 2 standard compounds from other groups to 
compare our newly designed dimeric SMs to the ones already described in literature. 
These molecules were Compound 3 (Li et al, 2004; called SM007 by us) and SM-164 (Sun 
et al, 2007; SM59). Several of our SMs tested showed similar and even increased affinity 
towards the targets (Table 2), supporting the idea that the modifications introduced by us 
enhanced the binding affinity for the BIR domains and therefore potentially increased the 
efficacy of these compounds. This technique, already employed by us for the 
characterization of the monomeric SMs synthesized (Nikolovska-Coleska et al, 2004; 
Seneci et al, 2009), detected different binding potencies among our SMs and could easily 
be employed in the XIAP BIR3 assay. Unfortunately, in the case of the BIR domains of 
cIAPl, the affinities quantified were very similar to the sensitivity limit of this test, making 
the characterization of the diverse compounds extremely difficult.
5.1.2. In vitro toxicity of SMs
Only the SMs that showed an affinity for the expected targets were employed in 
viability assays to evaluate the cytotoxic activity using a panel of cancer cell lines. In fact, 
we wanted to focus only on the compounds that were target-specific, excluding the ones 
that could still be cytotoxic in cancer cells, but whose mechanism of action would have 
been difficult to predict. For this purpose, we selected the human triple negative breast 
carcinoma MDA-MB231, the promyelocytic leukemia HL-60 and the prostate 
adenocarcinoma PC-3 cell lines, which are known to display different sensitivities to SM 
treatments. Our dimeric SMs showed a nanomolar activity in MDA-MB231 and HL-60 
cells, comparable to SM-164, while showing no or little effect in PC-3 cells (Table 3).
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Compound M D A -M B 231 HL-60 PC-3
S M 07a 0.175
SM12 3.28
SM38 4.84 7.39 >50
SM39 3.32
SM40 0.728
SM 59b 0.039
SM74
SM75 0.337 0.128 >50
SM76 1.60
SM83 0.055 0.071 >50
SM84 0.430
SM85 0.379 0.935 >50
SM86 0.567
SM87 2.30
SM88 0.540
SM 107 45.4
SM 108 10.6
SM 109 46.9
SM 110 0.582
SM111 10.7 20.6 >50
SM112 1.28
SM131 >50
Table 3. Toxicity of dimeric SMs. IC50 (pM) were measured in viability tests employing the human 
breast carcinoma MDA-MB231, acute promyelocytic leukemia HL-60 and prostate cancer PC-3 cell 
lines.a Called Compound 3 elsewhere (Li et al, 2004);b Called SM-164 elsewhere (Sun et al, 2007).
5.1.3. Characterization of SM83
On the basis of the capability to interact w ith the lAPs (5.1.1) and kill in vitro  sensitive 
cancer cell lines (5.1.2), I decided to proceed w ith my studies focusing on the SM83 
compound (Figure 11A). This molecule showed high affin ity for the BIR domains of XIAP, 
cIAPl (Table 2) and clAP2 (data not shown) and was one of the most potent compounds 
in MDA-MB231 and HL-60 cytotoxic assays (Table 3). Furthermore, it showed good 
solubility making its use ideal for in vitro and in vivo experiments. Conversely, other SMs 
of the library such as SM74 were almost completely insoluble, and precipitated in the
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medium and buffers used for cell culturing and mouse treatment. SM83 was then tested 
in pharmacokinetic tests to predict its employability in vivo, confirming that this 
compound is stable and soluble; it spreads in vivo reaching good concentrations in the 
plasma (Figure 11B) and crosses sufficiently the biological barriers despite the remarkable 
molecular weight (M.W.: 1409,54).
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Figure 11. Molecular structure of SM83 and kinetic profiles of SM83. SM83 is a dimeric SM with 
nanomolar affinities for XIAP and cIAPl (A). Mice were injected ip (2 mg/kg, left) or iv (5 mg/kg, 
right) with SM83 and the plasma levels of this SM were evaluated in time-course experiments (B).
5.2. Anti-tumor activity of SM83: the breast cancer model
5.2.1. Effect of SM83 treatment on IAPs
The interaction of SMs with the IAPs triggers the rapid proteasome-dependent 
degradation of cIAPl and clAP2 (Varfolomeev et ol, 2007; Vince et al, 2007), while XIAP 
levels are usually not affected. Accordingly, SM83 rapidly depleted cIAPl and clAP2 in a
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dose-dependent manner, w ithout modifying the levels of XIAP (Figure 12, left). 
Importantly, many works showed that the SM-triggered degradation o f clAP2 is 
dependent on cIAPl presence (Darding et al, 2011). In our experiments, clAP2 is depleted 
by SM83 also in cells w ith down-regulated cIAPl (Figure 12, right) suggesting a direct 
effect on clAP2 and therefore the existence of d ifferent mechanisms by which diverse 
SMs deplete the clAPs.
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Figure 12. SM83 administration depletes cIAPl and clAP2 and allows the stabilization of NIK.
MDA-MB231 cells were treated 3 h with SM83 at the indicated concentrations and western blot 
performed to detect the levels of SM targets cIAPl, clAP2 and XIAP (left panel). MDA-MB231 cells 
were transfected with a non-targeting siRNA and with 2 different siRNAs specific for cIAPl (right 
panel). After 72 h, cells were treated with 100 nM SM83 for 45 min and lysed. Western blot was 
performed to detect SM targets, as in the left panel, and NIK. Actin is shown as a loading control, 
the arrow indicates the specific XIAP band.
cIAPl and clAP2 constitutively ubiquitinate and cause the degradation of NIK 
(Varfolomeev et al, 2007; Vince et al, 2007); as expected, when they are depleted by 
SM83, NIK levels increase (Figure 12, right) and this protein activates the non-canonical 
NF-kB pathway resulting in cleavage of NF-kB2 plOO in p52 (Figure 13).
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Figure 13. SM83-dependent depletion of clAPs stimulates the activation of the non-canonical 
NF-kB pathway. MDA-MB231 cells were treated with 100 nM SM83 for the indicated time and 
harvested for western blot analysis. SM83 treatment causes the complete cIAPl depletion already 
at the first time-point. The activation of the non-canonical NF-kB pathway is demonstrated by the 
cleavage of NF-kB2 from the plOO to the p52 form, while NF-kBl (pl05/p50), a transcription 
factor regulated by the canonical NF-kB pathway is not affected. Actin is shown as a loading 
control. Arrows indicate the specific bands.
5.2.2. Cytotoxic activity towards sensitive cancer cell lines
Initially designed to target XIAP and facilitate the apoptotic cascade triggered by 
other compounds (LaCasse et al, 2008), SMs were later shown to kill some cancer cell 
lines also in monotherapy (Petersen et al, 2007). It was demonstrated that the cell death 
strictly relies on the autocrine secretion of TNF that is further stimulated by SM 
administration and becomes toxic when clAPs are depleted (Vince et al, 2007). In 
accordance with this mechanism, we observed that SM83 can kill some cancer cell lines 
also as a standalone and that its administration activates the apoptotic pathway triggered 
by caspase-8 (Figure 14).
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Figure 14. SM83 triggers a rapid apoptotic response in MDA-MB231 cells. MDA-MB231 cells 
were treated with 100 nM SM83 for the indicated time and harvested for western blot. SM83 
rapidly depletes both clAPl and clAP2 w ithout affecting XIAP levels (left). The apoptotic activation 
is demonstrated by PARP (p89) and caspase-8 (p43/p41), -3 (p l7 /p l9 ) and -9 (p37) cleavage 
(right). Actin is shown as a loading control. Arrows indicate the specific bands.
5.2.3. Combination of SM83 with TRAIL
SMs have been shown to kill a few cancer cell lines as standalones (Vince et al, 2007), 
but they can also be used to enhance the cytotoxic activity of o ther compounds (Probst et 
al, 2010). In particular, they synergize w ith the ligands of the TNF fam ily such as TNF itself 
and TRAIL (Li et al, 2004). The latter combination is extremely interesting from  a clinical 
point of view, because TRAIL treatm ent is well tolerated by patients and selectively kills 
cancer cells while sparing normal tissues. However, at the same tim e it is poorly effective 
in vivo due to short half-life and difficulty in reaching effective concentrations 
(Falschlehner et al, 2009). For this reason, we tested our SM83 in vitro in combination 
w ith soluble TRAIL as well as human CD34+ expressing membrane-bound TRAIL (Lavazza 
et al, 2010). Our results clearly show that SM83 can enhance the cytotoxic activity o f both 
sTRAIL and TRAIL-armed CD34+ cells reducing the viability of both MDA-MB231 (Figure 15
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left) and MDA-MB468 (Figure 15 right), by activating apoptosis (Figure 16).
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Figure 15. Viability of breast cancer cell lines treated with sTRAIL and TRAIL-armed CD34+ cells 
in combination with SM83. MDA-MB231 (left) and MDA-MB468 (right) cells were treated with 50 
ng/ml sTRAIL (izTRAIL) and/or CD34+cells (ratio 1:1 with cancer cells) transduced with 
adenoviruses that allow the expression of membrane-bound TRAIL in combination with SM83 (50 
nM for MDA-MB231, 100 nM MDA-MB468). Viability was measured by AnnV/PI staining after 24 
h of treatment.
It is important to note that MDA-MB231 cells are sensitive to SMs in monotherapy, 
but MDA-MB468 cells are not, confirming that SMs can sensitize to other compounds also 
cancer cells intrinsically resistant to SMs. As expected, treatm ent w ith SM83 completely 
depleted clAPl and clAP2, w ithout affecting XIAP levels (Figure 16A), and resulted in the 
activation of an apoptotic event (Figure 16B and C). In fact, the cleavage of the in itia tor 
caspase-8 and the effector caspase-3 was clearly detectable especially in combination 
treatm ent by western blot, along with the accumulation of cleaved PARP. Employment of 
a fluorescence substrate of caspase-3/-7 further confirmed that MDA-MB231 are partially 
killed by SM83 and TRAIL-CD34+ cells at the concentration used but the treatm ent 
becomes extremely more toxic when both SM83 and mTRAIL are administered (Figure 
16C).
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Figure 16. SM83 enhances the cytotoxic activity of mTRAIL by targeting the lAPs. MDA-MB231 
cells were treated with 50 nM SM83 for 6 h with and w ithout CD34+ cells transduced with 
adenovirus carrying the sequence for membrane-bound TRAIL. Cells were then analyzed by 
western blot detecting SM targets clAPl, clAP2 and XIAP (A), and the markers of apoptosis 
cleaved PARP and caspase-3, and caspase-8 (B). Actin is shown as a loading control. Apoptosis was 
also evaluated using a fluorescent substrate of caspases -3 and -7 (C).
5.2.4. In vivo activity of SM83
To test the employability of SM83 also in vivo, we subcutaneously engrafted 
NOD/SCID mice with the trip le negative breast cancer cell lines MDA-MB468 and MDA- 
MB231. Thirteen days after the inoculum, the animals were treated w ith  ip daily 
injections of 5 mg/kg SM83 and primary tumors were measured w ith a caliper twice a 
week. The treatm ent resulted in a significant reduction of the primary tum or growth in 
both models (Figure 17A and B), meaning that SMs can be effective in vivo also against 
cancer cells that are in vitro resistant to  the treatment. In fact, both MDA-MB231 and 
MDA-MB468 primary tum or volumes were reduced by about 50%. Importantly, the
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inhibitory effect was independent from the administration route (ip vs iv) used (Figure 
17C), and the primary tumors of treated mice started regrowing like the untreated ones 
after the interruption of the injections.
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Figure 17. SM83 inhibits the primary tumor growth of human breast cancers in xenograft 
models. NOD/SCID mice were engrafted with 5 x l06 MDA-MB468 (A) and MDA-MB231 (B). At day 
13, animals were randomized and divided in two groups. One group was treated with daily ip 
injections of 5 mg/kg SM83 showing a reduction of primary tum or growth of about 50% compared 
to untreated animals in both models. The MDA-MB231 model was employed in an independent 
experiment (C) to compare the two different administration routes ip and iv confirming a similar 
efficacy of the treatment in both cases. Dash lines indicate the starting of the treatment. At the 
end of the experiment, animals bearing both MDA-MB468 and MDA-MB231 were euthanized and 
primary tumor collected and weighted, confirming a good correlation between the real tum or size 
and the one deduced by caliper measurement (D).
At the end of the experiment, mice were euthanized and primary tumors, lymph 
nodes and lungs collected. Primary tumors were weighted confirming a good correlation 
between the measurement of the tum or volume by caliper and its actual mass (Figure
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17D). Furthermore, tumors were dissected and lysed fo r biochemical analysis and for RNA 
purification, and paraffin-embedded for IHC.
Protein lysates were then tested in western blots to detect the levels of SM83 targets 
and the markers of apoptosis. As expected, SM83 depleted clAP l (Figure 18) and clAP2 
(data not shown) also in vivo and, interestingly, also reduced the levels of XIAP (Figure 
18). Conversely, despite the fact that tumors were collected 6 h after the last injection, 
little  if any signs of activated apoptosis could be detected in western blots (Figure 18).
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Figure 18. SM83 depletes clAPl in primary breast tumor xenografts. MDA-MB468 (left) and 
MDA-MB231 (right) primary tumors collected from animals treated as in figure 18A and B were 
collected 6 h after the last injections of SM83 and analyzed by western blot. Both models 
confirmed that SM83 depletes clAPl to undetectable levels while reducing XIAP only partially. No 
sign of apoptosis (cleaved PARP and caspase-3) was detectable in MDA-MB231 primary tumors. 
Actin is shown as a loading control. 1641D and 1641S, and 1638D and 1638S are primary tumors 
collected from the two flanks of the same animal (right and left, respectively). The mouse 1634 
was treated with only one injection of SM83 6 h before tumor was collected. MDA-MB231 cells 
were treated in vitro with 100 nM SM83 for 6 h as a control of activated apoptosis.
As the absence of obvious apoptosis could be due to mechanisms of resistance
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acquired after several treatments, we also collected tumors after one single SM83 
injection and western blots were performed. Again, cleaved caspase-3 and reduction of 
caspase-8 were almost completely undetectable. Moreover, tumors were also OCT- 
embedded fo r caspase-3 immunofluorescence (figure 19 left). In this way, we observed 
that only few cells w ithin the primary tum or undergo apoptosis, suggesting that the 
markers of apoptosis might be too faint to be detected in western blot, but also that 
SM83, despite maintaining an anti-cancer potential, is less efficient in vivo in inducing 
apoptosis at the doses used compared to the in vitro settings (Figure 19 right).
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Figure 19. SM83 treatment activates a weak apoptotic event in vivo. Mice engrafted with MDA- 
MB231 cells were treated with one single injection of SM83 at the indicated doses. (Left) Primary 
tumors were collected and OCT-frozen 6 h after SM83 administration. Immunofluorescence 
reveals the activated form of caspase-3 showing that only few cells within the tumor are 
undergoing apoptosis. (Right) Primary tumors were collected from mice treated as in A and lysed 
for western blot. One single injection of SM83 was able to deplete clAPl and clAP2 in a dose- 
dependent manner, but no signs of cleaved PARP, caspase-8 and -3 could be detected. MDA- 
MB231 treated 6 h in vitro with 100 nM SM83 are loaded as positive controls of activated 
apoptosis. Actin is shown as a loading control.
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5.2.5. In vivo combination of SM83 with TRAIL-armed CD34+ cells
After testing the in vitro activity of SM83 in monotherapy and in combination with 
TRAIL, and in vivo as standalone, the capacity of SM83 was also tested in order to 
increase the anti-tum or effect of TRAIL-armed CD34+ cells in animal xenografts. For this, 
NOD/SCID mice engrafted with MDA-MB231 were treated with daily injections of 5 mg/kg 
SM83 plus 4 iv administrations with 106 TRAIL-armed CD34+. Conversely, in the MDA- 
MB468 model, NOD/SCID mice were treated only 4 times w ith SM83 before the 
administration o f TRAIL-armed CD34+cells.
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Figure 20. TRAIL-armed CD34+ cells are ineffective against breast cancer primary tumors.
NOD/SCID mice were engrafted with MDA-MB468 cells and treated 4 times with SM83 with or 
without CD34+ cells expressing membrane-bound TRAIL (A). NOD/SCID mice were engrafted with 
MDA-MB231 cells and after 13 days treated with daily injections of 5 mg/kg SM83 plus 4 
administrations of 105 TRAIL-armed CD34+ cells (B). Two weeks after the last treatment, tumors 
were collected and weighted (g) revealing no significant difference among the animal groups (C).
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In both cases, the outcome of the combination treatment on primary tumor was very 
modest and the reduction of tumor growth was only due to SM83 administration, while 
the combination with the TRAIL-CD34+ cells had no effect (Figure 20). Again, after the 
interruption of the treatment, tumor started growing at the same rate in both treated  
and untreated animals, and tumor masses were similar in each group.
5.2.6. Anti-metastatic effect of SM83
MDA-MB231 cells spontaneously metastasize in immunosuppressed animals. 
Therefore, at the end of the in vivo experiment, lungs were collected and IHC stained to  
study a possible effect of SM83 treatment on lung metastasis. MDA-MB231 micro and 
macro-metastasis are easily detectable by IHC in the lung tissues because they express 
high levels of vimentin. Analysis of the number and size of the metastasis showed a 
significant reduction of spontaneous lung metastasis in animals treated with SM83. Of 
note, despite the fact that the combination with CD34+ cells had no effect on primary 
tumors, it further increased the anti-metastatic effect of SM83 (Figure 21). Importantly, in 
an independent experiment, we tested the anti-metastatic effect of SM83 comparing two  
administration routes, i.e. intravenous and intraperitoneal injections (Figure 17C).
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Figure 21. SM83 reduces spontaneous metastasis to the lungs. As MDA-MB231 cells are known 
to spontaneously metastasize to distal organs, lungs from mice of the experiments described in 
figure 20B were collected and paraffin-fixed. IHC of lungs with anti-vimentin revealed a reduction 
of the capability to form lung metastasis in animals treated with SM83 alone and in combination 
with TRAIL-armed CD34+ cells (A). Analysis of the number (B) and size (C) of lung metastasis 
confirmed the anti-metastasis effect of SM83 treatment that was further increased in 
combination with TRAIL-armed CD34+ cells. *p<0.05, **p<0.01
As for the effect on primary tumors, the different routes had the same effect on 
metastasis: both reducing in a significant fashion the number of lung metastasis (Figure 
22). Of note, treatm ent w ith SM83 completely abrogated metastasis form ation in some 
animals (Table 4).
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Figure 22. SM83 administration in monotherapy reduces the formation of lung metastasis 
independently of the administration route. Lungs collected from animals of the experiment 17C 
were collected and paraffin-embedded for IHC analysis with the anti-vimentin antibody to reveal 
lung metastasis (A). Analysis of the number of lung metastasis confirmed the anti-metastasis 
effect of SM83 treatment independently whether the compound was administered ip or iv (B). 
***  P < 0.001
Treatm ent Metastasis-free mice
UN 0/7
SM83 i.p. 2/8
CD34-TRAIL 0/6
CD34-TRAIL + SM83 2/6
SM83 i.v. 3/6
Table 4. Summary of the various treatments of MDA-MB231 engrafted mice and number of the 
animals with no detectable lung metastasis. All NOD/SCID animals engrafted with MDA-MB231 
cells developed detectable lung metastasis. A few animals treated with SM83, alone or in 
combination therapy, showed no metastasis formation, whilst treatment with TRAIL-CD34+ did 
not prevent lung metastasis in any mice.
5.2.7. Modulation of tumor gene expression by IAPs
lAPs were in itia lly  though t to  be essentially negative regulators o f apoptosis, bu t it is
now clear that they are also apical modulators of several signaling pathways and control 
MAPK and NF-kB signaling. By causing the degradation of clAPl and clAP2, and also 
targeting XIAP, SMs can thus influence the trans-activation of several genes. Therefore, 
we speculated that the anti-metastasis effect observed in vivo could be at least in part 
mediated by the inhibition of expression of genes involved in the metastatic process. For 
this reason, RNA was extracted from MDA-MB231 primary tumors collected in treated 
and untreated mice (Figure 17B), and gene expression analysis was performed. In this 
way, we identified 15 genes significantly down- and 50 up-regulated regulated by the 
treatm ent (Figure 23).
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Figure 23. GEP of MDA-MB231 primary tumors collected 6 h after the last SM83 injection.
Primary tumors of experiment as described in figure 17B were collected and lysed fo r RNA 
extraction. Gene expression profiles revealed that 65 genes were significantly modulated by SM83 
treatment with 50 genes up-regulated and 15 down-regulated.
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Many of the up-regulated genes are known targets o f the NF-KB pathway (e.g. 
baculoviral IAP repeat containing 3/BIRC3, matrix metallopeptidase-9/MMP9, 
intercellular adhesion molecule 1/ICAM1) or are involved in its regulation (e.g. TRAF1, 
TRAF2, NFKBIA, NFKB2, RelB). To identify the genes responsible fo r the anti-metastasis 
effect o f SM83, we individually knocked-down by siRNAs each of the genes down- 
regulated in the GEF. Transfected MDA-MB231 cells were then tested in proliferation 
experiments (data not shown) and wound-healing migration assays. In this way, we 
selected three genes, whose down-regulation prevents in vitro  the m otility  o f cancer 
cells: Snai2/Slug, RNF144B and BDNF (Table 5). As Snai2/Slug is a mediator of the EMT, a 
fundamental step in metastasis formation, we decided to focus on this gene.
BDNF SNAI2 RNF144B PAPPA KLHL3 PTPRU FOXQ1 NT1 MERTK GPER CTGF HSDL1 A N TIM IR 221 RGS4 OSR1
T 'A, h 19.69 17.71 14.21 11.67 11 .04 10 .54 9.697 8 .78 8.45 8 .403 8 .348 7 .4 4 4 7.034 6 .09 5 .1 1 7
Table 5. Effect of the silencing of the 15 genes selected by GEP on MDA-MB231 in vitro 
migration. The 15 genes shown to be down-regulated in vivo by SM83 treatment and identified 
by GEP (Figure 23) were silenced in MDA-MB231 cells that were then tested in wound healing 
assays. Wound area was measured every hour and values plotted to evaluate the time necessary 
to close half of the gap (T l/2, h). NT1 is a non-targeting siRNA used as control.
5.2.8. SM83 treatment reduces Snai2 levels in vivo
GEP of primary tumors treated w ith SM83 showed a reduction of the expression 
levels of Snai2; we then investigated whether there was a reduction also at the protein 
level. Tumors were thus analyzed by western blot that confirmed a significant reduction 
of Snai2 protein along w ith clAPl (Figure 24). Interestingly, MDA-MB468 tumors, which 
are poorly metastatic in vivo, showed Snai2 levels below the detection level, both in 
treated and untreated tumors.
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Figure 24. SM83 treatment reduces the levels of Snai2 protein in primary breast cancer 
xenografts. MDA-MB231 (A) and MDA-MB468 (B) primary tumors collected from experiments 
shown in figure 17B and 17A respectively were lysed for protein extraction and analyzed by 
western blot to detect Snai2 and LRIG1 levels, along with clAPl. Actin is shown as a loading 
control. Upper panel show the densitometric analysis of the western blot shown in the lower 
panels. * p<0.05
5.2.9. clAPl, but not cIAP2, depletion is responsible for Snai2 down-regulation
To investigate whether SM83 treatm ent is sufficient to reduce the levels o f Snai2, 
MDA-MB231 cells were treated also in vitro  fo r 6 h (Figure 25A) or in time-course 
experiments (Figure 25B). These experiments confirmed that the targeting o f the lAPs 
reduces the levels of this protein. Furthermore, as SMs are known to target at least three
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members of the IAP family -  clAPl, clAP2 and XIAP -  and cause the degradation of clAPl 
and clAP2, we silenced these proteins in order to investigate whether their reduction is 
sufficient for Snai2 decrease (Figure 25A). By western blot, we observed that clAPl 
targeting, but not clAP2, affects Snai2 levels suggesting that clAPl is the IAP responsible 
for sustaining the levels of this pro-metastasis gene. As SM83 treatment is toxic for MDA- 
MB231, we also checked that the reduction of Snai2 does not stem from an SM83-related 
cytotoxic effect by pre-treatment of the cells with inhibitors of apoptosis and necroptosis. 
As Snai2 levels are reduced in the same manner also in the presence of death blockers 
(Figure 25C), we concluded that this effect is due to clAPl targeting and not to a toxic 
side-effect. Moreover, to test whether clAPl regulates Snai2 only in a cell-type manner or 
whether this effect is reproducible also in other cells, a panel of breast cancer cells was 
treated with SM83. By western blot, we found that only few cell lines express high levels 
of Snai2, and SM83 administration reduces its levels also in BT-549 cells (Figure 25D).
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Figure 25. SM83-mediated depletion of clAPl down-regulates Snai2 levels. MDA-MB231 cells 
were transfected with siRNAs targeting clAPl and/or clAP2 and treated with 100 nM SM83 for 6 h 
or left untreated. Western blot was performed to detect clAPl, clAP2 and Snai2 showing that 
clAPl silencing or depletion due to SM83 treatment reduces the levels of Snai2 (A). Time-course 
experiments showing the reduction of Snai2 after 100 nM SM83 administration (B). MDA-MB231 
cells were pre-treated for 1 h with caspase inhibitor z-VAD, RIP1 inhibitor Nec-1, IKK inhibitor and 
the protein translation inhibitor CHX, and then treated with 100 nM SM83 for 6 h. Levels of Snai2 
were studied whereas clAPl, cleaved caspase-3 and NF-kB2 were detected to confirm the efficacy 
of IKKi, SM83 and zvad administration. Only prevention of the NF-kB pathway partially blocked 
the SM83-dependent down-regulation of Snai2 (C). The capacity of SM83 to reduce the levels of 
Snai2 was confirmed also in other human breast cancer cell lines (D). Actin and vinculin are shown 
as loading controls.
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5.2.10. Activation of the non-canonical NF-kB pathway correlates with Snai2 
reduction
clAPl and clAP2 are known to negatively regulate the non-canonical while promoting 
the canonical NF-kB pathway. SM-mediated clAPl depletion thus results in the opposite 
effect, i.e. stimulation of the non-canonical NF-KB pathway and prevention of the 
activation of the canonical one. To understand which of these events is responsible for 
the reduction of Snai2, we silenced several mediators of the NF-kB pathways and 
stimulated MDA-MB231 cells with SM83. As expected, Snai2 was down-regulated by 
SM83 in cells transfected with a non-targeting siRNA, but depletion of NIK and NF-kB2 
resulted in stabilization of Snai2, strongly suggesting that the activation of this pathway 
inhibits Snai2 expression (Figure 26A). Moreover, we treated the MDA-MB231 cells with 
TWEAK, a ligand of the TNF family, which preferentially activates the non-canonical NF-kB 
pathway. In accordance with SM83 treatment, TWEAK administration resulted in lower 
levels of Snai2 (Figure 26B). In clear contrast, TNF administration stimulated Snai2 levels 
(Figure 26C).
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Figure 26. Snai2 down-regulation correlates with non-canonical NF-kB activation. MDA-MB231 
cells were transfected with siRNA targeting several mediators and regulators of the NF-kB 
pathway. After 72 h, cells were treated with 100 nM SM83 for 6 h and harvested. Western blot 
revealed that prevention of the non-canonical NF-kB activation by down-regulation of NIK and NF- 
kB2, blocked SM83-mediated Snai2 down-regulation (A). The MDA-MB231 cell line was treated 
with 200 ng/ml TWEAK, a ligand that preferentially activates the non-canonical NF-kB pathway, in 
a time-course experiment. Western blot shows that TWEAK-mediated activation of the non- 
canonical NF-kB pathway correlates with the down-regulation of Snai2 (B). On the contrary, 
stimulation of the MDA-MB231 cells with 50 ng/ml TNF stimulated the expression of Snai2 (C). 
Actin is shown as a loading control.
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5.3. Affecting the immune system: the ovarian model
Besides the investigation of SM83 activity in a model that is intrinsically sensitive to 
SM treatment such as the MDA-MB231 cell line, we also studied different models, using 
cell lines resistant to SMs in vitro. Furthermore, as SMs are known to modulate cancer 
microenvironment by causing the secretion of several cytokines, we tested the efficacy of 
SM83 in cancer ascites models, in which the environment greatly controls the tumor 
development and it is easy to detect cytokine levels and the number of cells, by collecting 
the ascitic fluid.
5.3.1. In vitro activity of SM83 against ovarian cancer cell lines
Despite SM83 showing a good cytotoxic activity in monotherapy towards few  cancer 
cell lines such as MDA-MB231 and Kym-1, it is unable to trigger apoptosis in the vast 
majority of cancer cell lines. Nonetheless, as shown above, SM83 can enhance the in vitro 
activity of other compounds in combination therapy. Due to this property, ovarian 
carcinoma IGROV-1 cells, not affected by SM83 treatm ent as a standalone (Figure 27A), 
are killed in combination with TRAIL and this is caused by the activation of the apoptotic 
pathway as demonstrated by PARP cleavage (Figure 27B and C). To compare the in vitro 
capacity of SM83 to activate apoptosis in combination with TRAIL with a literature 
standard, IGROV-1 were also treated with SM-164 (SM59), showing almost the same 
cytotoxic activity in this model (Figure 27C).
92
ATLX
T
□  -
□  SM83, 0.1 nM
□  SM83, 1 nM
0 0.1 1 0.1 1 0 0.1 1 0.1 1 SM83 pM
+ - - + + TRAIL
0 0.1 1 0.1 1 0 0.1 1 0.1 1 SM 59pM  
+ TRAIL
Cl PARP m t w r Cl PARP
m m  m clAPl m m  m - CIAP1
CIAP2 -------------- ~ CIAP2
—  —  — ■ —  — XIAP ->
XIAP
— » _ 7T " *■r 
« 9 9 f l a « r r n Actin Actin
Figure 27. SM83 enhances the pro-apoptotic activity of TRAIL. (A) IGROV-1 cells were treated 
with 0.1 or 1 pM SM83 alone or in combination with 2 or 10 ng/mL TRAIL and cells counted after 
72 h. Cell growth is expressed as a percentage relative to cells mock-treated with vehicle. Values 
are shown as mean with standard deviation (SD). Western blot analysis of XIAP, clAPl, clAP2 and 
cleaved PARP (Cl PARP) in IGROV-1 cells treated 3 or 24 h with 0.1 and 1 pM SM83 (B) or SM59 (C) 
in the absence or presence of 10 ng/mL TRAIL. Actin is detected as a loading control. Arrows show 
the specific XIAP band.
5.3.2. In vivo activity of SM83 in cancer ascites
IGROV-1 cells can grow both in vitro and in vivo, injected subcutaneously and in the 
peritoneum of immunosuppressed mice. In the latter case, tum or cells develop cancer 
ascites constituted by ascitic fluid heavily infiltrated w ith cells of the immune system such 
as macrophages and neutrophils, and floating cancer cells. Furthermore, tum or nodules 
develop in the inner side of the peritoneum wall. To investigate whether SM83 displays 
an anti-tum or effect also in vivo, ascites-bearing nude mice were daily injected w ith this
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compound in monotherapy or in combination with TRAIL (Figure 28A). As a control of the
efficacy of our compound, mice bearing IGROV-1 ascites were also treated with the SM- 
164 compound (Figure 28B).
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Figure 28. SMs increase the survival of mice engrafted bearing cancer ascites. (A) Nude mice 
were injected ip with IGROV-1 cells and left untreated (O) or treated 5 times a week, with 5 
mg/kg SM83 (^ ), 2.5 mg/kg TRAIL (V ), or with the same doses of SM83 and TRAIL together {M). 
Treatment lasted for 2 consecutive weeks and started the day after injection. Each treatment 
group contained 7 mice. Survival curve for SM83-treated mice and controls is shown. (B) Survival 
curve for SM59-treated and control mice. Untreated (O) or treated with SM59 (V ). (C) The 
formation of ascites was checked by monitoring body weight on day 17. BALB/c mice were 
injected with Meth A cells and, starting on day 7, were treated daily with 5 mg/kg SM83. (D) The 
formation of ascites was checked by monitoring body weight on day 13. The horizontal line 
represents the mean. (E) Survival curve for untreated (©) or mice treated with SM83 (O ) starting 
from day 7.
Surprisingly and conversely to what was observed in vitro, SM83 treatm ent was 
effective also in monotherapy, reducing the mouse ascites volumes (Figure 28C) and
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prolonging mouse survival (Figure 28A). The comparison with SM-164 showed little 
differences of activity between the two compounds (Figure 28B). Interestingly, the 
combination with TRAIL did not increase the efficacy of the treatm ent; once more 
supporting the idea that SMs can display different effects and mechanisms of activity in 
vitro and in vivo. To further assess whether the SM83 anti-tumor effect observed in 
IGROV-1 ascites was reproducible and not restricted to the model used, SM83 was used 
to treat immunocompetent BALB/c mice injected with syngenic Meth A cancer cells, 
which form ascites too. Even using this model, SM83 treatment reduced the ascites 
volume (Figure 28D) and increased mouse survival (Figure 28E).
5.3.3. SM83 rapidly kills the cancer cells within the ascites
To understand the mechanism of SM83 activity in vivo, mice bearing IGROV-1 
ascites were injected once with SM83 and the ascitic fluid was collected at different time 
points. Detached tumor cells were counted, showing a striking decrease in SM83-treated  
mice at 24 h compared to the control of untreated mice, without appreciable changes at 
3 or 6 h (Figure 29A). The autopsy revealed neither cancer cell peritoneal wall adhesion 
nor migration outside the peritoneum. Furthermore, a significant increase of human 
cytokeratin-18 was detected in the serum of mice treated for 24 h (Figure 29B). Since this 
protein is released from dying epithelial cells, this observation strongly supports the idea 
that SM83 treatm ent was reducing the number of human tumor cells within the ascites 
by killing them.
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Figure 29. SM83 rapidly kills the IGROV-1 cells floating in mouse ascites. (A) The ascitic fluids 
were collected from nude mice injected with IGROV-1 cells and left untreated or treated with a 
single injection of SM83 (5 mg/kg). The graph shows the number of tumor cells within the ascites 
of untreated animals (n= ll) or of animals treated for 3 h (n=4), 6 h (n=4) and 24 h (n=9). Data are 
mean and SD. (B) Levels of human cytokeratin-18 in the serum collected 24 h after a single dose 
of SM83 (5 mg/kg) or after no treatment. (C) Western blot of the SM targets in IGROV-1 cells 
cultured in vitro or recovered from the ascites of control mice (n=2) or mice treated with SM83 
(n=2) or TRAIL for 24 h. Actin is shown as the loading control.
To investigate the mechanism responsible fo r cancer cell killing, the tum or cells 
present in the ascites were lysed and used in western blot analysis that confirmed the 
capacity of SM83 to trigger, also in vivo, the degradation of clAPl and clAP2. As expected, 
XIAP was only slightly affected by the treatm ent (Figure 29C).
Moreover, in an attem pt to understand the cell death mechanisms responsible for 
the rapid decrease of floating tum or cells, we detected the markers of activated 
apoptosis at different time points. At 24 h, SM83 treatm ent led to  a fa int increase of 
cleaved PARP, there was no evidence of cleaved, active caspase-8 and only a modest 
effect on cleavage of caspase-3 (Figure 30A). As control, we also detected these apoptotic 
markers in ascites cells treated with TRAIL, which, despite being ineffective in reducing 
the ascitic cell number, still showed a greater activation of apoptosis (compare figure 30A
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and B).
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Figure 30. SM83 kills the cancer cells within the ascites mainly by a non-apoptotic mechanism.
(A) Western blot showing the activated apoptosis markers cleaved PARP (p89), caspase-8 
(precursor p55 and cleaved form p43/41) and cleaved caspase-3 (p l9 /p l7 ) in IGROV-1 cells 
cultured in vitro or recovered from the ascites (24 h) of control mice (n=2) and of mice treated 
with 5 mg/kg SM83 (n=2) or 10 mg/kg TRAIL. Actin is shown as a loading control. (B) Tumor cell 
counts from ascites of untreated nude mice (2 mice, UN) or treated with 5 mg/kg SM83 (2) or 2.5 
mg/kg TRAIL for 24 h. (C) Western blot of apoptotic markers in tumor cells collected from the 
ascites of untreated mice (n=2) or from mice treated for 3 or 6 h with SM83 (n=2 for both) or with 
TRAIL for 24 h. Arrow, specific band for XIAP. (D) Western blot to detect the autophagy mediators 
LC3B and beclin-1 in IGROV-1 cells harvested from the ascites of mice untreated (UN) or treated 
with a single dose of 5 mg/kg SM83 and collected at the indicated times, or treated with 2.5 
mg/kg TRAIL and collected 24 h later. Actin is the loading control.
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In an attem pt to detect the apoptotic events, western blot analysis was performed 
with cells collected after 3 and 6 hours of treatment. Also in this case, SM83 caused the 
complete degradation of clAPl and clAP2, but only a faint accumulation of the active 
forms of PARP, caspase-8 and caspase-3 (Figure 30C). The low activation of the apoptotic 
cascade suggested that the cause of tumor cell death was not mainly apoptotic. To test 
the possibility that autophagy was responsible for the loss of ascites tum or cells, we 
measured the levels of beclin-1 and of cleaved LC3B. Autophagy in fact is usually 
considered a protective cell mechanism to environmental insults but, when abnormally 
and continuously activated, it can also lead to cell death. Nonetheless, as SM83 treatment 
did not increase the levels of these proteins (Figure 30D), we concluded that autophagy 
was not involved in SM83-induced tumor cell death, strongly suggesting that the death 
was more likely to be necrotic.
5.3.4. SM83 triggers the secretion of pro-inflammatory cytokines in vivo
Since SM83 cell killing in monotherapy is known to be dependent on autocrine TNF 
secretion of sensitive cancer cells, we measured the levels of inflammatory cytokines in 
the ascites. There was a basal level of murine TNF in the ascites of untreated mice that 
significantly increased after SM83 treatm ent at 3 and 6 h, but not at 24 h (Figure 31A). 
Conversely, human TNF was at first not affected by SM83 treatment, but increased after 6 
h probably stimulated also by murine TNF (Figure 31B).
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Figure 31. SM83 rapidly induces the secretion of mouse TNF, which also stimulates the 
production of cancer cell TNF. Nude mice were injected ip with IGROV-1 cells and treated or not 
treated with a single dose of 5 mg/kg SM83; ascites was collected 3, 6 and 24 h after SM83 
administration. (A) SM83 transiently increased the level of murine TNF measured by ELISA. (B) 
Levels of human TNF in ascites of untreated nude mice or after 3 h of treatment with a single 
injection of 5 mg/kg SM83. * P < 0.05, ***  P < 0.001
To test the relevance of TNF in this model, mice were then pre-treated w ith two 
inhibitors of TNF, Etanercept and Infliximab. High doses of Etanercept completely 
prevented the cytotoxic effect of SM83 (Figure 32A). Importantly, Etanercept did not 
affect SM83-triggered degradation of clAPs (Figure 32B). This demonstrates tha t the 
production of TNF is the determining factor responsible fo r SM-mediated toxicity, while 
the down-regulation of the clAPs is a direct effect o f SM83 administration. However, it is 
not sufficient to kill cancer cells on its own. Overall, these data suggest tha t SM83 in vivo 
cytotoxic activity stems from the stimulation and secretion of murine TNF, which rapidly 
kills the detached cancer cells w ithin the ascitic fluid. Also human TNF, produced by 
IGROV-1 cells in response to mouse TNF, might play a role in cancer cell killing. Of note, 
Infliximab, which is more specific for human than mouse TNF, failed to rescue cells (data 
not shown), contrary to Enbrel (a much broader TNF blocker). However, we cannot 
exclude the fact that the different outcome observed is only due to the doses used and
1000
800
600
200
0
24h3h 6hun
99
not to a d ifferent role played by human and mouse TNF.
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Figure 32. SM83-mediated killing of cancer cells within ascites is TNF-dependent. (A) SM83 
treatment reduces the number of cancer ascites cells, but this effect is prevented when TNF is 
blocked with high doses of Etanercept. (B) Western blots of ascites tumor cell protein from 
untreated mice and mice treated with SM83 alone or in combination with 150 mg/kg Etanercept. 
Arrows indicate the specific band for XIAP.
As TNF is a pro-inflammatory cytokine, we checked whether the SM83-dependent 
secretion of TNF was indeed stimulating a pro-inflammatory environment and therefore 
tested murine cytokines IL-lp and IFN-y levels in the ascitic fluid. Interestingly, we found 
that they were all up-regulated in response to SM83 administration (Figure 33A and B). In 
clear contrast, the levels of some immunosuppressive cytokines, such as IL-10, TGF-p and 
IL-4, remained mostly unchanged, w ith the exception of IL-4, which significantly increased 
at 24 h, most likely secreted to restrain the strong inflammation in process (Figure 33C, D 
and E).
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Figure 33. SM83 triggers the secretion of pro-inflammatory cytokines in vivo. Nude mice bearing 
IGROV-1 cancer ascites were treated or not treated with a single dose of 5 mg/kg SM83; ascites 
was collected 3, 6 and 24 h after SM83 administration. ELISA results for IL-lp (A), IFN-y (B), IL-10 
(C), TGF-J3 (D) and IL-4 (E) in the ascitic fluid of mice treated as above. Results for IL-10 are shown 
as fold induction due to the lack of recombinant protein standard.
5.3.5. SM83 is toxic for macrophages and stimulates their cytokine secretion
To test if the pro-inflammatory effect of SM83 relied on the activation of 
macrophages, BMDMs from BALB/c mice were treated in vitro w ith SM83 and the cell 
supernatants assayed for TNF and IL-lp  levels. As expected, SM83-stimulated 
macrophages secreted TNF and also IL-1(3 at later time points (Figure 34A and B). 
Moreover, as macrophage activation depends on the NF-kB pathway, we checked 
whether SM83 modulated this pathway. For this purpose, we employed a macrophage 
cell line stably transfected with a luciferase reporter gene under the control o f the NF-kB 
response element. NF-kB activation was rapidly detectable after SM83 adm inistration but 
returned to basal levels after 24 h (Figure 34C).
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Figure 34. SM83 stimulates macrophage TNF, IL-ip secretion and NF-kB activation. BALB/c 
BMDMs were treated or not treated with 1 pM SM83 for up to 24 h. SM83 treatment promoted 
the secretion of the pro-inflammatory cytokines TNF (A) and IL-ip (B). (C) NF-kB activation by 
SM83 evaluated in the macrophage cell line RAW stably transfected with a NF-kB luciferase 
reporter gene.
Moreover, SM83 treatm ent also killed the BMDM through a necroptotic mechanism, 
which was evident after 24 h of treatm ent both by morphology and viability tests (Figure 
35). In fact, the cytotoxicity could be prevented by pre-treatment w ith the necroptosis 
inh ibitor necrostatin-1, but not by the pan-caspase inhibitor z-vad-fmk, which actually 
increased BMDM death (Figure 35B). Our data suggest that macrophages could be the 
first target of SM83. Macrophages are then stimulated and secrete various pro- 
inflammatory cytokines such as TNF and IL-ip, which favor the form ation of an anti­
tum or pro-inflammatory environment.
Importantly, to exclude the possibility that SM83-dependent activation of 
macrophages and IL-lp production could be due to a contamination of LPS, via the 
stimulation of TLR-4, we also employed BMDM from TLR4-KO mice and found tha t IL-1(3 
was secreted to a similar extent as it was from BALB/c cells (Figure 36).
102
A B
c o n tro l
S M 8 3 +  S M 8 3  +  z v a d - 
n e c ro s ta tin -1 fin k
Z, N  ■'
&  Ifc, '
f c ™ -c > -
.‘V & 80
£ □  rtc-'cs tatin-1. SO uM 
□  rv>>frn<. 20 uM
1000 100 10
Figure 35. SM83 kills BMDM by necroptosis. BALB/c BMDMs were treated with serial dilutions of 
SM83 in the absence or presence of Necrostatin-1 or z-vad-fmk to inhibit necroptosis or 
apoptosis, respectively. (A) Representative images showing cell morphology after 24 h of 
treatment. (B) Cell viability after SM83 treatment evaluated using the CellTiter-Glo assay.
Furthermore, SM83 preparations for injection were analyzed by the Endosafe-PTS 
(Charles River Laboratories) test. The test was negative, confirming that, if present, 
lipopolysaccharides (LPS) levels were under detectable levels.
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Figure 36. SM83-mediated secretion of IL-lp is not due to LPS contamination. Levels of mouse 
IL-ip secreted in the culture medium by wild-type or TLR4-/- BMDM, untreated or treated for 24 
h with 1 0M SM83, in the absence or presence of 100 pM glycyrrhizin (Glz).
5.3.6. SM83 treatment causes the recruitment of neutrophils in vivo
After having investigated the pro-inflammatory effect of SM83 in the tum or 
microenvironment, we next evaluated whether this resulted in a modification of the
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innate immune cells infiltrating the ascites. By IF, we identified both 
monocytes/macrophages (C D llb + G r-l', Figure 37A) and granulocytes (C D llb + Gr-1+, 
Figure 37A and B in mice that were either untreated or treated fo r 3 and 6 h, w ithout 
noticeable differences in cell density. However, after 24 h of treatm ent, neutrophils 
massively accumulated both in the ascitic fluid (Figure 37A and B) and in the tum or 
nodules (Figure 38).
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Figure 37. SM83 promotes peritoneal recruitment of neutrophils while TNF-blockers prevent 
this effect. (A) Cells were harvested from the ascitic fluid of mice treated with 5 mg/kg SM83 and 
immunofluorescence for CD llb (green) and Gr-l (red) was performed on cytospin cell 
preparations. SM83 treatment induced a massive recruitment of neutrophils (C D llb+ Gr-1+) at 24 
h but not at earlier time points. (B) DAPI nuclear stain and anti-Ly-6G immunofluorescence of cells 
collected from ascites of nude mice left untreated (UN), treated with 5 mg/kg SM83 alone, with 
SM83 and 150 mg/kg Etanercept, or with SM83 24 h after neutrophil depletion by injection of the 
mAb 1A8.
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Figure 38. SM83 also stimulates neutrophil accumulation in the solid tumors attached to the 
peritoneal wall. Histology (H&E stain) of IGROV-1 solid tumors from mice injected ip with IGROV- 
1 cells and treated or not with a single dose of 5 mg/kg SM83. Solid tumors were recovered from 
untreated animals (A-B) or from treated animals after 3 h (C), 6 h (D) and 24 h (E-F). SM83 
treatment increased the amount of infiltrating leukocytes mainly after 24 h of treatment.
In an attem pt to explain the massive neutrophil recruitment, we detected by dot blot 
the presence of HMGB-1 in the ascites (Figure 39A and B). This "alarm in" is in fact 
released during necrosis and immunogenic cell death and, together with TNF, attracts and 
activates neutrophils. We therefore checked whether this was true also in our model and, 
according to our hypothesis, we found that HMGB-1 accumulated in the ascitic fluid 
starting 6 h after SM83 treatm ent (Figure 39A) and was located w ithin the cytoplasm of 
dying tum or cells (Figure 39B).
105
A B
un 
3 h 
6 h 
24 h
• •©••  •• •
Figure 39. Treatment with SM83 causes the release of HMGB-1 into the ascitic fluid. (A) Dot blot 
of HMGB-1 (left panel) was performed on cleared ascitic fluids collected from untreated (un) or 
treated mice at 3, 6 and 24 h after a single injection of 5 mg/kg SM83. Right panel, loading 
control. (B) Infiltration of neutrophils (Gr-l; red) and HMGB-1 expression in dying tumor cells 
(green) in ascites untreated (upper row) and treated for 24 h (lower row) with a single injection of 
SM83. Left and right panels show two different magnifications (lOx and 40x).
To confirm that neutrophils can be recruited by HMGB-1 and TNF, we isolated the 
neutrophils from spleens of BALB/c (wild-type) and TNF-Rl-deficient mice. In Transwell 
assays, the migration o f wild-type neutrophils towards ascites from SM83-treated mice 
was greater than that from untreated mice. The HMGB-1 inhibitor partially reduced the 
migration, while neutrophils from TNFR-l-deficient mice did not migrate in response to 
ascites from SM83-treated mice (Figure 40). These findings suggest tha t neutrophil 
migration in the presence of ascites from SM83-treated mice is stimulated mainly by TNF. 
These in vitro data recapitulated the in vivo observations where TNF-inhibitor Etanercept 
blocked the recruitment of these cells into the ascites (Figure 37B).
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Figure 40. Neutrophils are recruited in a TNF-dependent manner. PMN migration assessed by 
Transwell assay. Wild type PMN from BALB/c mice (WT) or TNFR-l-deficient PMN from TNFR-KO 
mice (KO) were seeded into the upper chamber in the absence or presence of the HMGB-1 
inhibitor glycyrrhizin (GLZ), whereas the ascitic fluid of mice untreated or treated for 6 h (1:20 in 
medium) was added to the lower chamber of the Transwell insert. PMN were left to migrate 
overnight harvested and counted.
5.3.7. The recruitment of neutrophils is a by-stander effect of the treatment
Knowing that, in certain conditions, neutrophils can be responsible fo r tum or cell 
killing, we depleted the neutrophils of ascites-bearing mice prior to SM83 treatm ent. In 
nude mice, this depletion did not impede the ability of SM83 to reduce the number of 
floating tum or cells in the ascites (Figure 41A and B). Furthermore, in imm unocom petent 
BALB/c mice bearing Meth A ascites, depletion of neutrophils did not prevent SM83 from 
prolonging survival, even though these mice have CD8+ T cells that are known to  support 
the activity of neutrophils. On the contrary, neutrophil depletion improved the efficacy of 
SM83 treatm ent by a significant increase of the overall survival o f mice treated w ith 
SM83 (p=0.0458 vs 1A8 alone; figure 41C). These results support the notion that, in our 
models, neutrophils recruitment plays no role in SM-dependent cancer cell killing but 
rather, at least in the Meth A model, could be in some way detrimental fo r the host.
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Figure 41. Neutrophils are not responsible for SM83-mediated depletion of ascitic IGROV-1. (A)
Neutrophil depletion was checked in mice untreated, treated with 1 injection of 1A8, and in mice 
injected with both SM83 and 1A8. Flow cytometry of peripheral blood mononuclear cells (PBMCs) 
shows a reduction in circulating Ly6G+ C D llb+ neutrophils in lA8-treated mice. (B) Tumor cell 
counts in the ascites of untreated mice (UN), mice treated with a single injection of SM83 alone, 
or mice treated with SM83 24 h after depletion of neutrophils by injection with the 1A8 mAb. (C) 
BALB/c mice were injected ip with Meth A cells and treated with 1A8 alone (H) or in combination 
with 5 mg/kg SM83 (□), starting from day 7.
5.3.8. Proposed model for SM activity in cancer ascites
In conclusion, our work shows that SM83 acts in vivo in cancer ascites by targeting 
macrophages associated w ith tum or and most likely by causing the ir skewing from  an 
M2-like phenotype, which supports the tumor, to an M l-like  phenotype, endowed w ith 
anti-tum or activity. As a result, macrophages secrete cytokines such as TNF, IL-lp and 
IFNy that cause a rapid TNF-dependent necrotic death of the ascites cancer cells;
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subsequently, the dying cells release HMGB-1, which, together w ith TNF, stimulates a 
massive infiltration of neutrophils (Figure 42).
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Figure 42. Mechanism of SM83 activity in the ovarian cancer ascites. SM83 stimulates the 
reversal of macrophages from M2 to M l phenotype. TNF secreted by M l macrophages trigger 
necrotic death of the cancer cells within the ascitic fluid; the dying cells release HMGB-1, which, 
together with TNF, recruits neutrophils.
5.4. Looking for synthetic lethality: oncogenic KRAS
After having demonstrated that SM83 is endowed w ith anti-tum or activity and can be 
effective both in vitro and in vivo, we looked for genetic settings in which SM83 could be 
more active. SM83 was therefore tested alone, in combination w ith TRAIL and in 
association to several other pharmacological compounds.
5.4.1. Oncogenic KRAS sensitizes cells to drug treatment
As already mentioned, TRAIL is considered an attractive compound in cancer 
treatment, because its toxicity is highly specific fo r transformed cells while being almost 
completely ineffective against normal tissues. On the other hand, SMs display a poor anti-
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tum or efficacy as standalones, but can powerfully enhance the efficacy of other 
compounds in combined treatments. To identify novel compounds that can increase the 
effectiveness of TRAIL/SM administration, in 2010, a screening was performed at The 
Institute of Cancer Research, London, in which HeLa cells were treated w ith SM83 and 
izTRAIL, in addition to 3 libraries o f FDA-approved drugs. SM83/TRAIL was therefore 
combined with about 3000 drugs (2309 unique compounds screened). Interestingly, the 
best hits, which efficiently improved the cytotoxicity of the treatm ent, were 
topoisomerase inhibitors (Table 6), in agreement w ith several other studies.
Compound P-value
10-hydroxycamptothecin 0,000103319
Camptothecin 0,000040974
Camptothecine (S,+) 0,001697753
AMSACRINE 0,000274229
FLUOROURACIL 0,000537959
Aminacrine hydrochloride 0,015471379
Decitabine 0,000022640
MEFLOQUINE 0,000168791
Sutent 0,000444038
NETILMICIN SULFATE 0,005887782
Table 6. Drugs that enhance the activity of SM83 plus izTRAIL. Using a high-throughput approach 
we treated HeLa with SM83, izTRAIL and a library of about 3000 FDA-approved drugs. The best 10 
hits, capable of increasing the cytotoxic activity of the treatment, are shown.
Hits were then validated using the same cell line employed in the screening and in a 
panel of cancer cell lines (data not shown). Moreover, a number o f cancer and normal 
immortalized cells bearing knock-in and knock-out mutations in genes frequently 
associated to cancer were also treated. With this approach, we observed tha t G13D-
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mutated KRAS sensitizes human mammary epithelial (HME) cells to TRAIL and SM83/CPT 
treatm ent (Figure 43A-D).
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Figure 43. Oncogenic KRAS increases sensitivity of HME cells to DNA-damaging agents and 
TRAIL. (A) The parental human mammary epithelial (HME) cell line and the isogenic cell lines with 
knock-in mutations in KRAS (G13D), PI3K (H1047R) and EGFR (delE746A750) were treated with 
the indicated doses of CPT alone (A) or in combination with 100 nM SM83 (B). The parental 
human mammary epithelial (HME) cell line and the isogenic cell lines with knock-in mutations in 
KRAS (G13D), PI3K (H1047R) and EGFR (delE746A750) were treated with the indicated doses of 
izTRAIL alone (C) or in combination with 100 nM SM83 (D) and (E) with 8.8 nM NCS and 1 pM ETO, 
with or without 100 nM SM83 (lower panel). Viabilities are shown after 24 h of treatment.
To test whether this effect was specific to topoisomerase I inhibitors or a more
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general sensitiveness to cytotoxic compounds, the same cells were treated also with 
topoisomerase II inhibitor etoposide (ETO) and the DNA double strand maker 
neocarzinostatin (NCS) both in the presence of SM83 and not (Figure 43E). Our viability 
tests suggest that the presence of oncogenic KRAS generally sensitizes cells to death 
inducers and is not specific to a particular compound such as CPT.
5.4.2. Ectopic expression of G13D KRAS sensitizes cells to SM83/CPT treatment
To further assess whether the presence of oncogenic KRAS is indeed responsible 
for the increased sensitivity to treatment, we silenced KRAS and treated cells with CPT 
observing a notable reduction of sensitivity (Figure 44A). Moreover, we cloned G13D 
KRAS in an inducible lentiviral expression vector (Figure 44B) and transduced both HME 
and MCF10A cells in which we stimulated the over-expression with doxocyclin. Over­
expression was confirmed by western blot, detecting the phosphorylation of ERK (Figure 
44C), which is a downstream substrate of KRAS activation and by pull-down experiments 
with the Raf-1 RBD (Figure 44D).
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Figure 44. KRAS is responsible for increased sensitivity of HME to SM83/CPT treatment. (A) HME
+/+ and HME D13/+ were transfected with siRNA targeting KRAS for 48 h and subsequently 
treated with 100 nM SM83 and 1 pM CPT. Cell viability was determined after 24 h of treatment.
(B) plNDUCER20 used to transduce HME for transient expression of mutated KRAS. (C) HME 
plNDUCER20-Mock (Mock) and HME plNDUCER20-KRAS G13D (G13D) were incubated with Dox 
(250 ng/ml) for 48 h, lysed and western blot performed. The presence of activated KRAS was 
determined by detection of phosphorylated ERK. (D) Active GTP-RAS was purified in cells 
stimulated as in (C) by pull-down assay using the recombinant RBD domain of Raf-1; HME D13/+ 
are shown as a positive control for activated KRAS.
We then treated both HME with SM83/CPT (Figure 45A) and TRAIL (Figure 45B), 
observing an increased sensitivity in the presence of induced G13D KRAS in line w ith what 
was observed employing knock-in cell lines (Figure 44A). Oncogenic KRAS was induced 
also in MCF10A to exclude that the observed sensitization was a cell line-dependent
1 1 3
effect. Mutated KRAS induced the phosphorylation of ERK also in these cells (Figure 45C) 
and this was associated to increased sensitivity to SM83/CPT treatm ent (Figure 45D).
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Figure 45. Ectopic oncogenic KRAS sensitize different epithelial cells to SM83/CPT and TRAIL 
treatment. (A) HME pINDUCER-Mock and HME pINDUCER-KRAS G13D were incubated w ith Dox 
(250 ng/ml) for 48 h and treated with 100 nM SM83 and 1 pM CPT, or (B) izTRAIL. Cell viability 
was determined after 24 h. (C) MCF10A pINDUCER-Mock and MCF10A pINDUCER-KRAS G13D 
were incubated with Dox (250 ng/ml) for the indicated time, lysed and analyzed by western blot 
for the detection of ERK and phosphorylated ERK. Actin is shown as loading control. (D) MCF10A 
pINDUCER-Mock and MCF10A pINDUCER KRAS G13D were incubated with Dox (250 ng/ml) fo r 48 
h and treated with 100 nM SM83 and 0.1 pM CPT. Ceii viability was determined after 24 h.
5.4.3. KRAS G13D-expressing cells treated with SM83/CPT die by apoptosis 
Parental and KRAS G13D cells were then treated with CPT and SM83 (Figure 46A and
1 1 4
B). As expected, clAPs were depleted by SM83 in both cell lines (Figure 46B), but only 
HME KRAS G13D-bearing cells treated with the combination of SM83 plus CPT underwent 
apoptosis, revealed by cleavage of PARP, caspase-3 and caspase-8 (Figure 46A). As the 
latter caspase is responsible for the activation of the extrinsic pathway and SM 
cytotoxicity is often associated with TNF increased expression or sensitivity to it, we 
investigated a potential role of this cytokine in cell killing.
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Figure 46. SM83/CPT treatment activates a TNF-dependent apoptotic event in epithelial cells 
bearing oncogenic KRAS. (A, B) HME +/+ and HME D13/+ cells were mock treated and treated 
with 100 nM SM83, 1 pM CPT alone and in combination for 6 h. Cells were lysed and subjected to 
western blot to detect the apoptosis markers cleaved PARP, caspase-3 and caspase-8 (A) and the 
SM targets clAPl, clAP2 and XIAP (B). Actin is the loading control; asterisks show the cleaved 
forms p l7 /p l9  of caspase-3 and the pro-caspase p55/p57 forms of caspase-8, together with its 
cleaved forms p41/p43. (C) Before SM83/CPT treatment, HME D13/+ cells were pre-treated with 
the neutralizing antibody IFX. Viability was measured after a 24 h treatment by CellTiter-Glo.
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For this reason, we pre-treated cells with the TNF-neutralizing antibody, Infliximab 
and then treated HME with the SM83/CPT combination. In line with our hypothesis, we 
prevented CPT/SM83 toxicity and rescued cells from the treatment (Figure 46C), strongly 
supporting the notion that oncogenic KRAS-bearing cells are killed by the treatm ent via a 
TNF-dependent mechanism.
5.4.4. NOXA is at least in part responsible for KRAS G13D-dependent sensitivity 
to death
To understand the mechanisms that are responsible for the increased sensitivity of 
HME KRAS G13D cells to treatment compared to parental cells, we characterized both cell 
lines by western blot, detecting several proteins involved in the apoptotic pathway 
(Figure 47 and data not shown). The most striking difference between the two cell lines 
was represented by the over-expression of NOXA in the presence of mutated KRAS even 
in untreated cells. In fact, while wild type cells display very low levels of NOXA that can 
barely be detected in untreated cells, but increase after treatment, on the other hand, 
KRAS G13D cells show high basal levels of this pro-apoptotic protein in untreated cells, 
too (Figure 47A). Simultaneously, NOXA antagonist, the anti-apoptotic M c ll, is depleted 
more efficiently by the treatment in the presence of oncogenic KRAS (Figure 47A). The 
capability of mutated KRAS to increase the expression levels of NOXA was further 
investigated in HME and MCF10A transduced with the inducible KRAS G13D. In line with 
the G13D knock-in mutation of KRAS, time-course stimulation of ectopic G13D KRAS with 
doxocyclin also stimulated NOXA expression in these models (Figure 47B). Finally, to 
assess whether the increased levels of NOXA were indeed responsible for the enhanced 
sensitivity to treatment, cells with knock-in KRAS G13D mutation were transfected with 
siRNAs targeting NOXA and viability tested after SM83 and CPT treatment. Down-
regulation of NOXA enhanced resistance to treatm ent even if it did not completely rescue 
cells, strongly supporting the notion that NOXA plays an im portant role in the increased 
responsiveness to treatm ent (Figure 47C), but it is not the only protein involved, 
importantly, silencing of KRAS decreased NOXA levels, suggesting that KRAS sustains high 
levels of NOXA (Figure 47D).
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Figure 47. Oncogenic KRAS-dependent up-regulation of NOXA is responsible for the increased 
sensitivity to treatment. (A) HME +/+ and HME D13/+ cells were treated with 100 nM SM83 and 1 
pM CPT for 6 h, lysed and subjected to western blot to detect NOXA and M cll levels. (B) HME 
(upper panel) and MCF10A (lower panel) transduced with plNDUCER20-Mock and plNDUCER20- 
KRAS G13D lentiviruses were incubated with Dox (250 ng/ml) for the indicated time points and 
subjected to western blot to detect NOXA levels. (C) HME +/+ and HME D13/+ were transiently 
transfected with siRNA targeting NOXA for 48 h and subsequently treated with 100 nM SM83 and 
1 pM CPT. Cell viability was determined after 24 h. (D) HME cells bearing the G13D knock-in 
mutation were transfected with siRNAs targeting KRAS and NOXA for 72 h. Western blot was 
performed to evaluate NOXA and RAS levels. Actin is shown as a loading control.
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5.4.5. Increased sensitivity to treatment stems from KRAS-dependent MAPK 
activation
We next investigated the mechanisms that are responsible for this acquired sensitivity 
of KRAS-mutated HME to cell death. Hence, both parental and G13D HME cells were 
treated with CPT and SM83 in the presence of various inhibitors of MAPK, AKT and PI3K 
kinases which can be activated by mutated RAS and transmit its signaling. In parental 
cells, the administration of MEK1/2 inhibitors PD98059 and U0126, AKT inhibitor 
triciribine or PI3K inhibitor LY294002 did not significantly affect the toxicity of SM83/CPT 
treatm ent (Figure 48A). In clear contrast, both MEK1/2 inhibitors partially protected 
D13/+ HME cells from SM83/CPT treatment and conferred resistance to the same extent 
as parental cells (Figure 48A). Having found that NOXA is a pivotal mediator of KRAS- 
dependent increased sensitivity to the combination (Figure 47C), we evaluated whether 
the MAPK pathway was responsible for the increased levels of NOXA and found, as 
expected, that both MEK inhibitors reduced the levels of phosphorylated ERK1 and ERK2, 
and also concurrently reduced the levels of NOXA (Figure 48B). Importantly, MEK 
inhibition slightly reduced NOXA basal levels also in parental HME (left panel) suggesting 
that the MAPK pathway stimulates NOXA in physiological conditions as well. To 
understand whether MEK targets ERK1 and ERK2 both contribute the NOXA regulation, 
we silenced each of them in G13D HME cells thereby finding that only ERK2 down- 
regulation results in reduced NOXA levels, while ERK1 silencing has an even opposite 
effect causing a faint accumulation of NOXA (Figure 48C). In line with these findings, ERK1 
silencing slightly enhances the sensitivity of D13/+ HME cells to SM83/CPT treatment, 
while ERK2 results in an opposite effect (Figure 48D).
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Figure 48. ERK2, but not ERK1 is responsible for KRAS-dependent NOXA-induction. (A) HME +/+
and HME D13/+ cell lines were pre-incubated 2 h with 50 pM PD98059, 25 pM U0126, 20 pM 
Triciribine and 20 pM LY294002, and then treated with 100 nM SM83 and 1 pM CPT. Cell viability 
was quantified after 24 h. (B) HME +/+ (left panel) and HME D13/+ (right panel) cell lines were 
treated 2 h with 50 pM PD98059; 25 nM U0126, 20 pM Triciribine and 20 pM LY294002 and 
subsequently analyzed by western blot to detect NOXA and the phosphorylated forms of AKT; 
ERK1 and ERK2, and their total levels. Actin is shown as a loading control. (C) HME +/+ and HME 
D13/+ were transiently transfected with the indicated siRNAs for 72 hours and subsequently 
analyzed by western blot to detect phosphorylated ERK1 and ERK2, and their total levels, NOXA 
and Actin as the loading control. (D) Parental HME +/+ and HME D13/+ cells were silenced for 48 
h and then treated with DMSO and 100 nM SM83 plus 1 pM CPT for a further 24 h. Statistical 
analysis was performed with GraphPad Prism 5.02 using the two-tailed unpaired t-test * P < 0.05 
vs siCtr.
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5.4.6. Cancer cells are not sensitized to treatment by KRAS G13D mutations
Having shown that normal immortalized epithelial cells are sensitized to treatm ent by 
the presence of oncogenic KRAS, the next question was whether this effect was also true 
in tum or cells. For this purpose, a panel of colorectal cancer (CRC) cells w ith knock-in and 
knock-out KRAS G13D was used. Surprisingly and contrary to what had observed with 
HME, SW48, DLD-1, HCT-116 and Liml215 displayed the same sensitivity to treatm ent in 
the presence of both wild type or mutated KRAS (Figure 49A-D). Moreover, SM83 
administration made little, if any, difference, again in opposition to what had been 
observed with the treatm ent of HME KRAS G13D.
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Figure 49. Oncogenic KRAS does not confer sensitivity to combined SM83/CPT treatment in CRC 
cell lines. SW48 +/+ and SW48 D13/+ (A), HCT116 +/- and HCT116 D13/- (B), Liml215 +/+ and 
Liml215 D13/+ (C), DLD1 D13/- and DLD1 +/- (D) cell lines were treated with DMSO and the 
combination of SM83 and CPT at the indicated concentrations. Cell viability was evaluated after 
24 h.
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5.4.7. KRAS G13D does not stimulate NOXA levels in cancer cells
Having previously shown that HME cells are more sensitive to treatm ent due to a 
KRAS-dependent increase of NOXA levels, we investigated the levels of NOXA in the panel 
of CRC cell lines. Interestingly, almost all cell lines have increased basal level of NOXA 
compared to HME (data not shown), but the presence of wild type or mutated KRAS did 
not affect its levels (Figure 50A-D). This observation could explain why each couple of 
isogenic cells with knock-in or knock-out KRAS G13D exhibited the same sensitivity to 
CPT/SM83 treatm ent (Figure 49A-D).
SW48
SM83
CPT
11
55 H 
36
SM83
CPT
HCT116 
♦/- D13/-
11 -
W"*.---- *  M M B ... ... tmm -we*
— ------- ------- - ---------- M cll
55 -
Actin
36 -
e w e s . . ____
HOXA
M cll
Litn1215
SM83
CPT
55 -  
36 -
D13<
NOXA
M cll
Actin
SM83 
CPT 
11 -
55
36 4
DLD1
013/- ♦/-
NOXA
Mcll
Figure 50. Oncogenic KRAS does not stimulate NOXA up-regulation in cancer cells. SW48 +/+ and 
SW48 D13/+ (A), HCT116 +/- and HCT116 D13/- (B), Liml215 +/+ and Liml215 D13/+ (C), DLD1 
D13/- and DLD1 +/- (D) cell lines were treated with DMSO and 100 nM SM83, 0.1 pM CPT in 
monotherapy and in combination for 6 h. Cells were lysed and analyzed by western blotting for 
NOXA and M cll levels. Asterisk indicates the specific band of Actin that is shown as a loading 
control.
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As NOXA levels are not affected by the presence of oncogenic KRAS in this panel of 
cancer cells, we also checked whether its antagonist, M c ll, is depleted by CPT treatm ent 
w ith the same kinetic found in HME cells. Dose-response experiments show that M c ll is 
slightly more stable in cancer cells compared to normal epithelial cells and its degradation 
occurs at higher CPT doses compared to HME (Figure 51).
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Figure 51. NOXA antagonist M cll is more stable in colorectal cancer cells treated with CPT, 
compared to HME ceils. SW48, HCT116, Liml215, DLD1 colorectal and mammary epithelial HME 
cell lines were treated with increased concentrations of CPT for 6 h. Western blots were 
performed to detect M cll levels. Actin is shown as a loading control.
5.4.8. Aberrant activation of AKT counterbalances the KFtAS-mediated pro- 
apoptotic scenario in colorectal cancer cell lines
Despite the presence of mutant KRAS, our findings suggest that cancer cells are not 
sensitized to SM83/CPT treatment. Therefore, we hypothesized tha t malignant 
progression might have caused the deregulation of other pathways tha t can
122
counterbalance the potential apoptotic effect of oncogenic KRAS. Interestingly, HCT116 
and DLD1 cells bear mutated PI3K, which results in hyper-activation of the PI3K/AKT 
pathway, a signaling cascade known to promote cell survival. For this reason, we treated 
HCT116 bearing mutated and wild type KRAS with SM83/CPT after pre-treatment with 
inhibitors of MEK1/2, AKT and PI3K.
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Figure 52. Aberrant AKT activation protects HCT116 cells from the pro-death effect of oncogenic 
KRAS. (A) HCT116 and (B) DLD1 cells were pre-incubated 2 h with 50 pM PD98059, 25 pM U0126, 
20 pM Triciribine and 20 pM LY294002, and then mock-treated or treated with 100 nM SM83 and 
1 pM CPT. Cell viability was quantified after 24 h. (C) FICT116 cells were treated for 2 h with the 
indicated inhibitors as in (A) and then analyzed by western blot to detect the NOXA levels and the 
phosphorylated and total levels of AKT and ERK. Actin is shown as loading control. (D) HCT116 
cells were transfected with siRNAs targeting ERK1 and ERK2, after 72 h cells were collected and 
analyzed by western blot to detect NOXA and the total and phosphorylated levels of AKT and ERK. 
Actin is shown as loading control.
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Interestingly, and concordant with our hypothesis, AKT inhibition restored sensitivity 
to the treatm ent only in the presence of mutant KRAS (Figure 52A and B). NOXA levels 
were lowered by MAPK blocking (Figure 52C) as already observed in HME cells (Figure 
48B), but were not affected by AKT inhibition, suggesting that the AKT pathway blocks the 
pro-death effect triggered by oncogenic KRAS in an independent fashion. We further 
investigated the mechanisms by which NOXA levels are controlled in HCT116 cells and 
demonstrated that the findings described for HME are true also in this cancer cell line. In 
fact, the targeting of ERK1 by silencing enhanced the levels of NOXA, while a specific 
siRNA targeting ERK2 slightly reduced its expression (Figure 52D).
5.4.9. AKT counterbalances the KRAS-mediated pro-apoptotic effect also in the 
absence of mutations activating the PI3K/AKT pathway
The observation that AKT inhibition specifically sensitizes oncogenic KRAS-bearing 
CRC cells to treatment in the presence of mutated PI3K stimulated us to check whether 
this was true also in PI3K wild type cells. We then treated Lim l215 and SW48, in which 
PI3k is not mutated and bearing wild-type or mutated KRAS, with SM83/CPT after pre­
treatment with AKT inhibitors. Confirming the previous observations, AKT blocking 
sensitized Liml215 bearing G13D KRAS to the treatment (Figure 53, left). Importantly, a 
similar effect was shown also in the SW48 cell line that was already particularly sensitive 
to AKT inhibition, independently of KRAS status (Figure 53, right).
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Figure 53. Aberrant AKT activation protects HCT116 cells from the pro-death effect of oncogenic 
KRAS also in the presence of wild type PI3K. (Left) Liml215 and (right) SW48 cells were pre­
incubated 2 h with 50 |iM PD98059, 25 pM U0126, 20 pM Triciribine and 20 pM LY294002, and 
then mock-treated or treated with 100 nM SM83 and 1 pM CPT. Cell viability was quantified after 
24 h.
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6. DISCUSSION
In these last few years, the focus of our attention has been on a class of compounds, 
called SMs, which were described and proposed for cancer therapy about 10 years ago (Li 
et al, 2004). The aim of our work has therefore been to design new molecules in order to 
increase their cytotoxic activity, modifying their pharmacokinetic features, the affinity for 
the known targets and introducing novel modifications also on the basis of the most 
recent findings. In fact, SMs were initially considered only XIAP inhibitors (Sun et al,
2007). Nowadays, however, they are known to target other members of the IAP family, 
such as clAPl, clAP2 and ML-IAP (Condon et al, 2014; Cossu et al, 2009a). Consequently 
different affinities for these proteins result in diverse activities and treatm ent outcome.
The initial discovery of the SMs immediately generated great interest, because their 
targets, the lAPs, are considered pivotal players in the acquired cancer cell resistance to 
death and this is a major issue in cancer therapy (Fulda, 2014b). Accordingly, several 
groups have generated thousands of modified molecules and a few of these compounds 
are currently being tested in clinical trials (Fulda, 2014b). Nevertheless, the latest findings 
have somewhat dampened the initial enthusiasm showing a limited efficacy in cancer 
healing and highlighting a few side-effects (Wong et al, 2014). These results have 
significantly changed the concept of SM activity. For example, it has been suggested that 
SM XIAP inhibition could even be detrimental and could result in excessive cytokine- 
related inflammation. For this reason, a few new SMs have been designed to reduce the 
affinity for XIAP (Condon et al, 2014), which was the original target of this class of 
compounds, and specifically deplete clAPl and clAP2.
Although many works have been published to date, it is still however necessary to
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fully comprehend the mechanisms of SM activity in order to avoid the negative side- 
effects and to identify the ideal settings in which to employ these compounds 
successfully. To this end, in collaboration with the University of Milan, we have built a 
library of about 140 SMs and have characterized their affinity for clAPl, clAP2 and XIAP, 
together with their, cytotoxic activity as standalones and in combination with other 
compounds. Thanks to the data obtained in this multi-laboratory project, we selected 
SM83, a compound with nanomolar affinities for the IAP BIR domains, extremely 
cytotoxic for sensitive cancer cells, capable of enhancing the activity of other compounds 
and employable both in vitro and in vivo (Lecis et al, 2012). Thus, almost all my PhD work 
focuses on the use of this SM.
So far, SMs have been tested in many different tumors and their efficacy has not 
been correlated to the cancer type studied. Hence, in our work, diverse tum or models 
were exploited focusing on breast cancer triple negative carcinoma and ovarian cancer 
ascites. Finally, in an attempt to identify the genetic lesions that enhance the sensitivity 
to SM/TRAIL treatment, we investigated the effect of KRAS mutations and consequently 
employed CRC cells, which are often characterized by this type of genetic lesion.
6.1. The anti-metastatic effect of SM83 in triple negative breast cancer
Triple negative breast carcinomas are intensively studied, because they represent one 
of the most aggressive subtypes of breast tumors and there is the need for new  
therapeutic approaches. Furthermore, the MDA-MB231 cell line is probably the most 
characterized in SM-related works, because it is one of the few cell lines to be killed by 
SM treatment in monotherapy (Varfolomeev et al, 2007). It thus offers a standardized
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model for comparing SM efficacy and to identify the mechanisms that are responsible for 
responsiveness to SMs. Accordingly, along with Kym, SKOV3 and A2058 cell lines, the 
MDA-MB231 cell line was used in the papers which demonstrated for the first time that 
SM cytotoxic activity stems from clAPl depletion and is triggered by autocrine TNF 
secretion (Varfolomeev et al, 2007; Vince et al, 2007). The effect on XIAP is therefore 
surprisingly dispensable for SM toxicity in monotherapy (Sun et al, 2014). Finally, MDA- 
MB231 cells easily engraft immunosuppressed mice and are extremely prone to forming 
spontaneous metastasis not only in lungs, but also in bones and the brain (Bos et al, 2009; 
Kang et al, 2003; Minn et al, 2005). As a result, they are therefore intensively used for the 
study of the metastasizing process and to identify the compounds that could prevent or 
reduce metastasis formation.
In our work, the capability of SM83 to reduce the growth of triple negative breast 
cancers both In vitro and in vivo was tested. SM83 was administered both as a standalone 
and in combination with other compounds, and especially in association with TRAIL. This 
ligand was proposed for cancer therapy in the late 90s because of its capability to 
selectively kill transformed cells without affecting normal tissues (Walczak et al, 1999). 
Moreover, genetic in vivo studies employing transgenic mice with depleted TRAIL-Rs 
suggested a natural anti-cancer role of TRAIL (Finnberg et al, 2008; Grosse-Wilde et al,
2008) and generated great enthusiasm regarding its employment in medical treatm ent. 
Although pre-clinical data were extremely promising and supported the testing of a 
number of TRAIL agonist compounds, the clinical trial results betrayed the expectations 
(Yang et al, 2010). The reasons for the in vivo ineffectiveness have not been fully 
understood, but it is speculated that TRAIL short half-life, together with its inability to 
stimulate both TRAIL-R1 and R2, and the intrinsic mechanisms of cancer cell resistance
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impede its efficacy (Falschlehner et al, 2009). Several approaches have therefore been 
suggested to increase TRAIL efficacy, modifying its molecule to increase the stability and 
capability to trimerize (Ganten et al, 2006), and to improve its pharmacokinetic profile. 
Interestingly, SMs were shown to represent the ideal compound for combination with 
TRAIL and the other ligands of the TNF family (Li et al, 2004). XIAP, in fact, plays a crucial 
role in protecting from TRAIL-mediated cytotoxic activity (Cummins et al, 2004). 
Moreover, the other SM targets, clAPl and clAP2, are components of the TNF-RS 
complexes (Emmerich et al, 2011; Gerlach et al, 2011; Lu et al, 2011), where, upon the 
stimulation of the cognate ligand, they regulate the switch from a pro-death to a pro­
survival signaling.
In our work, we tried to increase the in vivo efficacy of TRAIL by means of a genetic 
approach, employing CD34+ cells transduced with adenoviruses that allow the expression 
of TRAIL bound to the membrane. This technique allows the expression of mTRAIL, which 
is more stable and it is continually expressed by engineered cells, at least for 3-4 days. 
This approach has already been employed successfully in models of lymphomas and 
multiple myeloma (Carlo-Stella et al, 2006; Lavazza et al, 2010). TRAIL-armed CD34+ cells 
were shown to accumulate in the tumors and increase mice survival by reducing the 
number of cancer cells. Interestingly, even though TRAIL-armed CD34 cells were shown to 
poorly inhibit the growth of the solid primary tumors, they caused the formation of large 
necrotic areas within the tumors and this effect was caused by the destruction of the 
tumor-associated vasculature (Lavazza et al, 2010).
In accordance with previous literature, our SM83 synergized with sTRAIL in vitro using 
both the SM-sensitive MDA-MB231 and the SM-resistant MDA-MB468. Moreover, co­
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culture experiments of these breast cancer cells with TRAIL-armed CD34 cells showed 
that SM83 favors the activation of apoptosis, in these settings also. Nonetheless, several 
experiments failed to confirm an improvement of TRAIL-armed CD34 cell in vivo activity in 
combination with SM83. Primary MDA-MB231 and MDA-MB468 tumors were both 
reduced by SM83 administration by about 50%. This is surprising as only MDA-MB231 are 
intrinsically sensitive to SMs suggesting that SM83 interacts in vivo with something 
present in the micro-environment which enhances its activity. TNF produced by the host 
(Probst et al, 2010), the cytokines (Beug et al, 2014) or other factors could be responsible 
for the enhanced sensitivity to SM83, but another hypothesis is that SMs might also affect 
other processes, such as angiogenesis, and consequently could indirectly delay the 
primary tumor growth. This idea seems to be supported by recent findings in transgenic 
mice which reported that the triple targeting of clAPl, clAP2 and XIAP, by knock-out, is 
lethal due to damaged vasculature endothelium (Moulin et al, 2012).
As previously mentioned, SM83 did not enhance the efficacy of TRAIL-expressing 
CD34 cells in our experiments and mTRAIL had only a negligible effect both alone and in 
combination therapy. A number of reasons may have contributed to this limited-efficacy 
result. However, most probably, 4 injections of 106 cells are not sufficient to eradicate or 
significantly reduce the volume of already established and developed tumors. 
Furthermore, the presence of large necrotic areas also in untreated tumors, which is a 
common feature of triple negative breast cancers, may have impeded us from  
appreciating a potential effect in killing restricted areas of the primary tumors. 
Nonetheless, we demonstrated that SM83 depletes the clAPs in vivo and reduces XIAP 
levels. The latter effect might stem from clAPl down-regulation as it is also observable in 
vitro in cells silenced for clAPl. This strongly supports the notion that the levels of the
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diverse lAPs are interlinked (Silke et al, 2005) and some can affect the levels of the others 
by increasing the protein stability or the gene expression.
Of note, as MDA-MB231 form lung metastases in vivo (Minn et al, 2005), we 
investigated whether SM83 could have a role in this process and noticed a significant 
reduction of the size and number of MDA-MB231 colonies in the lungs of treated animals. 
Having shown that SM83 treatm ent kills by apoptosis only a small portion of cancer cells, 
we speculated that the anti-metastasis effect could have been caused by another 
mechanism. As clAPl and clAP2 are apical regulators of several signaling cascades that 
eventually control gene trans-activation (Varfolomeev et al, 2012), we analyzed by GEP 
the primary tumors collected from mice. According to our hypothesis, the analysis of 
treated tumors revealed that 15 genes were significantly down-regulated and 50 up- 
regulated. The down-regulated genes were all tested in wound-healing assays using an 
unbiased approach. Cancer motility is an important feature for metastasizing cancer cells 
(Reymond et al, 2013), in particular in the first steps of dissemination. We therefore 
silenced the selected genes and found that Snai2, RNF144B and BDNF, 3 of the 15 genes 
down-regulated in vivo by SM83 treatment, down-regulation prevented cancer motility 
and could most probably be responsible for the reduced number of metastases. We then 
focused our attention on Snai2 because it is a mediator of the EMT process (Villarejo et al, 
2014) and it is known to play a role in metastasis formation (Kim et al, 2014).
Further work confirmed that Snai2 is inhibited by SM83 through the depletion of 
clAPl. We also demonstrated that Snai2 down-regulation parallels the activation of the 
non-canonical NF-kB pathway in cells treated with SM83 or TWEAK, whilst it is stimulated 
by TNF administration. The down-regulation of Snai2 could therefore depend on multiple
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effects triggered by SM83 such as the non-canonical NF-kB pathway activation or the 
simultaneous canonical NF-kB pathway inhibition. These mechanisms are difficult to 
investigate because they are strictly interlinked. Consequently, the modification of one 
pathway inevitably results in the variation of the other.
The analysis of a panel of breast cancer cell lines belonging to different subtypes 
showed that the triple negative breast cancer cells usually express higher Snai2 levels 
compared to other cells. Importantly, SM83 treatment broadly reduces its expression, 
excluding a cell line-specific effect. Our work therefore suggests that clAPl might concur 
with cancer cell aggressiveness by supporting the high levels of the metastasis-favoring 
gene Snai2. This evidence is in accordance with previous works by others that 
demonstrate a pro-metastasis effect of lAPs independently of their capability to control 
apoptosis (Mehrotra et al, 2010). In conclusion, SM adjuvant treatm ent could represent a 
possible approach for reducing the formation of metastasis in Snai2-positive cells. 
Moreover, the observation that clAPl plays a role in controlling this process supports the 
investigation of the signaling controlled by this IAP in order to identify new targets for 
anti-metastasis treatment.
6.2. Affecting the cross-talk between tumor and micro-environment: 
SM83 efficacy in ovarian cancer ascites
Ascites formation is a feature of the ovarian cancer and of the advanced tumors 
arising from other organs. Ascites are caused by the cancer cell obstruction that results in 
the accumulation of the ascitic fluid. Ovarian carcinomas rarely form metastasis outside 
the peritoneum (Lengyel, 2010), therefore the ascites themselves are responsible for
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cancer deaths. Cancer ascites are characterized by the massive accumulation of liquid in 
which detached cancer cells can grow in close contact to the cells of the immune system. 
Despite the fact that this environment is extremely infiltrated with immune cells, such as 
macrophages, these are often anergic and do not display anti-cancer cell activity. On the 
contrary, they stimulate the tumor by secretion of several cytokines and chemokines. 
Macrophages are numerous in the cancer ascites, but instead of protecting from the 
tumor, they are polarized in a particular state, termed M2, which, in contrast, favor 
cancer growth (Sica et al, 2006; Sica and Mantovani, 2012). For this reason, a possible 
approach to treating tumors could be represented by the targeting of the immune system 
in order to inhibit the support received by the micro-environment. Importantly, 
macrophage skewing is controlled by the NF-kB pathway (Hagemann et al, 2008), which 
could therefore represent a potential target for therapy directed against cancer- 
associated immunity.
An opportunity to study the efficacy of SMs in the treatment of ovarian 
carcinomas is constituted by the IGROV-1 cells, which can grow in vitro, both attached to 
a cell culture surface and in suspension, and in vivo. In immunosuppressed mice, they can 
form solid tumors when engrafted subcutaneously, but also cancer ascites if injected in 
the peritoneum (De Cesare et al, 2010). Of note, IGROV-1 cells are completely resistant in 
vitro to SM83 treatment even though this compound completely depletes the levels of 
clAPl and clAP2. As already noted in SM-resistant breast cancer models, SM83 can 
nevertheless enhance the activity of TRAIL in combination therapy and trigger an 
apoptotic event in IGROV-1 cells, but does not affect their growth when administered as a 
standalone. Nonetheless, the efficacy of SM83 changes in vivo and, in accordance to what 
was observed in the MDA-MB468 xenografts, SM83 treatment inhibits in vivo the growth
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of cancer cells intrinsically resistant in vitro.
Our data therefore suggested that SM83 exploits the tumor micro-environment to 
be effective in the ovarian model as well. In particular, our data revealed that continued 
treatments significantly increased mice survival, while one single injection dramatically 
depleted the detached cancer cells floating in the ascitic fluid. It is known that the cells 
killed by SMs in monotherapy secrete high levels of TNF and this becomes toxic when the 
lAPs are inhibited (Varfolomeev et al, 2007; Vince et al, 2007). Thus, we first studied the 
levels of diverse cytokines after SM83 administration. This can be easily studied in the 
case of the IGROV-1 ascites model because the tumor environment is constituted by the 
ascitic fluid that can simply be collected by syringe and analyzed in ELISA assays. After one 
single injection of SM83, we noticed that the TNF levels rapidly increased and, 
importantly, mouse TNF was produced before human TNF, suggesting that SM83 
administration was acting on the host before being effective on the tumor cells. TNF was 
indeed responsible for cancer cell killing, because its blocking by means of Enbrel 
prevented cancer cell depletion. We can therefore conclude that SM83 caused the 
secretion of TNF from mouse cells and this was then responsible for the establishment of 
an inflammatory environment. Accordingly, other pro-inflammatory cytokines such as 
IFNy and IL-1|3 were induced 6 h after the injection, whereas the immunosuppressive 
TGF|3, IL-4 and IL-10 were not affected by the treatment.
In these experiments, we used immunosuppressed nude mice. These animals are 
athymic and therefore lackT cells, resulting in severe impairment of the adaptive immune 
compartment. To investigate the mechanisms by which SM83 rapidly kills the detached 
cancer cells within the ascites, induces a rapid inflammatory event and delays cancer
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growth prolonging engrafted animals, we therefore focused on the innate immunity. In 
particular, we studied the role of macrophages because they are known to produce the 
studied cytokines (Hagemann et al, 2008; Heusinkveld et al, 2011), are numerous in the 
ascites and play a role in cancer-supporting when skewed in the M2 state. In vitro 
experiments employing BMDMs showed that SM83 stimulates their rapid TNF secretion 
together with the activation of the NF-kB pathway. Furthermore, in accordance with 
other previous reports (Muller-Sienerth et al, 2011), we demonstrated that SMs kill 
macrophages via a necroptotic, but not apoptotic, mechanism. Treatment with the RIP1 
kinase inhibitor Necrostatin-1, in fact, prevented the toxicity, while the pan caspase 
inhibitor event enhanced BMDM death.
The analysis of the immune cell populations that infiltrate the IGROV-1 ascites 
revealed that SM83 causes an enormous recruitment of neutrophils 24 hours after the 
treatment. This was evident both in the ascitic fluid and in the solid nodules attached to 
the peritoneum wall. We then investigated whether these cells also played a role in 
cancer cell killing. We employed various approaches, including in vitro co-culture of 
spleen-derived neutrophils and IGROV-1 cells, and arrays to measure neutrophil 
activation (data not shown), migration assays and in vivo depletion. Our experiments 
strongly support the idea that the neutrophils are recruited in response to the SM83- 
dependent inflammatory event, which is caused also by the rapid death of millions of 
cancer cells that most likely release numerous immunogenic factors, but do not play a 
role in IGROV-1 cell killing. Neutrophil depletion before SM83 treatment did not prevent 
its efficacy, but on the contrary prolonged mouse survival. This demonstrates that 
neutrophils are not necessary for SM83 activity and are even detrimental, either 
supporting tumor growth or causing excessive inflammation that becomes toxic for
animals already weakened by the tumor. Further experiments confirmed that ascites 
derived by animals treated with SM83 significantly attract neutrophils in migration assays 
and this is TNF dependent, but HMGB-1 independent. This protein is known to be 
released by dying cells and is responsible for immunogenic death (Sims et al, 2010). In our 
models, we found a relevant release of FIMGB-1 in the ascitic fluid, which nevertheless 
was not responsible for neutrophil recruitment. HMGB-1 and ATP release are considered 
markers of immunogenic death (Kepp et al, 2011), a type of cell death often considered 
desirable in cancer therapy because it could direct the immune system against the cancer 
cells, further increasing the efficacy of traditional chemotherapy. Of note, SMAC-triggered 
cell death has recently been shown to be inflammation-related (Emeagi et al, 2012) and 
our work demonstrated that SMs could also produce a similar cytotoxic effect.
As the immune system plays a fundamental role in the activity of SM83 in cancer 
ascites, we decided to further study the efficacy of this compound in immunocompetent 
mice. W e therefore engrafted BALB/c mice with syngeneic sarcoma Meth A cells, which 
rapidly evolve into cancer ascites and kill the mice (Watanabe et al, 1986). Also in this 
case, SM83 significantly prolonged mouse survival, in a few cases being also curative, 
further demonstrating that SM treatment can be effective in cancer ascites treatment. 
Preliminary experiments were also performed to check whether SM treatm ent might also 
stimulate an immune memory, supported by the observation that mice cured though the 
administration of SM83 did not develop ascites even if re-challenged with further Meth A 
injections.
Of note, in both the ascites model used, the concomitant administration of TRAIL 
did not improve the efficacy of SM83 treatment, again supporting the notion that the in
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vivo employment of TRAIL needs to be carefully planned in terms of doses, schedule and 
the cancer model used. Nonetheless, our in vitro data still support the idea that the 
SM/TRAIL combination could be extremely effective in cancer cell killing.
6.3. Enhancing SM83 efficacy through novel drug combinations and 
genetic interactions
As previously mentioned, SMs are unlikely to be effective in cancer treatm ent as 
standalones. In fact, very few cells are killed by SMs in vitro in monotherapy (Petersen et 
al, 2007) and these cells can acquire resistance in vivo (Bai et al, 2012). Nevertheless, SMs 
could be successfully employed in combination therapies and, confirming this, several 
works have reported a plethora of drugs that synergize with different SMs (Lecis et al, 
2010; Probst et al, 2010; Servida et al, 2010; Steinhart et al, 2013; Wagner et al, 2012). 
Keeping this in mind, in 2010, we performed a high-throughput screening at the Institute 
of Cancer Research (ICR) in London, looking for FDA-approved drugs whose cytotoxic 
activity could be enhanced by simultaneous administration of SM83 and/or TRAIL. 
Traditional chemotherapeutic drugs commonly used in cancer treatm ent and already 
known to enhance SM and TRAIL activity represented the best hits of the screening. In 
fact, we identified the topoisomerase I inhibitor camptothecin (Singh et al, 2003), and 
decitarabine and fluorouracil.
Whether a specific genetic lesion could render the cancer cells more prone to cell 
death was our next question. Therefore, we exploited a panel of isogenic cell lines 
bearing mutations frequently associated to tumors. The use of isogenic cells with Kl and 
KO mutations, in fact, allows the investigation of the effect of a single gene, but avoiding
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the genetic variability that affects the results when comparing two different cell lines 
(Arena et al, 2007). Furthermore, the introduction of Kl and KO mutations by-passes the 
artefacts introduced by the ectopic expression of transgenes, thus producing non- 
physiological protein levels due to the presence of several copies of the transgenes, the 
absence of transcription regulation due to the use of strong constitutive promoters and 
unnatural post-transcription maturation of the mRNA, because transgenes are usually 
constituted by cDNAs. On the contrary, isogenic cell lines can be used to identify 
oncogene and non-oncogene addiction, and to study synthetic lethality (Roulston et al, 
2013; Steckel et al, 2012).
In our work, a panel of CRC and human mammary epithelial cell lines with 
mutations in the PI3K, EGFR, BRAF and KRAS genes was used. Viability tests showed that 
normal cells with G13D mutations in the KRAS gene are more prone to cell death when 
treated with several compounds such as camptothecin, neocarzinostatin, etoposide and 
TRAIL. The increased death was mediated by the pro-apoptotic protein NOXA, whose 
basal levels were over-expressed in an ERK2-dependent manner. In fact, oncogenic KRAS 
stimulates the MEK/ERK pathway and this results in NOXA up-regulation in agreement 
with previous works (Elgendy et al, 2011). Other groups, in fact, showed that mutated 
KRAS stimulates NOXA-dependent autophagic cell death in human ovarian surface 
epithelial (HOSE) cell line or sensitizes cancer cells to cisplatin-mediated apoptosis (de 
Bruijn et al, 2010). Importantly, mutated KRAS has also shown to induce senescence in 
primary cells (Serrano et al, 1997; Vizioli et al, 2014), further supporting the notion that 
activated oncogenes could sensitize cells to death, at least when cells are not fully 
transformed and represent a premalignant lesion. This increased proneness to death in 
the presence of mutated oncogenes could derive from a protective mechanism of the
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cells from oncogenic transformation. Normal cells might therefore sense a genetic lesion, 
become more sensitive to cells and easily be removed by the organism before forming a 
possible tumor. In accordance to this hypothesis, treatm ent of our premalignant models -  
HME cells with Kl G13D mutations of KRAS and ectopic expression of oncogenic KRAS in 
HME and MCF10A cells -  with SM83 and CPT caused the activation of an apoptotic 
cascade.
Interestingly, ERK2 and not ERK1 is responsible for NOXA up-regulation suggesting 
that, even if extremely conserved and activated by the same up-stream stimuli, these two  
kinases display peculiar and even opposite functions. Nonetheless, MEK chemical 
inhibition, which switch off the activation of both ERK1 and ERK2, resulted in NOXA 
down-regulation and cell protection from the treatment.
In our work, we demonstrated that NOXA enhanced the sensitivity to the 
treatment, but we did not fully comprehend the mechanisms that were responsible for 
the killing. Again, we focused on the TNF and saw that TNF blocking by means of 
Infliximab and Enbrel, and silencing of TNF and TNF-R1, but not TNF-R2 (data not shown), 
rescued treated cells. As in preliminary experiments, we did not observe an increased 
release of TNF in the medium of treated cells. As a result, we can conclude that TNF 
becomes toxic upon CPT/SM83 treatment most likely by increase of TNF-R1 exposure or 
by removal of factors that usually protect from TNF.
Because the epithelial cells bearing KRAS mutations only represent a premalignant 
model, we then considered whether our observations were true in transformed cells also. 
For this reason, we treated a panel of CRC bearing Kl and KO KRAS mutations with 
SM83/CPT. In clear contrast to what had been observed in HME and MCF10A cells, CRC
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sensitivity to the treatm ent was completely independent from KRAS status. Moreover, 
NOXA levels were not up-regulated in the presence of G13D KRAS despite the fact that 
ERK2 was still controlling its expression. We then speculated that another parallel 
pathway was protecting cancer cells from the pro-death stimulus deriving from oncogenic 
KRAS. As HCT116 and DLD1 cells bear activating mutations of PI3K, which is the up-stream  
activator of AKT, we inhibited both these kinases in combination to SM83/CPT. 
Interestingly, we observed that AKT suppression sensitized cancer cells to treatment, 
especially in cells KRAS mutated. These results were further confirmed in the Lim l215 cell 
line in which AKT inhibition still sensitized oncogenic KRAS-bearing cells to treatment, 
despite the fact that these cells bear wild-type PI3K. On the contrary, SW48 were 
particularly sensitive to the treatm ent and therefore we did not observe a specific 
sensitization to treatment in the presence of mutated KRAS. Altogether, these data 
support the notion that mutated KRAS has the potential of sensitizing cancer cells to 
death, but its effect is prevented by AKT.
Therefore, our findings present two main implications. First, it is possible to 
increase sensitivity to cancer cells bearing mutated KRAS by simultaneous inhibition of 
the AKT pathway. Second, the inhibition of the pathway directly activated by KRAS, such 
as the MAPK pathway, might even result in an immediate anti-proliferative effect, but 
could also switch off the potentially pro-death stimuli arising from oncogenic KRAS.
6.4. Conclusions and future research
In conclusion, our work shows that SMs, and, in particular, our SM83, can be 
successfully employed to target the lAPs both in vitro and in vivo as tools to study IAP
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functions, and potentially as adjuvant therapy in cancer treatment. SM83, in fact, can 
enhance the cytotoxic activity of other compounds, but can also target the tumor micro­
environment and affect the immune system associated to the tumors. Nonetheless, much 
work is still required in order to eliminate the side-effect deriving from excessive cytokine 
production and to identify precise settings in which SM therapy could be more effective. 
In line with this, we showed that KRAS mutations have the potential to increase 
sensitivity to treatment, but further studies will permit understanding as to how AKT 
protects from this stimulus and therefore determining the best combination approach to 
enhance the efficacy of the therapy.
Finally, our work proposed an anti-metastasis effect of SM83 due to its capability 
to modulate gene expression. In particular, we showed that clAPl promotes high levels of 
Snai2 and, as a result, SM83 treatm ent significantly reduces the levels of this mediator of 
the EMT process. Our work in progress is therefore focused on the comprehension of the 
mechanisms by which clAPl up-regulates Snai2 expression in order to identify other 
target-specific compounds that could reduce its levels without preventing IAP activity 
that, as we have shown, produces many side-effects.
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cDNA Complementary DNA
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CRC Colorectal cancer
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DcR Decoy receptor
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DISC Death inducing signaling complex
DMEM Dulbecco's Modified Eagle's medium
DMSO Dimethylsulfoxide
DNA Deoxyribonucleic acid
Dox Doxycicline
DR Death receptor
DTT Dithiothreitol
EGF Epidermal growth factor
EGFR Epidermal growth factor receptor
ELISA Enzyme-linked immunosorbent assay
EMT Epithelial to mesenchymal transition
ER Estrogen Receptor
ERK Extracellular signal-regulated kinase
ETO Etoposide
FAK Focal adhesion kinase
FBS Fetal bovine serum
FDA Food and Drug Administration
FITC Fluorescein isothiocyanate
GDP Guanosine diphosphate
GEP Gene expression profiling
GTP Guanosine triphosphate
H&E Hematoxylin and eosin
HER2 Human epidermal growth factor receptor 2
HME Human mammary epithelial
HMGB-1 High mobility group box 1
IAP Inhibitor of apoptosis protein
IBM IAP binding motif
IF Immunofluorescence
IFN Interferon
IHC Immunohistochemistry
IkB Inhibitor of NF-kB
IKK Inhibitor of NF-kB kinase
IL Interleukin
ILP2 Insulin-like peptide 2
IMDM Iscove's modified Dulbecco's medium
ip Intraperitoneal
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iv Intravenous
izTRAIL Isoleucine zipper TRAIL
Kl Knock-in
KO Knock-out
LRIG-1 Leucine-rich repeats and immunoglobulin-like domains protein 1
LUBAC Linear ubiquitin chain assembly complex
MALT Mucosa-associated lymphoid tissue
MAPK Mitogen-activated protein kinases
Mcll Induced myeloid leukemia cell differentiation protein
MEK MAPK/ERK kinase
ML-IAP Melanoma-IAP
MOMP Mitochondrial outer membrane permeabilization
mP Millipolarization units
mRNA Messenger RNA
mTRAIL Membrane TRAIL
NCS Neocarzinostatin
NEMO NF-kB essential modulator
NF-kB Nuclear factor kappa-light-chain-enhancer of activated B cells
NIK NF-kB inducing kinase
NOD Nucleotide-binding oligomerization domain-containing protein
NOD/SCID Non-obese diabetic/severe combined immunodeficiency disease
PARP Poly-ADP ribose polymerase
PBS Phosphate-buffered saline
PBS-T PBS-Tween
PI Propidium iodide
PI3K Phosphatidylinositol 4,5-bisphosphate 3-kinase
PMN Polymorphonuclear leucocytes
PR Progesterone receptor
PUMA p53 up-regulated modulator of apoptosis
Racl Ras related C3 botulinum toxin substrate
RBD Ras binding domain
RING Really interesting new gene
RIP1 Receptor interacting protein 1
RNA Ribonucleic acid
RNF144 RING finger protein 144B
RPMI-1640 Roswell Park Memorial Institute-1640
RT Room temperature
sc Subcutaneous
SDS Sodium dodecyl sulfate
siRNA Short interfering (siRNA)
SMAC Second mitochondria-derived activator of caspases
SM Smac mimetic
sTRAIL Soluble TRAIL
TAB TGF-beta-activated kinase 1-binding protein 3
TAK TNF-associated kinase
TGF-P Transforming growth factor
TLR Toll-like receptors
TNF Tumor necrosis factor
TNF-R TNF-receptor
TNF-RS TNF-R superfamily
TRADD TNF-Rl-associated death domain
TRAF TNF-R-associated factor
TRAIL TNF-related apoptosis-inducing ligand
TRAIL-R TRAIL-receptor
TWEAK TNF-related weak inducer of apoptosis
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